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1.1 The Glutamatergic System 
 
 L-Glutamate is the primary excitatory neurotransmitter in the mammalian 
central nervous system (CNS).  It is capable of participating in standard fast 
synaptic communication, as well as in higher order signal processing linked to 
development, synaptic plasticity, learning and memory (Balazs, Bridges and 
Cotman, 2006).  Excessive concentrations of glutamate can overstimulate the 
excitatory amino acid (EAA) receptors, leading to cell damage and eventual cell 
death (excitotoxicity).  Excitotoxicity is believed to play key roles in disorders of 
the CNS including: stroke, epilepsy, spinal cord injury, ALS, and Alzheimer’s 
disease (for reviews see: Rao and Weiss 2004; Won et al., 2002; Malva et al., 
2003; Hynd et al., 2004).  The primary regulators of extracellular glutamate in the 
CNS are the excitatory amino acid transporters (EAATs), which are capable of 
influencing the amount and/or time course that L-glutamate is in contact with the 
excitatory amino acid (EAA) receptors.   
 The glutamate-glutamine cycle is a crucial component of neuronal 
communication (Berl et al., 1968).  It begins with the packaging of glutamate into 
vesicles via the vesicular glutamate transporter (VGLUT) (for a review see: 
Takamori, 2006).  Action potentials in the presynaptic neuron cause the 
concentration of intracellular calcium to increase.  The calcium binding protein, 
calmodulin (CaM) activates CaM Kinase II which phosphorylates synapsin I.  
Phosphorylation of synapsin I decreases the affinity of this protein for the actin 
cytoskeleton and/or the vesicles and causes the vesicles to undock.   
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Figure 1. The Glutamatergic Synapse; figure by Brent Lyda of the Esslinger 
research group. 
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Simultaneously, calcium causes synaptotagmin, a Ca2+ binding protein located 
on the synaptic vesicle, to prime the vesicle for fusion with the presynaptic 
membrane.  For fusion to occur a trimeric trans-SNARE (soluble N-
ethylmaleimide-sensitive factor attachment protein receptor) complex must form 
consisting of the vesicle associated membrane protein (VAMP2 or 
synaptobrevin) on the synaptic vesicle, and syntaxin-1 and synaptosomal 
associated protein of 25 KDa (SNAP-25) from the plasma membrane (for a 
review see: Martens and McMahon, 2008).  Upon fusion, the synaptic vesicle 
membrane is incorporated into the presynaptic membrane and glutamate is 
released into the synaptic cleft where it can stimulate pre- and postsynaptic 
glutamate receptors.  This translates the chemical signal into an electrical signal 
either directly by opening ion channels (ionotropic) or indirectly through second 
messenger systems (metabotropic) (Nakanishi and Masu, 1994).   
 The EAA receptors are grouped into two categories.  The ionotropic 
receptors AMPA, Kainate and NMDA, named after the selective agonists that act 
at each receptor: N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl 
isoxazole-4-propionate (AMPA) and kainic acid (KA) (Figure 2).  The 
metabotropic glutamate receptors mGluR1-5, are G-protein coupled receptors 
linked to multiple second messenger systems.  These two classes of receptors 
mediate and modulate information transfer at the majority of excitatory CNS 
synapses (Mayer, 2005; Swanson et al., 2005). 
    The ionotropic glutamate receptors are a family of heteromeric ligand-gated 
ion channels that span the plasma membrane.  They are believed to mediate the  
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majority of excitatory neurotransmission in the vertebrate CNS.  The binding of L-
glutamate causes a conformational change which opens the receptor associated 
ion channel thereby allowing Na+ and/or Ca2+ to flow into the cell (Armstrong and 
Gouaux, 2000).  If the influx of positive ions sufficiently depolarizes the 
membrane potential past a critical threshold value of approximately -55mV, 
measured at the axon hillock, sodium channels open.  This allows sodium ions to 
rapidly enter the cell causing an action potential.  Potassium channels, which 
respond slower than sodium channels restore the membrane potential by 
allowing potassium to exit the cell.  Sodium channels then close, resulting in a 
short period of hyperpolarization during which the cell is less likely to fire an 
action potential.  The cell then returns to its resting potential of approximately -70 
mV.  
 
H
NHOOC
HOOC
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NO
OH
H2N
OHO
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Figure 2. Selective agonists of the glutamate ionotropic receptors. 
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 AMPA and Kainate receptors (AMPARs and KARs) are responsible for 
mediating fast synaptic transmission (Collingridge et al., 1983; Ganong et al., 
1983) and are activated by low frequency stimulation (Davies et al., 1989).  
AMPARs are responsible for most fast excitatory responses.  In addition, the 
recruitment of AMPARs to the cell surface from an intracellular pool may be an 
important component of long term potentiation, LTP.  LTP is a process whereby 
synapses become more robust through the insertion of AMPARs into the 
postsynaptic membrane.  This occurs via the calcium/calmodulin dependent 
protein kinase (CAMKII) which phosphorylates AMPARs in the synaptic 
membrane.  Phosphorylation increases sodium conductance and promotes the 
migration of AMPARs from intracellular stores to the membrane (Breedlove et al., 
2007).  This results in the enhancement of AMPAR activation, thereby increasing 
synaptic current (Luscher et al., 1999; Luthi et al., 1999).   
 Kainate receptors (KARs) are found throughout the CNS and are present 
both pre- and post-synaptically.  Postsynaptic KARs are believed to carry part of 
the charge that contributes to the post synaptic response along with AMPARs 
and NMDA receptors (NMDARs).  Presynaptic KARs are hypothesized to 
regulate neurotransmitter release at inhibitory and excitatory synapses 
(Rodrigues-Moreno et al., 1997).   
 The NMDA receptors (NMDARs) contain a Mg2+ and a glycine recognition 
site in addition to a glutamate site.  The Mg2+ site is situated deep within the 
channel pore and is removed when the cell is partially depolarized (Flatman et 
al., 1983) causing NMDARs to respond only after repetitive synaptic activation 
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(Manabe, 2008).  In addition to the removal of the Mg2+ block NMDARs require 
the co-agonist glycine in order to be activated (Johnson and Ascher, 1987).  
NMDARs are permeable to Ca2+, Na+ and K+.  The increase in postsynaptic 
calcium is an important step to activating further processes which may constitute 
long term potentiation LTP as well as higher cognitive functions such as learning 
and memory (Cavara and Hollman, 2008).   
  The metabotropic glutamate receptors are G-protein coupled receptors 
(GPCRs) of which 8 have been cloned (Nakanishi, 1992; Pin and Duvoisin, 
1995).  They are subdivided into three groups based on sequence similarity, 
intracellular signaling mechanisms and pharmacology.  Group I mGluRs consist 
of mGluR1 and mGluR5 and are coupled to phospholipase C-β (PLC-β) and 
intracellular Ca2+ signaling.  Group I mGluRs modulate NMDA receptor-mediated 
synaptic transmission and plasticity and mediate mGluR-dependent plasticity 
(Cheyne and Montgomery, 2008).  Group I mGluRs are primarily expressed at 
postsynaptic sites.  Group II (mGluR2, mGluR3) and group III (mGluR 4,6,7 & 8) 
inhibit adenylyl cyclase (AC) activity, which results in a decrease in cAMP levels 
and PKA activity.  A decrease in PKA activity is required for the induction of 
group II mGluR dependent long term depression. Group II mGluRs are 
expressed both pre- and post-synaptically and Group III mGluRs are expressed 
primarily at presynaptic sites where they regulate neurotransmitter release 
(Reviewed in Kim et al., 2008).     
 In order to prevent overstimulation of the glutamate receptors, which can 
lead to excitotoxicity, glutamate must be quickly cleared from the synaptic cleft.  
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This occurs via diffusion or by EAAT mediated substrate uptake (Auger and 
Attwell, 2000; Huang and Bergles, 2004).  The EAATs, of which 5 have been 
identified to date, are expressed in glial cells (EAAT1 and EAAT2) and in 
neurons (EAAT3, EAAT4 and EAAT5).   
 Once glutamate has been transported into the astrocyte by EAAT1 and/or 
EAAT2, it is converted to the neutral amino acid glutamine by glutamine 
synthetase.  Glutamine can then be transported out of the astrocyte by SNAT3 
(SN1), a system N amino acid transporter localized to perisynaptic astrocytes.  
Glutamine is thought to be transported into the neuron by (SNAT1 & SNAT2), 
system A transporters, though the localization of these transporters is mainly in 
the somatodendric domain and rarely axon terminals (Cont and Melone, 2006).  
In addition, the inability of system A inhibitors to affect basal transmission 
suggest that transporters not yet identified may be responsible for the uptake of 
glutamine into the neuron (Kam and Nicoll, 2007). 
 The glutamatergic system has a central role in excitatory signaling in the 
CNS.  Glutamate levels must be tightly regulated to maintain excitatory signaling 
as well as to prevent the overstimulation of the glutamate recpetors.  Regulation 
of this system relies on multiple factors, one being the rapid clearance of 
glutamate from the synaptic cleft by the glutamate transporters.   
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1.2 Characterization, Localization and Function of the EAATs 
 
Historically, the glutamate transporters have been grouped into three 
categories depending upon their substrate specificity: the C-4 dicarboxylate 
transporters found in bacteria, the glutamate/aspartate transporters found in 
bacteria and eukaryotes and the neutral amino acid transporters also found in 
bacteria and eukaryotes (Slotboom et al., 1999).  
 Recently, the glutamate transporters have begun to be classified 
according to the Human Genome Organization (HUGO) nomenclature.  The five 
glutamate transporters EAAT1-5, which share 50-60% amino acid homology, 
along with two neutral amino acid transporters ASCT1 and ASTC2, comprise the 
solute carrier family 1 (SLC1).  EAAT1 is encoded by the gene SLC1A3, EAAT2  
by SLC1A2, EAAT3 by SLC1A1, EAAT4 by SLC1A6 and EAAT5 by SLC1A7, 
ASCT1 by SLC1A4 and ASCT2 by SLC1A5 (Kanai and Hediger, 2004). 
The five glutamate transporters have been identified by molecular cloning 
and functional expression.  EAAT1-5 have been isolated and cloned from 
mammalian tissue: GLAST (glutamate and aspartate transporter 1) and GLT1 
(glutamate transporter 1) from rat brain (Storck et al., 1992; Pines et al., 1992) 
and EAAC1 (excitatory amino acid carrier 1) from rabbit small intestine (Kanai & 
Heidger, 1992).  The almost simultaneous cloning of these three transporters 
was quickly followed by the cloning of the corresponding human homologues by 
Arriza, who suggested using a standard naming system, the excitatory amino 
acid transporters (EAATs), of which EAAT1 is the human homologue of GLAST1, 
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EAAT2 of GLT1 and EAAT3 of EAAC1 (Arriza et al., 1994).  Four additional 
transporters were quickly isolated using homology screening, EAAT4 from the 
retina, EAAT5 from the cerebellum (Fairman et al., 1995; Arriza et al., 1997), and 
the two neutral amino acid transporters of the SCL1 family; ASCT1 and ASCT2 
(Alanine, Serine and Cysteine Transporters 1 and 2) (Arriza et al., 1994).  
The EAATs are found throughout the brain and periphery with enrichment 
in certain tissues and brain regions depending on the specific EAAT.  EAAT1 is 
expressed throughout the brain with high levels in the heart and skeletal muscle 
and lower levels in the placenta and lung.  EAAT2 expression is largely restricted 
to the brain with low levels found in the placenta.  EAAT3 is expressed 
throughout the brain with high levels in the kidney and lower levels expressed in 
the lung, placenta, liver, muscle and heart (Reviewed in Danbolt, 2001). 
In the CNS, EAAT1 and EAAT2 are expressed on glial cells and EAAT 3 
and EAAT4 on neurons. The glial transporters, EAAT1 and EAAT2 and the 
neuronal transporter EAAT3 are the primary transporters of synaptic glutamate 
(Arriza et al., 1994).  They are found throughout the brain with enrichment in 
differing regions.   
EAAT1 is the primary transporter of glutamate in the cerebellum where it 
is found in high levels in Bergmann glia.  EAAT1 is also found in lower levels 
throughout the CNS.  Mice deficient in mEAAT1 are susceptible to cerebellar 
injury and display reduced motor coordination (Watase et al., 1998).   
EAAT2 is the dominant glutamate transporter throughout the CNS except 
in the cerebellum where EAAT1 dominates.  EAAT2 expression is particularly 
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high in the hippocampus, lateral septum, cerebral cortex and the striatum (Lehre 
et al., 1995; Chaudhry et al., 1995).  EAAT2 is found on most astrocytes 
throughout the CNS, and on all astrocytes in the neocortex, striatum and 
thalamus.  Mice deficient in mEAAT2 are susceptible to lethal spontaneous 
seizures and acute forebrain injury (Tanaka et al., 1997).   
EAAT3 is enriched in the hippocampus, cerebellum and basal ganglia, 
though the levels of EAAT3 protein are much lower than the other glutamate 
transporters (Haugeto et al., 1996).  EAAT3 has a unique distribution, being 
found over neuronal bodies and processes as well as presynaptically at GABA 
terminals (For a review see Nielullon et al., 2006). The localization of EAAT3 to 
presynaptic GABAergic terminals implicates it as a source of glutamate for GABA 
synthesis (Sepkuty et al., 2002).  The perisynaptic localization of EAAT3 
suggests that this transporter helps to regulate spillover, in addition EAAT3 may 
be the major route for neuronal cysteine uptake (Zerangue and Kavanaugh 
1996b; Himi et al., 2003), a necessary precursor for neuronal glutathione 
synthesis (Aoyama et al., 2006).  Glutathione is a major antioxidant, directly 
linked to the metabolism of nitrosyl oxidants and peroxide (Dringen, 2000).  
EAAT3 knock-out mice present significantly reduced spontaneous locomotor 
activity at 12 months of age but otherwise the CNS appears normal.  A major 
dysfunction of EAAT3 knock-out animals is the onset of dicarboxylic 
aminoaciduria due to the loss of uptake from the renal tubules by EAAT3 
(Peghini et al., 1997).    
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The highest expression of EAAT4 is found in cerebellar Purkinje cells with 
very low levels expressed in the hippocampus, neocortex, striatum, brain stem 
and thalamus (Furuta et al., 1997; Reviewed in Danbolt, 2001).  EAAT4 is 
hypothesized to remove extracellular glutamate that is not cleared from the 
synapse by EAAT1-3 (Mim et al., 2005).  In Purkinje cells EAAT1 seems to be 
the major contributor to the uptake of glutamate from the synaptic cleft and 
EAAT4 appears to remove low concentrations of glutamate that escape the glial 
transporters, thereby preventing glutamate spillover to neighboring synapses 
(Takayasu et al., 2005). 
EAAT5 is restricted to the retina where it is found in cone and rod 
photoreceptor terminals and in axon terminals of rod bipolar cells (Fairman et al., 
1995; Rothstein et al., 1994; Arriza et al., 1997; Localization reviewed in detail in 
Danbolt, 2001).  Here, EAAT5 has a unique role and is believed to act as a 
presynaptic receptor in mouse bipolar cells and may play a major role in 
controlling the output from these cells (Wersinger et al., 2006).  
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1.3 Transport Mechanisms and Molecular Structure of the EAATs 
 
It is estimated that glutamate transporters can concentrate glutamate 
5x106 fold in cells under physiological conditions (Zerangue and Kavanaugh, 
1996a).  In order to accomplish this, the EAATs couple the transport of glutamate 
into the cell to the influx of 3 sodium ions and one proton (for review see; 
Danbolt, 2001; Kanai and Hediger, 2004).  The transporter returns to the 
extracellular side of the membrane by coupling this movement to the transport of 
one potassium ion (Zerangue and Kavanaugh, 1996a).  In this manner the 
EAATs harness energy derived from the concentration gradients of sodium and 
potassium, to import glutamate into the cell and to return to the extracellular side 
of the plasma membrane.  
In addition to the transport current, substrate applied to the EAATs creates 
a substrate gated anion conductance that is not stochiometrically linked to 
glutamate transport (Fairman et al., 1995; Wadiche et al., 1995).  The anion 
current is a small component of the EAAT1-3 total current associated with the 
transporter.  In contrast, the current associated with EAAT4 and EAAT5 is almost 
entirely made up of the anion current.  This suggests that the primary role of 
EAAT4 and EAAT5 may be to regulate cellular excitability via glutamate gated 
anion channels (Torres-Salazar and Fahlke, 2007).   
 Advancements in determining the structure of the EAATs has been made 
through the crystallization of a glutamate transporter homologue from 
Pyrococcus horikoshii (Gltph), a sodium dependent aspartate transporter, which 
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shares a 37% amino acid identity with human EAAT2. The transporter 
homologue was recently crystallized with bound aspartate (closed state) and the 
glutamate transport inhibitor threo-β-benzoylaspartic acid (bound TBOA, open 
state).  An advantage of having crystal structures of the transporter in these two 
states is the mechanistic information it affords (Yernool et al., 2004; Boudker et 
al., 2007).    
 Data suggests that the transporter is a trimer with a bowl shaped basin 
facing the extracellular space (Figure 3).  Three binding sites lay at the bottom of 
the basin, each gated by two loops.  Helical hairpin loop 1 (HP1) acts as the 
intracellular gate and helical hairpin loop 2 (HP2) acts as the extracellular gate. 
The substrate binding site is located about 5 Angstroms below the bottom of the 
aqueous basin buried in a polar cavity formed by the tips of HP1 and HP2, the 
unwound region of transmembrand 7 (TM7) and polar residues of 
transmembrane 8 (TM8).  HP2, which acts as the extracellular gate is initially in 
the open position, allowing access of the extracellular solution to the aqueous 
basin.  The authors predict that two sodium ions bind with aspartate, one sodium 
coupled to HP1, below aspartate, and the other coupled to HP2, above 
aspartate.  The sodium ions are hypothesized to help stabilize the loops.  Binding 
of two sodium ions and substrate induces the HP2 loop to close, giving the 
“occluded” state.  Next, the HP1 loop opens to create an aqueous pathway to the 
cytoplasm.  When HP1 opens, HP2 moves into the space previously occupied by 
HP1 in order to prevent an open pore thereby allowing “alternating access” from 
 
the extracellular to intracellular s
Boudker et al., 2007).  
 
Figure 3. EAAT3 homology model shown with three bound sodium ions and 
aspartate bound in one of the three active sites.  
 
 In addition to structural
the manner in which ligands recognize and bind to the active site.  
aspartate were observed to bind by the same recognition points, thereby 
validating that TBOA works in a competitive manner, 
to the modeling based on the belief that the protein recognizes
ides of the membrane (Yernool
 
 
 information, the crystal structure lends
as well as giving credence 
 compounds by at 
14 
 et al., 2004; 
 
 insight into 
TBOA and 
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least 3 points; the α carboxyl group, C1; the distal carboxyl group, C2 and the 
nitrogen, N (Esslinger et al., 2005).  The bulky aromatic group of TBOA is 
believed to interfere with the closing of HP2, effectually blocking further 
conformational changes (Boudker et al., 2007).  This interference may result in 
the observed inhibitory acitivity of TBOA.  Figure 4 illustrates this point by 
showing TBOA in the active site of the EAAT3 homology model.  The homology 
model was created by aligning the EAAT3 sequence (Yernool et al., 2004) to the 
crystal structure coordinates of Gltph TBOA bound (Boudker et al., 2007).     
Valuable information, such as the generation and analysis of EAAT 
homology models, can be extracted from the Gltph crystal structures.  This 
information can be used to examine the basic structure of the EAATs as well to 
determine where changes in amino acids surrounding the binding site may affect 
substrate binding across the different EAATs.  In spite of the wealth of 
information the EAAT homology models afford, the template from which this 
information is based upon, Pyrococcus horikoshii, remains a generic model of the 
EAATs.  By itself, it is not sufficient to delineate the subtle variations between the 
individual EAAT binding sites. 
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Figure 4.  TBOA in the active site of the EAAT3 homology model (threading 
done by Holley D. and Mavencamp T.). 
 
 
 
 
 
 
 
 
 
 
 
HP2 loop
HP1 loop
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1.4 Molecular Pharmacology of the EAATs 
 
In order to determine the subtle differences between the individual EAAT 
subtypes, selective inhibitors can be employed.  By examining the structure 
activity data of compounds at the EAATs, hypotheses about individual binding 
sites can be formed.  These hypotheses can be tested by the synthesis of new 
analogues designed from the analysis of structure activity data of previous 
inhibitors.  This method aids in elucidating the subtleties of the individual EAAT 
binding sites and often results in more selective and potent inhibitors with each 
round of synthesis.         
Molecular pharmacology played an important role in the initial 
characterization of the EAATs.  Radiolabeled glutamate was used early on to 
examine the substrate specificity of the EAATs.  It was found that other 
neurotransmitters did not affect glutamate transport but that L-glutamate, D-
aspartate and L-aspartate (Figure 5) are good substrates (Ki = 1-10µM) and that 
D-glutatmate is not transported (Ferkany and Coyle, 1986; Rauen et al., 1992; 
Arriza et al., 1994).   
 
H2N CO2H
HO2C
L-Aspartate
H2N CO2H
HO2C
L-Glutamate
H2N CO2H
HO2C
D-Aspartate  
 
Figure 5. Natural amino acid substrates 
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The first EAAT inhibitors were mostly developed via simple modifications 
to known substrates and thus, many showed substrate activity.  The downfall of 
using substrates to characterize the EAATs is that substrates induce 
heteroexchange, a process whereby exogenously applied substrate induces the 
efflux of internal substrate.  Heteroexchange may increase the amount of 
glutamate in the synaptic cleft making it difficult to study the role of the EAATs 
(Shigeri et al., 2004).   
 One of the first analogues used to characterize glutamate uptake by the 
EAATs was β-threo-hydroxyaspartate (THA) shown in Figure 6 (Fletcher and 
Johnston, 1991; Bridges and Esslinger, 2005).  THA, a competitive substrate of 
EAAT1-4 and a non-substrate inhibitor of EAAT5, is one template for EAAT 
inhibitors that has been used as a lead molecule in the development of many 
potent and selective inhibitors.  TBOA, one of the first β-carbon substituted 
analogues of THA, continues to be the most widely used non-substrate inhbitior 
of the  EAATs.  The L-enantiomer of TBOA is the more potent enantiomer with 
IC50 values of 23 µM, 3.8 µM and 7 µM for EAAT1-3, respectively (Shimamoto et 
al., 1998; Sakaguchi et al., 2004).  Modifications to the aryl moiety of TBOA 
(Figure 6) generally increase the potency over TBOA while retaining non-
substrate activity.  Replacing the benzyl moiety of TBOA with a naphthyl moiety 
(L-TNOA1 and L-TNOA2) yields IC50 values of 15 µM, 1.3 µM and 4.8 µM for L-
TNOA1 and 16 µM, 2.2 µM and 6.5 µM for L-TNOA2 (Shimamoto et al., 2000).  
To date the most potent TBOA analogue, (2S,3S)-3-{3-[4-
[trifluoromethyl)benzoylamino]benzyloxy}aspartate (TFB-TBOA, Figure 6) 
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displays IC50 values of 22 nM, 17 nM and 300 nM for EAAT1-3, respectively 
(Shimamto et al., 2004). 
 
H2N CO 2H
HO 2C O
N
H
O
CF 3
H2N CO 2H
HO 2C O
H2N CO 2H
HO 2C OH
THA L-TBO A TFB-TBOA  
 
Figure 6. β-threo hydroxy aspartate and derivatives. 
 
  Another approach to inhibitor design is to utilize conformationally 
constrained analogues.  This allows for the better prediction of functional group 
positions as well as decreases the possible binding conformations, which often 
leads to an increase in selectivity.  This method has been shown to be quite 
robust at enhancing the potency and selectivity of analogues at EAAT2 (Bridges 
and Esslinger, 2005).   
 Pyrrolidine dicarboxylate (PDC) and PDC derivatives are conformationally 
constrained analogues of glutamate similar in structure to dihydrohainate (DHK), 
an analogue of kainic acid (Figure 7).  Kainic acid was isolated in 1953 from red 
algae in Japan and is a potent, specific agonist of the Kainate Receptor.  DHK is 
an EAAT2 selective non-substrate inhibitor which not surprisingly shows cross 
reactivity at the Kainate Receptors due to its similarity to KA (Shimamoto et al., 
1998).   
 The PDC derivatives, 2,4 and 2,3 dicarboxylate PDC, were designed as 
conformationally constrained mimics of glutamate and aspartate, respectively.    
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The lead molecule, L-trans-2,4 PDC, is a substrate of EAAT1-4 and a non-
substrate of EAAT5.   When a methyl group is introduced at the 4 position of 2,4 
PDC (4-Me-L-trans 2,4 PDC) the compound exhibits increased potency and can 
no longer be translocated at EAAT2, transforming the substrate to a non-
substrate inhibitor.  By switching the position of the carboxylate group of L-trans-
2,4 PDC from the 4 position to the 3 position (L-trans-2,3 PDC), the selectivity for 
EAAT2 increases approximately 10 fold (Ki in Xenous Oocytes of roughly 12 µM) 
and displays non-substrate activity at EAAT1-4 (Willis et al., 1996, Bridges et al., 
1999).  In order to gain insight into the binding site of EAAT2 and in particular to 
elucidate the differences between substrate and non-substrate inhibitors a 
pharmacophore model was created.  A pharmacophore model is “the ensemble 
of steric and electrostatic features of different compounds which are necessary to 
ensure optimal supramolecular interactions with a specific biological target 
structure and to trigger or to block its biological response” (Langer and Wolber, 
2004).  An overlay of EAAT2 substrate inhibitors revealed a tight overlap of the α-
amine, α-carboxyl and distal carboxyl groups as well as a constrained volume 
that the backbones occupied within the binding site.  When non-substrate EAAT 
inhibitors were fit onto the model, such as DHK and TBOA, the non-substrate 
inhibitors aligned with the α-amine, α-carboxyl and distal carboxyl groups but had 
density outside of the volume taken up by the substrates (Koch et al., 1999; 
Esslinger et al., 2002; Esslinger et al., 2005).  These results suggest that the 
steric bulk outside of the volume taken up by substrates is responsible for the 
non-substrate activity.  
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H
NHOOC
HOOC
H
NHOOC
HOOC
KA DHK
H
NHOOC
HOOC
H
NHOOC
COOH
L-trans 2,3 PDCL-trans 2,4 PDC
H
NHOOC
COOH
CH 3
4-Me-2,4 PDC  
Figure 7. Pyrrolidine dicarboxylates. 
 
 
 
 
 In addition to steric bulk, the preferred conformation of the analogue plays 
an important role in how well the compound will bind to the active site, as well as 
the ability of the compound to be translocated across the plasma membrane.  To 
address this important issue, Esslinger et al., 2002 synthesized conformationally 
“locked” analogues of 2,4 PDC.  The mimics were designed to capture the most 
extreme conformations 2,4 PDC may adopt, the folded (pseudo-axial) 
conformation and the extended (pseudo-equatorial) conformation.    The folded 
conformation was achieved by synthesizing a methyl bridge from carbon 3 and 4 
of the pyrrolidine ring (3,4-MPDC).  If the methyl bridge is placed between carbon 
2 and 4 (2,4 MPDC) the ring is forced into an extended conformation (Figure 8).  
The biological results from these compounds were striking with 3,4 MPDC acting 
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as a non-substrate inhibitor with a Ki of roughly 5 µM in rat forebrain 
synaptosomes and 2,4 MPDC displaying better substrate activity than L-
glutamate, as measured by synaptosomal efflux of 3H-D-aspartate (Koch et al., 
1999).  These results reveal that both conformations effectively bind to the active 
site but their conformations determine if they are translocated (substrate) or not 
(non-substrate) across the plasma membrane (Esslinger et al, 2002).   
 
H
NHOOC
COOH
2,4 MPDC
H
NHOOC
3,4-MPDC
COOH
 
Figure 8. Bridged Pyrrolidines. 
 
 In spite of the progress made in the field of glutamate transport inhibitors 
one problem remains: specificity.  It has proven to be very difficult to create 
inhibitors that show more than modest selectivity.  The only EAAT1 inhibitor 
available to date is L-serine-o-sulfate (L-SOS), an EAAT1 and EAAT3 substrate.  
The ki values of L-SOS display modest selectivity for EAAT1: 107 µM, 1157 µM 
and 150 µM for EAAT1-3, respectively (Bridges et al., 1999; Vandenberg et al., 
1998; Arriza et al., 1994).   
 The most selective and potent EAAT inhibitors are active at EAAT2.  This 
likely follows from EAAT2 being the first EAAT intensely studied due to its 
prevalence in synaptosomal preparations, the earliest and most common system 
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used to characterize the EAATs.  Two inhibitors that show modest to good 
selectivity for EAAT2 are DHK and WAY-855 (3-amino-tricyclo[2.2.1.02.6[heptane-
1,3-dicarboxylic acid).  WAY-855 is an EAAT2 preferring non-substrate inhibitor 
with IC50 values in Xenopus laevis oocytes of 125.9 µM, 1.3 µM, and 52.5 µM in 
EAAT1-3, respectively (Dunlop et al., 2003).       
 Recently a series of compounds designed to be structurally distinct from 
other well known inhibitors were synthesized.  The compounds were constructed 
by attaching a lipophilic group to the terminal amine  of 2,3 diaminopropionic acid 
and to the terminal carboxyl of aspartic acid.  Both series of compounds are 
potent, competitive, non-substrate inhibitors of EAAT2.  The most potent 
compound (figure 9a) [N4-[4-(2-bromo-4,5,difluorophenoxy)phenyl]-L-asparagine 
(WAY 213613) does not interact with metabotropic or ionotropic glutamate 
receptors and displays an IC50 value of about 85nM and a 59 and 45 fold 
selectivity over EAAT1 and EAAT3 respectively (Greenfield et al., 2005; Dunlop 
et al., 2005).    
 In 2006, Greenfield and Dunlop published a review reporting the discovery 
of a preferential EAAT3 inhibitor, (S)-4-(9H-fluoren-2ylamino)-2-amino-4-
oxobutanoic acid (NBI-59159, figure 9b) (Dunlop et. al., 2006).  In Xenopus 
oocytes expressing EAAT1-3 this compound acts as a non-substrate inhibitor 
with IC50 values of .212 µM, .055 µM and .023 µM, respectively.  In HEK cells 
expressing EAAT1-3 the compound also displays a preference for EAAT3 
yielding IC50 values of 1.03 µM, 1.4 µM and .09 µM, respectively (Dunlop et al., 
2006).   
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a. WAY-213613
 
 
Figure 9.  Aspartamide acid analogues displaying preference for EAAT2 (a) and 
EAAT3 (b). 
 
 
 Based upon previous inhibitors of the EAATs and their corresponding 
structure activity data, we hypothesize that the conservation of the alpha 
carboxylate, alpha amine, and distal carboxylate mimic are crucial for protein 
recognition of the ligand.  In addition, we envision that the positioning of a bulky 
lipophilic group around the backbone will result in increased potency and non-
substrate activity of the analogue.  By restricting the movement of this lipophilic 
group in three-dimensional space we suggest that the compounds will show 
greater selectivity for one EAAT subtype over another.  If specific inhibition of 
one EAAT subtype can be achieved this will aid in the creation of a binding site 
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map as well as in the elucidation of the EAATs role in CNS function.  To achieve 
the stated goal, the Specific Aims follow a re-iterative strategy of synthesis, 
assay of activity and molecular modeling.  
 
Specific Aim 1:  Design and synthesize L-β-Benzyl Aspartate (described in 
chapter 2) and L-β-Benzyl Aspartate analogues in order to increase interaction 
with an adjacent lipophilic domain of EAAT3. 
Specific Aim 2:  Determine the concentration dependence with which the 
analogues block 3H-D-aspartate uptake in mammalian C17.2 cells expressing 
EAAT1, 2 or 3. 
Specific Aim 3:  Apply the structure activity data generated from Aim 2 to refine 
the EAAT3 binding site map using advanced computational molecular modeling 
techniques. 
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ABSTRACT 
 
The excitatory amino acid transporters (EAATs) play key roles in the regulation of 
CNS L-glutamate, especially related to synthesis, signal termination, synaptic 
spillover, and excitotoxic protection.  Inhibitors available to delineate EAAT 
pharmacology and function are essentially limited to those that non-selectively 
block all EAATs or those that exhibit a substantial preference for EAAT2.  Thus, it 
is difficult to selectively study the other subtypes, particularly EAAT1 and EAAT3.  
Structure activity studies on a series of β-substituted aspartate analogues identify 
L-β-benzyl-aspartate (L-β-BA) as among the first blockers that potently and 
preferentially inhibits the neuronal EAAT3 subtype.  Kinetic analysis of 3H-D-
aspartate uptake into C17.2 cells expressing the hEAATs demonstrate that L-
threo-β-BA is the more potent diastereomer, acts competitively, and exhibits a 
10-fold preference for EAAT3 compared to EAAT1 and EAAT2.  
Electrophysiological recordings of EAAT-mediated currents in Xenopus oocytes 
identify L-β-BA as a non-substrate inhibitor.  Analyzing L-threo-β-BA within the 
context of a novel EAAT2 pharmacophore model suggests: 1) a highly conserved 
positioning of the electrostatic carboxyl and amino groups, 2) nearby regions that 
accommodate select structural modifications (cyclopropyl rings, methyl groups, 
oxygen atoms) and 3) a unique region occupied by the benzyl moieties of L-
TBOA, L-β-threo-BA and related analogs. It is plausible that the preference of L-
β-threo-BA and L-TBOA for EAAT3 and EAAT2, respectively, could reside in the 
latter two pharmacophore regions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key Words:  Glutamate uptake, transport inhibitors, pharmacophore model 
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1. INTRODUCTION 
 
 The high-affinity, sodium-dependent excitatory amino aid transporters 
(EAATs) are readily acknowledged as key players in the regulation of 
extracellular L-glutamate levels in the mammalian CNS (for review see: Danbolt, 
2001; Maragakis and Rothstein, 2004; Bridges and Esslinger, 2005).  This 
regulation takes on considerable significance given that L-glutamate is the 
primary excitatory neurotransmitter in these systems and capable of participating 
not only in standard fast synaptic communication, but also in the higher order 
types of signal processing linked to development, synaptic plasticity, learning and 
memory (for review see multiple chapters in Balazs et al., 2005).  Besides its 
action in neuronal signaling, excessive levels of L-glutamate can also trigger a 
host of pathological pathways in the CNS through the process of excitotoxicity.  
In this manner, glutamate-mediated neuronal damage is thought to be a 
contributing pathological mechanism in both acute CNS injury (e.g., stroke, head 
trauma, spinal cord injury) and chronic neurodegenerative disease (e.g., 
amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease) (for 
review see: Choi, 1994; Mattson, 2003; Olney, 2003; Maragakis and Rothstein, 
2004).  Consequently, the ability of the EAATs to efficiently sequester L-
glutamate into neurons and glia, places these integral membrane proteins in a 
position where they can influence the amount and/or time course with which L-
glutamate is in contact with EAA receptors within the context of either normal 
signaling or pathologic injury. 
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 The EAATs are members of a distinct family sodium-dependent solute 
carriers (SLC1) that includes five subtypes of glutamate transporter (EAATs 1-5), 
as well the neutral amino acid transporters ASCT1 and ASCT2 (Kanai and 
Hediger, 1992; Pines et al., 1992; Storck et al., 1992; Arriza et al., 1994; Fairman 
et al., 1995; Eliasof et al., 1998; Hediger et al., 2004). While the EAATs share a 
level of homology of about 50-60% with one another, as well as a dependency on 
sodium and a high-affinity for L-glutamate (Km values in the µM range), each 
exhibits a distinct anatomical and cellular distribution (Furuta et al., 1997; 
Gegelashvili and Schousboe, 1998; Seal and Amara, 1999; Danbolt, 2001; 
Maragakis and Rothstein 2004). The presence of distinct EAAT subtypes raises 
obvious questions regarding potential differences in their physiological roles, 
especially within the context of excitatory signaling and excitotoxic protection.  In 
turn, such questions highlight the need for selective inhibitors and substrates that 
could be used to differentiate the EAATs and delineate their individual 
contributions to glutamate-mediated signaling.  Significant advances have been 
made in generating inhibitors and substrates that can be used to assess EAAT 
activity with little or no cross-reactivity with EAA receptors, such as L-trans-2, 4-
pyrrolidine dicarboxylate (L-trans-2, 4-PDC) and β-threo-benzyloxy-aspartate 
(TBOA) (Bridges and Esslinger, 2005)).  Much of this success has been the 
direct result of synthetic efforts to produce novel conformationally constrained 
analogues of glutamate and aspartate (Chamberlin et al., 1998).  Limiting the 
positions that can be occupied by required functional groups (e.g., carboxylate 
and amino groups) has the potential to both increase potency, as well as reduce 
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cross-reactivity. It is this same approach that has so effectively been exploited in 
development of selective agonists and antagonists for the EAA receptors.  
Additionally, the fact that the functional groups on these rigid and semi-rigid 
analogues can be accurately mapped in three-dimensional (3D) space allows for 
the construction of 3D pharmacophore models (Gelin, 1995; Martin, 1998).  In 
this respect, our transporter workgroup has been focused on rigorously probing 
the structural commonalities and differences amongst EAAT selective ligands 
(especially EAAT2, see; Esslinger et al., 2002; Bridges and Esslinger, 2005;) 
through the fabrication of multidimensional superposition pharmacophore models 
(Perkins and Dean, 1993; Dean and Perkins, 1998; Martin, 1998). 
 Unfortunately, identifying compounds that readily differentiate among the 
individual EAAT subtypes has proven to be more elusive than developing 
analogues that discriminate glutamate transporters from glutamate receptors.  
The exception to this limitation has been the progress made in pharmacologically 
delineating EAAT2, particularly within the context of the most commonly studied 
EAATs 1-3.  Thus, glutamate analogues, such as dihydrokainate (DHK), L-anti-
endo-3,4-methanopyrrolidine dicarboxylate (L-anti-endo-3,4-MPDC) (Bridges et 
al., 1994), S-2-amino-3-(3-hydroxy-1,2,5-thiadiazol-5-yl)propionic acid (TDPA) 
(Brauner-Osborne et al., 2000) and 3-amino-tricyclo[2.2.1.02.6]heptane-1,3-
dicarboxylate (WAY-855) (Dunlop et al., 2003) potently and preferentially interact 
with EAAT2 to a high enough degree that they can be used to distinguish its 
activity from the other EAAT subtypes.  In the instance of the other EAATs, only 
more subtle indications point to chemical templates that might be used to create 
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subtype selective blockers.  For example, EAAT 1 has the distinguishing feature 
of being able to effectively use 4-methyl-glutamate and L-serine-O-sulfate as 
substrates and to exhibit a sensitivity to inhibition by (R,S)-2-amino-3-(1-hydroxy-
1,2,3-triazol-5-yl)propionate (Arriza et al., 1994; Vandenberg, 1998; Stensbol et 
al., 2002).  Similarly, hints to the potential selectivity of EAAT3 may be traced 
back to the pioneering characterizations of glutamate uptake, where it was 
reported that L-aspartate β-hydroxamate was more effective at inhibiting 
glutamate uptake into neurons than into glia (Roberts and Watkins, 1975).  In the 
present work we carry out a structure activity study on a series of aspartate 
analogues that have been modified at the β-carbon position.  We find that one of 
these analogues, L-β-benzyl-aspartate, may be among the first transport 
blockers to be identified that potently and preferentially inhibits the neuronal 
EAAT3 subtype.  Further, molecular modeling studies in which this new inhibitor 
has been positioned within a current EAAT2 pharmacophore suggest that its 
specificity of action may be the result of the side chains of L-β-benzyl-aspartate 
and L-β-TBOA interacting with similar lipophilic residues within the substrate 
binding domain of the EAATs in addition to distinct residues between EAAT 
isoforms.  These finding represent an important step in developing the reagents 
that are critically needed to elucidate the physiological roles played by the 
neuronal EAAT3 glutamate transporter within the processes of excitatory 
transmission and excitotoxicity. 
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2. METHODS 
 
2.1. Chemicals and Reagents 
General cell culture supplies were purchased from Becton Dickinson 
(Franklin Lakes, NJ), Corning (Corning, NY), and Life Technologies (Grand 
Island, NY).  D-[3H]Aspartic acid was purchased from Dupont NEN (Boston, MA).  
L-Aspartate, L-β-threo-hydroxy-aspartate (L-β-THA), and D,L-threo-methyl-
aspartate were obtained from Sigma (St. Louis, MO).  D,L-β-threo-Benzyloxy-
aspartate was obtained from Tocris (Ballwin, MO).  L-trans-2,3-Pyrrolidine 
dicarboxylate (L-trans-2,3-PDC) was prepared as described (Humphrey et al., 
1994).  The cis-3-methyl-L-trans-2,3-PDC (cis-3-Me-L-trans-2,3-PDC) was 
prepared in a similar manner by A.R. Chamberlin via methylation of the β-enolate 
of protected 2,3-PDC, giving a 2:1 mixture of diastereomers from which the 
desired major isomer was isolated, deprotected, and purified.  The synthesis of 
L-β-benzyl-aspartate was performed by Terri Mavencamp under the mentorship 
of Dr. Esslinger.  The following pharmacological comparisons are included 
because they provide a basis for interpreting structure activity relationship (SAR) 
data.  This analysis is crucial to both the full evaluation of L-β-BA as well as to 
the design of a second round of L-β-benzyl aspartate derivatives. The synthesis 
of L-β-BA begins with L-aspartic acid and utilizes methodology similar to that 
previously reported (Humphrey et al., 1994).  Protection as dimethyl ester using 
thionyl chloride in methanol, followed by N-tritylation with trityl chloride and 
triethylamine afforded the protected aspartate derivative.  Base promoted 
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alkylation at the beta carbon afforded a ca. 2:1 ratio of diastereomers as 
distinguished by 1HNMR and correlated to a similar compound previously 
reported (Humphrey et al., 1994).  Deprotection using refluxing 6N HCl followed 
by ion exchange chromatography afforded the target compound L-β-benzyl 
aspartate (L-β-BA) as the mixture of diastereomers and aspartate free, as 
determined by 1HNMR analysis.  Optical activity of the mixture ([α]=+29.8o) 
suggests the alpha carbon stereochemical integrity remained intact.  Separation 
of the two diastereomers by preparative HPLC using a C18 column in 0.1M 
ammonium acetate buffer pH 6.4 afforded the individual threo and erythro 
diastereomers.  Full experimental details for these syntheses are reported in 
Mavencamp et al., 2008. All other chemicals were purchased from Sigma (St. 
Louis, MO).   
 
2.2. EAAT Expression and Cell Culture  
EAAT1, and EAAT3 cDNA were PCR amplified from pBlueScript-hEAAT1 
and pBlueScript-hEAAT3 (provided by Dr. M Kavanaugh) using primer pairs 
(forward; 5’ATAAGGATCCA-TGACTAAAAGCAACGGA3’ and reverse 
5’TATTGATAT-CCTACATCTTGGTTTCACT3’) and (forward: 
5’ATAAGGATCCATGGGGAAACCGGCGAGG3’ and reverse 
5’TATTGATATCCTAGAACTGTGAGGTCTG3’) respectively. Each primer pair 
introduced BamHI sites at the 5’ ends and EcoRV sites at the 3’ ends of each 
amplified fragment. The PCR fragments were then subcloned into the BamHI and 
EcoRV sites within the polylinker of the AAV vector pAM-CAG-WPRE (kindly 
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provided by Dr. Mathew During, University of Auckland, NZ) to create pAM-CAG-
EAAT1-WPRE and pAM-CAG-EAAT3-WPRE. Final clones were confirmed by 
double stranded sequencing. A 1.9kb EcoRI fragment containing the hEAAT2 
cDNA clone was subcloned from pBlueScript-hEAAT2 (Dr. M Kavanaugh) into 
the EcoRI site of pAM-CAG-WPRE by standard molecular biology techniques to 
create pAM-CAG-EAAT2-WPRE. 
C17.2 cells (obtained from Dr. Evan Snyder, Burnham Inst., La Jolla, CA) 
between passages 10-20 were seeded at 1 X 105 cells/well in 12 well plates and 
grown in complete DMEM supplemented with 10% fetal bovine serum, 1mM 
sodium pyruvate, 0.1 mM nonessential amino acids solution, and 0.05% 
Penicillin-Streptomycin (5,000 units/ml) and Gentamicin sulfate (0.05mg/ml).  At 
24 hours after plating, cells were transfected using Lipofectamine 2000 
Transfection Reagent (Invitrogen, Carlsbad, CA) in a ratio of 4µl of Lipofectamine 
to 3µg of purified plasmid DNA in accordance with manufacturers instructions. 
After 24 hours, the relative levels of functional 3H-D-Asp uptake were determined 
by the method of Martin and Shain (1979 as described below). 
 
2.3. Transporter Activity in C17 Cells 
C17.2 cell assays were performed by the Bridges lab.  Transfected C17.2 
cells were grown in DMEM containing 10% FCS in a humid atmosphere of 5% 
CO2. Near-confluent cells (plated at 7x10
4 -1x105 cells/well) were rinsed with a 
physiological buffer (138 mM NaCl, 11 mM D-glucose, 5.3 mM KCl, 0.4 mM 
KH2PO4, 0.3 mM Na2HPO4, 1.1 mM CaCl2, 0.7 mM MgSO4, 10 mM HEPES, pH 
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7.4) and allowed to preincubate at 37oC for 5 min.  Uptake was initiated by 
replacing the pre-incubation buffer with buffer containing 3H-D-aspartate (5-100 
µM) and inhibitors (10-100 µM).  Following a 5 min incubation, the media was 
removed by rapid suction and the cells rinsed 3 times with ice-cold buffer.  The 
cells were dissolved in 0.4N NaOH for 24 hours and analyzed for radioactivity by 
LSC and protein by the BCA (Pierce) method. Transport rates were corrected for 
background: i.e., radiolabel accumulation at 4oC. Initial studies confirmed that 
uptake quantified in this manner was linear with time and protein levels and that 
uptake in untransfected C17.2 cells was indistinguishable from background.  
Kinetic analyses of the transport inhibitors were carried out using k•cat kinetic 
computational software (BioMetallics Inc.) to generate Lineweaver-Burk plots 
with curve-fit weighting based on constant relative error.  Ki values were also 
determined using this software on the basis of a replot of Km,app values. 
 
2.4. Transporter Activity in Xenopus Oocytes 
Capped cRNA was transcribed from the human brain glutamate 
transporter EAAT1-3 cDNAs as described (Arriza at al., 1994). Transcripts were 
microinjected into Xenopus oocytes (50 ng per oocyte) and membrane currents 
were recorded by the Kavanaugh lab 3-6 days later. Ringer recording solution 
contained 96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, and 5 mM 
HEPES (pH 7.4). Two microelectrode voltage-clamp recordings were performed 
at 22°C with an Axon Instruments GeneClamp 500 amplifier interfaced to a PC 
using a Digidata 1200 converter controlled using the pCLAMP program suite 
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(version 6.0; Axon Instruments). Microelectrodes were filled with 3 M KCl solution 
and had resistances of 0.5 to 2 Mohm. Steady state data were sampled at 1 kHz 
and low pass filtered at 500 Hz. Data were fitted by least squares using 
Kaleidagraph v3.0 (Synergy Software) to the Michaelis-Menten function. L-β-BA 
was applied 10-30 sec before glutamate for competition experiments; recovery 
from block was complete within 1 min following inhibitor washout. 
 
2.5. Molecular Modeling 
Computational work was performed by Shailesh Agarwal of the Bridges 
lab on Silicon Graphics, Inc. (SGI) Octane workstations with R12,000 processors 
coupled to an SGI Origin 2000 server.  The software application suite Sybyl 
(versions 6.8-7.0), with the Advanced Computation module (Tripos; St. Louis, 
MO), was used adjunct with the industrially derived stochastic random search 
algorithm AESOP (Masek, 1998).  Molecular databases were prepared in Sybyl 
formats. Data extracted from the molecular spreadsheets were occasionally 
exported for sorting and other manipulations in PERL and C code formats that 
were subsequently automated. Inspections of conformations and multifit 
superpositions were performed in Sybyl stereoview with CrystalEyes viewers.  
The pharmacophore models were constructed as steric-strain, gas-phase 
derived conformation compositions employing established comprehensive 
conformational analysis methods (Marshall, 1995; Oprea et al., 1995) with four 
EAAT2 inhibitor training set ligands, i.e. L-anti-endo-3,4-methanopyrrolidine-3,4-
dicarboxylate (L-anti-endo-3,4-MPDC), cis-5-methyl-L-trans-2,3-pyrrolidine 
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dicarboxylate (cis-5-Me-L-2,3-trans-PDC), (2S,3R,4S)-2-(carboxy-
cyclopropyl)glycine (CCG-IV) , and L-β-threo-benzyloxy-aspartate (L-TBOA) (for 
comparative pharmacological properties see Bridges et al., 1999; Bridges and 
Esslinger, 2005). The important EAAT2 inhibitor classes were carefully 
considered for inclusion in the training set and those selected satisfied the major 
criteria of high potency, structural diversity amongst common moieties, and 
relatively high selectivity, as well as little or no substrate activity.  
Conformational space of the EAAT inhibitors was comprehensively 
searched employing two computational protocols: random search (Tripos Sybyl) 
and the stochastic technique AESOP (Masek, 1998) (See Figure 1).  The random 
search procedure locates energy minima by randomly adjusting the selected 
bonds and minimizing the energy of the resulting geometry. Chiral centers, ring 
closure distances, and energy ranges were checked for consistency. This 
comparison was based on an RMS match between non-hydrogen atoms in the 
previously found conformers and the current conformer.  Three random searches 
(or more) were performed on each training set ligand and other test cases.  Data 
from the Sybyl random searches were deposited into a molecular database.  
AESOP is an alternative stochastic derived program used to search 
conformational space.  It applies high temperature to the molecule (which results 
in molecule being torqued and tensed), and was set to capture a conformer 
snapshot every 5 femtoseconds.  Temperatures and times were set between 
1600-1800 0K and 60-80K femtoseconds. Data from the AESOP spreadsheets 
was deposited into the databases established earlier. Subsequently, all 
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conformers from both search protocols were minimized to zero energy change 
defining their nearest energy well profile.  Conformer database entries were 
sorted as a function of conformer total energy and cases of degenerate energy 
profiles were crosschecked as plausible duplicates, based on select distances 
and angles defined in an exported Molfile spreadsheet.  Duplicate or nearly 
identical conformers (e.g., some non-essential rotamers for TBOA) were 
eliminated. Some conformations would not have been found if only one 
conformer search routine had been used. 
Four final training set ligand conformational molecular databases were 
derived. An extended closed form analysis method, which used the 
conformational data, was developed to select one conformer of each of the four 
ligands to form the 3D superposition models.  To compare one conformation of 
one ligand to all conformations of each of the remaining three training set 
ligands, an all-combination comparison regime was used by forming 
conformational comparison groups (shown as double headed arrows in Fig. 1).  
For each comparison group, six distinct measures were assessed between each 
ligand conformer, thus permitting an assessment of molecular similarity.  These 
six measures included the three distances and angles between the α-carboxylate 
carbon, C1; α-amino nitrogen, N and distal carboxylate carbon, C2 common to 
each training set ligand (see Figure 4).  Additional molecular spreadsheets were 
also constructed in which i) the ether oxygen of L-TBOA and ii) the cyclopropyl 
centroid of L-CCG-IV were substituted for point C2  to consider alterative relative 
alignments. 
39 
 
The resulting 3.4 X 106 conformational comparison groups were analyzed 
for 3D molecular similarity using a relative difference scoring function (Figure 1), 
defined as a sum of the average of the four conformations (as per the all-
combination regime and denoted as nconformers) using absolute value relative 
difference measurements (nmeasures).  Averaging precluded the use of weighting 
factors.  The relative difference comparison measures between the conformers in 
a group (double headed arrows, Figure 1) included three distance and three 
angle values. The six conformer-to-conformer measurements were extracted 
from the molecular database spreadsheets and the calculations of the scoring 
function values were made. Conformer energies were not used in these 
calculations, thus making the scoring function energy independent. The 
comparison group that had a low scoring function value (least amount of 
differences amongst the six variable conformer measures in 3D space) was 
identified. Thus, the lower the score the more similar the conformers are to one 
another, representing molecular similarity of their space groupings.  The selected 
ligand conformer set was brought together with a 1 cal spring constant, and the 
superposition models were appraised in stereoview using CrystalEyes viewers. 
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>2 Sybyl random searches
2000 iterations
>2 AESOP stochastic search
60-80 K fsec, 1600-1800? K
Conformers: merged, duplicates eliminated, zero energy change
Conformer spreadsheet databases established for each ligand
Selected final conformer of each of the four ligands
1 cal spring constant multi-fit superposition
Compare each comformer of 4 ligand data sets to each other 
within comparsion groups. Measurements were assessed
using the summed relative difference Equation 1 to generate
a scoring function for each comparison of the alignment
scenario under study. Four alignment scenarios tested.
Plot Eqn 1 scoring function values  for each comparison group 
and select low scoring conformer set = similar points in 3D space
Superposition
pharmacohore 
models
Training set ligands: MPDC, PDC, CCG-IV, and TBOA
Repeat process for other 
ligand alignments
Σ
Σ     |Vx - Vy|____
i=1 (|Vx | + |Vy |) / 2
nvar
nvar
nconfs
i=1
nconfsMPDC
CCG-IV TBOA
Eqn 1
Eqn 1: V are 6 variable measures ( 3 distances and 3 angles) as 
compared for ligand x vs. ligand y; nvar = 6 (measures); nconfs = 6 as per 
comparison group regime (double headed arrows).
6
6
6
6
6
6
PDC
MPDC PDC CCG-IV TBOA
Conformer
Number
Energy Range
Kcal/mol
100 107 151 208
107.16-
157.48
10.00-
91.62
103.59-
109.67
1.64-
>500
 
 
 
Figure 1.  Computational paradigm used to generate the EAAT2 pharmacophore 
model. 
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3. RESULTS 
 
3.1. L-threo-Benzyl-aspartate preferentially inhibit the EAAT3 transporter 
subtype 
To delineate the pharmacological specificity of the individual EAATs, the 
Bridges lab utilized a relatively new expression system that employed C17.2 
neuroprogenitor cells and a vector adapted from an Adeno-associated virus 
(AAV) packaging plasmid (Stone et al., 2005).  The vector contains a number of 
elements that facilitate the expression of the EAATs, including a ubiquitous CAG 
promoter and a 567 bp woodchuck hepatitis regulatory element (WPRE) that 
stimulates the expression of intronless viral messages.  We and other have 
observed that the insertion of the WPRE sequence between the stop codon and 
the poly-A sequence results in a substantial increase in stable transgene 
expression (Loeb et al., 1999; Paterna et al., 2000).  This system proved to be 
both easy and efficient (approximately 50% transfection), as C17.2 cells 
transfected 24 hrs after plating with the desired EAAT vector exhibited robust and 
reproducible levels of activity 48 hrs later.  When uptake was quantified with 3H-
D-aspartate in untransfected cells, the levels of uptake were indistinguishable 
from background determined either at 4oC or in the absence of sodium (see 
Methods, data not shown).  In cells expressing the individual subtypes the 
transport of 3H-D-aspartate exhibited KM and VMax values (mean ± SEM), 
respectively, of:  40 ± 4 µM (n ≥ 5) and 501 ± 72 pmol/min/mg protein (n ≥ 5) for 
EAAT1, 44 ± 3 µM (n ≥ 5) and 1997 ± 270 pmol/min/mg protein (n ≥ 5) for 
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EAAT2, and 19 ± 3 µM (n ≥ 5) and 334 ± 52 pmol/min/mg protein (n ≥ 5) for 
EAAT3. 
 A series of β-substituted aspartate analogues, that included L-benzyl-
aspartate (L-BA), were screened at 10 µM and 100µM for the ability to inhibit the 
uptake of 3H-D-aspartate (25 µM) into C17.2 cells expressing EAAT1, EAAT2 or 
EAAT3.  The data are reported in Table 1 as the mean % of Control (± SEM) 
measured in the absence of inhibitors.  Several of these compounds are well 
known blockers of the EAATs, (e.g., β-THA, TBOA), and were included in the 
present study so that structure activity comparisons would be based on assay 
data collected under identical conditions.  Consistent with previous reports 
(summarized in Bridges et al., 1999) the introduction of a hydroxyl group at the β-
carbon of L-aspartate (β-THA) produced a small increase in inhibitory activity 
when compared to L-aspartate (more easily observed at 10 µM).  While the L-
enantiomer of THA was used in the present study, earlier work quantifying 3H-L-
glutamate uptake into synaptosomes reported that the L- and D enantiomers of 
THA were approximately equipotent as inhibitors (Robinson et al., 1993).  A 
similarly placed methyl group (D,L-β-threo-methyl-aspartate), also produced a 
level of inhibition essentially equivalent to its unsubstituted counterpart.  
Significantly, all three of these compounds produced comparable levels of 
inhibition at each of the three EAAT subtypes. 
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Compound Conc. EAAT1 
3
H-D-Asp Uptake 
(% of Control) 
EAAT2 
3
H-D-Asp Uptake 
(% of Control) 
EAAT3 
3
H-D-Asp 
Uptake 
(% of Control) 
L-Aspartate 
 
100 µM 
10 µM 
4 ± 2 (3) 
70 ± 9 (3) 
16 ± 4 (3) 
82 ± 4 (3)  
15 ± 3 (3) 
87 ± 11 (3) 
D,L-β-threo-CH3-
Asp 
HOOC
COOH
NH2
CH3  
100 µM 
10 µM 
33 ± 4 (3) 
6 5 ± 13 (3)  
32 ± 3 (3)  
76 ± 4 (3) 
42 ± 2 (3)  
74 ± 51 (3) 
L-β-threo-OH-
Asp 
 
100 µM 
10 µM 
5 ± 3 (3) 
47 ± y (3)  
10 ± 3 (3)  
53 ± 4 (3) 
9 ± 3 (3)  
61 ± 7 (3) 
L-trans-2,3-PDC 
 
100 µM 
10 µM 
102 ± 9 (3) 
 
81 ± 5 (3) 89 ± 11 (3) 
cis-3-CH3-L-
trans-2,3-PDC 
 
100 µM 
10 µM 
51 ± 2 (3)  
71 ± 5 (3) 
12 ± 5 (3)  
44 ± 3 (3) 
15 ± 2 (3)  
63 ± 3 (3) 
D,L-β-threo-BOA 
 
100 µM 
10 µM 
5 ± 2 (3)  
50 ± 4 (3) 
2 ± 1 (3) 
30 ± 2 (3) 
9 ± 3 (3) 
53 ± 5 (3) 
L-β-Benzyl-Asp 
 
100 µM 
25 µM 
10 µM 
20 ± 4 (3)  
50 ± 9 (3) 
63 ± 9 (3) 
15 ± 3 (3)  
39 ± 5 (3) 
70 ± 1 (3) 
4 ± 2 (3)  
20 ± 4 (3) 
46 ± 3 (3) 
L-β-threo-BA 
 
100 µM 
10 µM 
8 ± 1 (3)  
50 ± 3 (3) 
9 ± 1 (3)  
53 ± 2 (3) 
1 ± 1 (3)  
30 ± 4 (3) 
L-β-erythro-BA 
 
100 µM 
10 µM 
59 ± 4 (3)  
7 9 ± 3 (3) 
48 ± 2 (3)  
90 ± 5 (3) 
14 ± 2 (3)  
66 ± 8 (3) 
             TABLE 1. Inhibitory activity of β-substituted aspartate analogues at EAAT1, 
EAAT2 and EAAT3. 
HOOC
COOH
NH2
HOOC
COOH
NH2
OH
N
H
COOH
COOH
N
H
COOH
COOH
H3C
HOOC
COOH
NH2
O
HOOC
COOH
NH2
HOOC
COOH
NH2
HOOC
COOH
NH2
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Embedding L-aspartate into a 5-membered pyrrolidine ring (L-trans-2,3-
PDC) produced a substantial decrease in the inhibitory activity exhibited at each 
of the EAATs.  This is in marked contrast to the analogous modification to L-
glutamate, where L-trans-2,4-PDC proved to be a potent inhibitor of each 
subtype, especially EAAT2 (Bridges et al., 1991; Arriza et al., 1994).  
Interestingly, however, when a methyl group is introduced at the β-carbon 
equivalent of L-trans-2,3-PDC (i.e., carbon 3), there is a substantial increase in 
potency as an inhibitor of 3H-D-aspartate uptake.  Further, it appears as if cis-3-
Me-L-trans-2,3-PDC, like almost all of the pyrrolidine dicarboxylate-based 
analogues, preferentially blocks uptake through EAAT2 (Bridges and Esslinger, 
2005).  A similar pharmacological profile is exhibited by D,L-TBOA, one of the 
more potent EAAT blockers identified to date (Shimamoto et al., 2000). 
L-β-BA stands apart from all of the other aspartate analogues tested in 
that it more potently inhibited uptake mediated by EAAT3 than either EAAT1 or 
EAAT2.  As reported in Table 1, this effect could be seen at each of the 
concentrations examined.  Thus, in the presence of 25 µM L-β-BA EAAT3 activity 
(≈ 20% of Control) was about half that observed with EAAT1 (≈ 40% of Control) 
or EAAT2 (≈ 50% of Control).  L-β-BA produced similar levels of inhibition at both 
EAAT1 and EAAT2 and in each case, it was less than that observed with D,L-
TBOA.  On the other hand, L-β-BA and D,L-TBOA exhibited comparable levels of 
inhibition at EAAT3.  Direct comparisons of potency, however, must be made 
cautiously, as L-β-BA was included in this assay as a mixture of its threo and 
erythro diaseteromers (i.e., 2:1, respectively), while D,L-TBOA was a mixture of 
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its L and D enantiomers (1:1, respectively).  Prompted by its preferential action at 
EAAT3, the diastereomers of L-β-BA were separated and tested individually. 
Similar to the trend observed with THA and TBOA (Shimamoto et al., 2000), the 
majority of the inhibitory activity resided with the threo diastereomer (Table 1). 
 To calculate Ki values, as well as to verify that L-β-threo-BA acts as a 
competitive inhibitor, more detailed kinetic studies examined the concentration 
dependence with which the analogue inhibited the uptake of 3H-D-aspartate into 
C17.2 cells expressing each of the three EAAT subtypes.  As illustrated in the 
Lineweaver-Burk plots depicted in Figure 2, L-β-threo-BA blocked uptake of 3H-
D-aspartate mediated by EAAT3 in a manner that was consistent with that of a 
competitive inhibitor.  Similar patterns of inhibition were also observed for EAAT1 
and EAAT2.  The resulting Ki values, reported as mean ± SEM from at least 3 
separate kinetic assays for each transporter were found to be: 8.7 ± 2.6 µM for 
EAAT1, 10.0 ± 2.0 µM for EAAT2 and 0.8 ± 0.2 µM for EAAT3.  These findings 
confirm the results of the initial pharmacological screening and suggest that L-β-
threo-BA is not only one of the more potent inhibitors of EAAT3 identified to date, 
but also one that exhibits approximately a 10-fold preference for the EAAT3 
compared to EAAT1 and EAAT2. 
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Figure 2. Representative Lineweaver-Burk plots of single experiments 
demonstrating L-threo-BA as a competitive inhibitor of 3H-D-aspartate uptake by 
(A) hEAAT1, (B) hEAAT2 and (C) hEAAT3 expressed in C17.2 cells.  Data was 
collected and analyzed as described in Methods and Materials.  The inset within 
each graph shows a replot of KMapp vs L-threo-BA that was used to determine the 
indicated KI value for the depicted experiment.  At least three such experiments 
for each transporter were carried out and averaged to derive the KI, KM and VMax 
values reported in the text. 
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3.2. L-Benzyl-aspartate is a preferential competitive inhibitor of EAAT3 that 
does not exhibit substrate activity at any of the EAATs 
 
 The actions of L-β-BA, cis-3-Me-L-trans-2,3-PDC and L-glutamate at 
human EAAT1, EAAT2 and EAAT3 expressed on X. laevis oocytes were 
examined by the Kavanaugh lab in real time using electrophysiological recording 
techniques.  As the EAAT-mediated co-transport of L-glutamate and its requisite 
ions is electrogenic, substrate-induced currents serve as a direct measure of the 
translocation process (Wadiche et al., 1995).  This provides a distinct advantage 
over radiolabeled flux assays, where inhibitory activity is indicative of binding, but 
does not directly address the issue of whether or not a particular inhibitor also 
acts as an alternative substrate for the transporter.  As illustrated in Figure 3A, 
the application of L-glutamate (100 µM) to a voltage-clamped oocyte expressing 
EAAT3 produced the expected inward current.  When L-glutamate was co-
applied with β-L-BA (2:1 mixture of threo and erythro diastereomers) the 
glutamate-induced currents were inhibited in a concentration-dependent manner.  
Similar curves were produced when cis-3-Me-L-trans-2,3-PDC was co-applied 
with L-glutamate (individual traces not shown).  The application of either β-L-BA 
or 3-Me-L-trans-2,3-PDC alone did not produce a current.  These results are 
consistent with the ability of the analogue to bind to the glutamate substrate site 
but not be transported.  The concentration dependence with which the analogues 
blocked these glutamate-mediated currents was also determined.  The parallel 
shifts observed in the dose-response curves for all of the compounds tested with 
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increasing concentrations of the inhibitors are consistent with competitive 
inhibition (representative traces shown for β-L-BA at EAAT3, Figure 3B). KD 
value were determined using Schild analysis (representative curves for β-L-BA at 
EAAT1-3 are shown in Figure 3C). As was observed with the radiolabel flux 
assays, 3-Me-L-trans-2,3-PDC exhibited the highest affinity for EAAT2, yielding 
KD values at EAAT1, EAAT2 and EAAT3 of 31 µM, 1 µM, and 7 µM, respectively.  
Schild analysis of β-L-BA, on the other hand, yielded KD values at EAAT1, 
EAAT2 and EAAT3 of 12 µM, 9 µM, and 2 µM, once again demonstrating the 
preferential action of β-L-BA at EAAT3.  
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Figure 3. (A) Inhibition of hEAAT3 transport by L-β-BA in a representative oocyte 
voltage-clamped at –30 mV (glutamate and inhibitor applied for the durations 
indicated by corresponding bars above traces). (B)  Parallel glutamate dose-
response shift with increasing [3-benzylaspartate] is consistent with competitive 
inhibition. Data points represent mean +/- SEM for 3-5 oocytes. (C) Schild 
analysis of L-β-BA inhibition in analogous competition experiments with EAATs 
1,2, and 3 (slope values constrained to 1) gave ) yielded KD values of 12, 9, and 
2 µM, respectively.  
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3.4. Conformational molecular modeling with L-threo-Benzyl-aspartate 
identifies potential points of divergence between the pharmacophores for 
EAAT2 and EAAT3. 
The molecular modeling was performed by Shailesh Agarwal under the 
guidance of Dr. Bridges and Dr. Gerdes and is described in the Methods section.  
The described regimen led to the identification of four plausible pharmacophore 
models for EAAT2.  While the positions of the two carboxylate carbons and the 
amino nitrogen in L-anti-endo-3,4-MPDC and cis-5-Me-L-trans-2,3-PDC were 
remarkably aligned in all four models, each differed with respect to the 
positioning of these same groups in CCG-IV and L-TBOA.  The model shown in 
Figure 4 was selected from among the four because it afforded the best 
alignments of both carboxylate groups, the amino moieties, and the carbon 
backbone.  The other models, which were based upon the superpositioning of i) 
the ether-O of L-TBOA at the C2 carboxylate position, ii) the centroid of the 
cyclopropyl ring of L-CCG-IV at the C2 carboxylate position, or iii) both, were 
discounted because they resulted in an inappropriate positioning of the carbon 
backbone and/or relevant side chains.  For example, when the centroid of the 
cyclopropyl ring of L-CCG-IV was superpositioned on the C2 carboxylate 
position, the carbon backbone markedly deviated outside the bounds defined by 
the other analogues.  The model that was selected as the most plausible EAAT2 
pharmacophore (and used to evaluate the selectivity of L-β-threo-BA, see 
Discussion) is shown in Figure 4, with critical distances and angles between the 
various functional groups listed in an inset.  The model conformer energy profiles 
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were: L-anti-endo-3,4-MPDC, 107.16 -157.48 Kcal/mol; cis-5-Me-L-trans-2,3-
PDC, 10.00-91.62 Kcal/mol; CCG-IV, 103.59-109.67 Kcal/mol and L-TBOA, 1.64-
>500 Kcal/mol. The almost identical positioning of the two carboxylate Cs among 
the inhibitors suggests a very regimented interaction (i.e., electrostatic) between 
these groups and corresponding residues in the binding.  Another notable feature 
of this pharmacophore is the planar arrangement of the α-C, β-C, amino-N and 
distal carboxylate-C atoms (i.e., x-y plane of the graphical representation shown 
in Figure 4).  The positioning of the cyclopropyl ring of CCG-IV and L-anti-endo-
3,4-MPDC, as well as the inhibitory activity observed when this ring is replaced 
with a cyclohexenyl group (see analogues in (Denton et al., 2002)), suggest a 
unique role for possible Π bond-like interactions with the protein.  Lastly, the area 
delineated by the phenyl ring highlights regions facilitating lipophilic interactions 
between the analogues and transporter binding site. 
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 Distance (A) 
N-C1 2.52 ± 0.16 
N-C2 3.38 ± 0.24 
C1-C2 3.42 ± 0.23 
 Angle 
N-C1-C2 66.02 ± 0.41 
N-C2-C1 43.01 ± 1.32 
C1-N-C2 70.97 ± 1.28 
 
 
 
55 
 
Fig 4. EAAT2 Binding-Site Pharmacophore Model.  Views (A) and (B) of the 
superpositioned (1cal spring constant), color-coded four training-set ligands that 
highlight the spatial placements of the amino nitrogen (N), α-carboxyl carbon 
(C1) and the distal carboxyl carbon (C2), along with other key structural features. 
A graphical representation depicting the averaged position of these structural 
features is also shown, with the averaged specific angle and distance 
measurements reported in the inset. 
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4. DISCUSSION 
The ability to pharmacologically manipulate EAAT activity, and thereby 
assess its potential contribution to given processes, such as shaping an 
excitatory post synaptic signal or affording excitotoxic protection, is dependent 
upon the development of potent and selective inhibitors.  Indeed, transport 
inhibitors such as L-trans-2,4-PDC and TBOA have been used to differentiate 
those synaptic connections in which EAATs likely contribute to signal shaping or 
termination (e.g., excitatory inputs on cerebellar Purkinje neurons) from those 
where uptake may not play such a role (e.g., excitatory signaling in CA1 
hippocampal pyramidal neurons) (Isaacson and Nicoll, 1993; Sarantis et al., 
1993; Barbour et al., 1994; Wadiche and Jahr, 2001).  These or similar inhibitors 
have also been employed to demonstrate that compromised EAAT activity 
increases the likelihood and/or extent of excitotoxic damage (Robinson et al., 
1993; Rothstein et al., 1993).  Significantly, the compounds presently available 
for such applications have been limited to those that non-selectively block all of 
the EAATs or those that exhibit a substantial preference for EAAT2, thus leaving 
in question the specific contributions of EAAT1 and EAAT3.  In the present work 
we identify L-β-BA as one of the first EAA analogues that inhibits EAAT3 activity 
more potently than it does EAAT1 or EAAT2.  This effect was observed with 
EAATs expressed in two different cells systems, Xenopus oocytes and C17.2 
neuroprogenitor cells, where, in each case, its mechanism of inhibition was 
confirmed as competitive.  Consistent with the actions of the other β-substituted 
aspartate-based inhibitors, the threo configuration proved to be the more potent 
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diastereomer, exhibiting a sub-micromolar Ki at EAAT3 representative of about a 
10-fold preference for the subtype.  L-β-BA did not induce currents in oocytes 
expressing EAAT3 (or any of the EAATs), though it did block glutamate-mediated 
currents, further delineating its action as a non-substrate inhibitor.  
The actions of L-β-BA are similar to those of TBOA in several respects.  
Significantly, each is a relatively effective inhibitor of all three EAAT subtypes, yet 
L-β-BA exhibits a preferential activity at EAAT3, while reports of TBOA activity 
have typically reported a preference for EAAT2 (Shimamoto et al., 2004).  While 
the observed 10-fold preference of L-β-threo-BA for EAAT3 is not sizeable 
enough to be classified as an EAAT3-specific inhibitor, its action raises 
interesting questions regarding what properties it has in common with other 
inhibitors of EAATs1-3 and what might be the basis for increased activity at 
EAAT3.  Phrased another way, can L-β-BA and TBOA provide any insight into 
where the pharmacophores (and consequently the structural domains of the 
transporters) for EAAT2 and EAAT3 diverge?  Given the lack of EAAT3-
preferring ligands compared to those selective for EAAT2 and our previous SAR-
modeling studies of EAAT2, we have begun to examine these issues by 
analyzing L-β-BA within the context of an EAAT2 pharmacophore model. 
The EAAT2 pharmacophore model was constructed (see Methods for 
details) using four potent competitive non-substrate EAAT2 inhibitors that were 
as structurally diverse as possible.  As shown in Figures 4 and 5, the nearly 
equivalent superposition of the three selected electrostatic bearing moieties (the 
two carboxyl groups and the amine moiety) of the training set ligands (as well as 
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in L-β-threo-BA) in 3D space suggests that these regions may define a critical 
ligand triad that serves as an initial recognition group plane.  Thus, the 
electrostatic triad might initially interact with a limited collection of complimentary 
residues located at the EAAT protein binding site, most likely in combination with 
select ions.  Additionally, other structural properties beyond this electrostatic 
configuration may serve to influence more subtle pharmacological properties, 
such as substrate versus non-substrate activity, potency, and EAAT subtype 
selectivity.  In this respect, three additional regions exclusive of the carboxyl and 
amino functionalities are found within distinctive regions of 3D model space.  The 
region occupied by introduction of a hydroxyl group (L-β-THA), methyl group (cis-
3-Me-L-trans-2,3-PDC) or most prominently the extended arm of a benzyloxy 
group (TBOA) at the β-carbon of aspartate suggests the presence of a lipophilic 
pocket, consistent with our earlier work (Esslinger et al., 2002), or a related 
region of lipophilic protein contacts near the initial recognition binding site 
residues.  The sheer size of aromatic rings that appears to be tolerated at the 
binding site (i.e., see the recently described series of TBOA analogs in 
Shimamoto et al., 2004) support the notion of regional protein contacts (e.g., 
along various transmembrane residues) rather than a distinctive lipophilic pocket.  
Some of these same residues may also interact with a methyl group of cis-4-
methyl-L-trans-2,4-PDC.  Interestingly, the addition of the methyl moiety to L-
trans-2,4-PDC has little effect on potency, but converts this substrate into a non-
substrate inhibitor of EAAT2 (Esslinger et al., 2002).  Taken together with the 
activity of TBOA, this suggests that interaction with these domains may 
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determine whether or not a bound ligand can be translocated.  The orientation of 
this lipophilic domain relative to the carboxyl-carboxyl-amine group triad may 
occur in two ways, as suggested by the L-BOA erythro and threo stereoisomer, 
(see Figure 5B).  Since the threo form exhibits greater potency, it is thought that 
the benzyl group projected within this model orientation (Figures 4 and 5) 
presents a ligand motif that is more favorable for complimentary interaction with 
residues at the binding site.  Another feature of L-TBOA that may come into play 
is the arm linking the phenyl group to the aspartate backbone.  Thus, the regio- 
and stereochemical placement of the ether oxygen of L-TBOA is suggestive of 
possible H-bonding at the binding site, potentially conferring enhanced ligand 
potency and/or influencing L-TBOA selectivity.  The close 3D proximity of the two 
cyclopropyl rings of MPDC and CCG-IV are suggestive of a Π-bond like 
character to the region shown in Figure 4B that may also influence binding.  
Consistent with this proposition, the cyclohexenyl-based inhibitor structurally 
similar to the CCG class of compounds also shows increased selectivity for 
EAAT-2 (Denton et al., 2002).  Lastly, the unique regio- and stereochemical 
placement of the methyl group of cis-5-Me-L-trans-2,3-PDC, away from the 
benzyl extension of L-TBOA (or L-β-BA), points to the possibility of an additional 
region where modest lipophilic groups are tolerated.  It remains less clear 
whether this area is a distinct lipophilic pocket associated with the EAAT protein 
(s). 
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Fig 5. Assessment of conformations and activities of L-β-threo-BOA, L-β-erythro-
BOA, L-β-threo-BA and L-β-erythro-BA against the EAAT2 binding-site 
pharmacophore.  The pharmacophore model is shown in (A) without either TBOA 
or L-β-BA.  In (B) the superposition (1cal spring constant) of L-β-threo- and L-β-
erythro-BOA with the model illustrating the better fit of aspartyl backbone of the 
threo diastereomer with other aligned molecules, in addition to the distinct 
placements of the ether ‘O’ and the benzyl group that might influence the potency 
and selectivity for this inhibitor at EAAT2.  A similar conclusion is reached 
regarding L-β-threo-BA, when the two diastereomers of the L-β-BA are compared 
(C).  The superposition of L-β-threo-BOA and L-β-threo-BA with the model (D) 
suggesting that possible points of divergence between the EAAT2 and EAAT3 
pharmacophores may include subtle differences in the size, location and/or 
orientation of the aromatic ring or in the oxygen atom present in the linking group 
of L-β-threo-BOA, but not L-β-threo-BA. 
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Similar analyses for the novel L-β-BA analogue (Figure 5), leads to the 
conclusion that the benzyl group of the more potent threo diastereomer is 
locating to similar regions as its L-TBOA conformer counterpart.  This suggests 
that like EAAT2, EAAT3 proteins may accommodate these lipophilic groups to 
various extents, providing ligand-protein residue contacts lending to their 
respective potency profiles.  The subtype selectivity, however, indicates that 
there are differences between the ways in which L-β-threo-BA and L-TBOA bind 
more favorably to EAAT3 and EAAT2, respectively.  One underlying factor may 
reside in subtle difference in the size, location and/or orientation of the aromatic 
ring with respect to the lipophilic residues on the transporters.  It is also 
interesting to consider that the specificity may be a result of the aromatic ring 
linkage to the aspartyl backbone relative to the protein residues that interact with 
this ligand region.  Thus, the oxygen atom of L-TBOA may be preferentially 
hydrogen bonding with a residue in EAAT2, whereas within EAAT3 there may be 
reduced hydrogen bonding, yet preserved lipophilic contacts.  Conversely, the 
carbon linking atom of the benzyl aspartate ligand is devoid of hydrogen bonding 
opportunity within the EAAT 2 binding domain, yet, may interact favorably with a 
lipophilic side chain residue within EAAT3 binding region.  Hence, selectivity for 
one EAAT relative to another may be driven by both favorable and unfavorable 
ligand-protein residue side chain interactions involving the ligand benzyl group 
linking region.  
Collectively, the superposition model coupled to ligand potency and 
selectivity data results in the following distinctive pharmacophore region map: 1) 
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a discrete three point area (triad) that is comprised of the electrostatic carboxyl 
and amino groups that are conserved in space across substrates and inhibitors 
and may be essential for initial ligand protein recognition, 2) areas nearby this 
electrostatic group triad that can accommodate select structural modification 
(e.g., cyclopropyl ring, methyl groups, and oxygen atoms), and 3) the unique 3D 
region consumed by the pendant benzyl ring moieties of L-TBOA, L-β-threo-BA 
and related analogs.  These first two model regions suggest there exists an 
intimate and highly ordered region of the EAAT protein binding domain that may 
be associated with initial ligand recognition.  Conversely, the area that 
accommodates the pendant benzyl groups is distinct and extended from the 
initial ligand recognition site, and also is more tolerant of steric bulk (e.g., 
additional aromatic rings and functional groups).  It is particularly notable in this 
respect that the recent report of a crystal structure for a eukaryotic glutamate 
transporter homologue may now set the stage for the potential integration of 
emerging structural models of the EAATs (Yernool et al., 2004; Kanner and 
Borre, 2002) with proposed pharmacophore models.  From a functional 
perspective, the benzyl appended ligands may lend to greater lipophilic ligand-
protein contacts thereby enhancing potency, but at a loss in the ability of the 
transporter to translocate the compound.  Based on the comparison of these 
model details relative to the profiles described for the ligands in Table 1, it 
appears that respective preferential action of L-β-threo-BA and L-TBOA at 
EAAT3 and EAAT2, likely resides in the latter two distinctive pharmacophore 
regions, and in particular, a function of atom type (oxygen or carbon) extending 
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from the β-aspartyl backbone position.  All of these SAR details are valuable for 
the subsequent design of more refined EAAT inhibitor ligands.  Since the 
stereochemically defined pendant aromatic region is a more tolerant one, it is this 
area of the pharmacophore model that we are currently exploring to develop 
additional inhibitors to differentiate among the EAAT subtypes. 
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Chapter 3. 
Synthesis and preliminary pharmacological evaluation of novel derivatives 
of L-β-threo-benzylaspartate as inhibitors of the neuronal glutamate 
transporter EAAT-3. 
 
Terri L. Mavencamp, Joseph F. Rhoderick, Richard J. Bridges, C.Sean 
Esslinger  
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Abstract 
A series of β-benzylaspartate derivatives were prepared from N-trityl-L-aspartate 
dimethyl ester and evaluated as inhibitors of neuronal glutamate transporter 
EAAT3.  The result of the structure-activity studies suggest that the position 
occupied by the aromatic ring of β-benzylaspartate within the binding site of 
EAAT3 may be different from that occupied by comparable groups in previously 
identified inhibitors, such as L-threo-benzyloxy aspartate (TBOA).  Further, 
halogen substitutions at the 3-postition of the aromatic ring of β-benzylaspartate 
can increase the potency with which the analogues inhibit EAAT3.   
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1. Introduction 
L-Glutamate is the most abundant excitatory neurotransmitter in the 
mammalian CNS and, as such, contributes to neuronal signaling and cognitive 
function through its activation of a wide variety of ionotropic and metabotropic 
excitatory amino acid (EAA) receptors (Balazs, R., Bridges, R. J. and Cotman, 
2006).  If extracellular glutamate concentrations in the CNS become excessive, it 
can lead to the over-activation of EAA receptors and the triggering of numerous 
neuropathological pathways (Balazs, R., Bridges, R. J. and Cotman, 2006; Hynd 
et al., 2004; Foster and Kemp, 2006).  Termed excitotoxicity, glutamate-mediated 
neuronal injury is believed to contribute to CNS pathology in acute insults 
(ischemia, traumatic injury), as well as chronic neurological disorders (e.g., ALS, 
Alzheimer's disease, epilepsy, and Huntington's disease).  Excitatory amino acid 
transporters (EAATs) present on neurons and glia play a critical role in regulating 
extracellular levels of glutamate and are thereby positioned to influence: i) the 
access of neurotransmitter to synaptic and extrasynaptic EAA receptors, ii) the 
recycling of the neurotransmitter and iii) the accumulation of excitotoxic levels of 
glutamate (Danbolt, 2001; Bridges and Esslinger, 2005).  The expression of 
EAATs has also been found to be altered in neurological disorders such as 
epilepsy, ischemia, spinal cord injury, amyotrophic lateral sclerosis (ALS), 
Alzheimer’s and schizophrenia (Beart and O’Shea, 2007).  Much of our 
understanding of the function of the EAATs has been dependent upon the 
development of substrates and inhibitors with which to probe transporter function 
and the physiological consequences of decreased activity.  
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Five distinct glutamate transporters (EAATs 1-5) have been identified by 
molecular cloning that, along with the sodium-dependent neutral amino acid 
transporters ASCT1-2, comprise a novel gene family (i.e., SLC1 in the Human 
Genome Organization HUGO nomenclature) (Hediger et al., 2004).  Uptake 
through the EAATs occurs via an alternate access mechanism that is 
electrogenic and driven by ionic gradients across the cell membrane.  In this 
manner, the transport of one molecule of glutamate into a cell is 
stoichiometrically coupled to the import of three Na+ ions and one H+, and to the 
counter transport of one K+ (Zerangue and Kavanaugh, 1996).  While the EAATs 
share a similar mechanisms and ionic dependence, each exhibits a distinct 
localization (Danbolt, 2001).  EAAT1 and EAAT2 are primarily considered to be 
glial transporters that exhibit a preferential distribution in the cerebellum and 
forebrain, respectively.  In contrast EAAT3 is present on neurons and is enriched 
in forebrain areas.  EAAT4 is localized to purkinje neurons in the cerebellum and 
EAAT5 is restricted to the retina.  To a large degree the EAATs can be 
pharmacologically distinguished from one another based upon the comparative 
actions of a number of substrates and inhibitors, although EAAT2 stands alone 
with respect to readily available, well-characterized subtype-selective inhibitors 
(Bridges and Esslinger, 2005; Kanner et al., 2001).  Not surprisingly, 
considerable effort has been focused on the development of inhibitors that can 
be used to selectively modulate the activity of the other individual transporters. 
Toward this goal our laboratories prepared L-β-benzylaspartate (L-β-BA) 
and identified it as one of the few EAAT inhibitors that exhibits a marked 
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selectivity for EAAT3 (Esslinger et al., 2005).  The more potent enantiomer, L-
threo-β-benzylaspartate ((2S,3S) 3-benzylaspartate, L-t-β-BA), shows an 
approximate 10-fold preference for blocking EAAT3 compared to either EAAT1 or 
EAAT2 in C17.2 cells expressing the human isotypes.  This contrasts with activity 
of the closely related and widely used inhibitor L-threo-benzyloxy aspartate 
(TBOA) which has been reported to more potently inhibit the activity of EAAT2 
than EAAT3 (Shimamoto et al., 2000; Shimamoto et al., 2004; Humphrey et al., 
1994).  In the present study a new series of L-β-benzylaspartate derivatives has 
been prepared from the easily accessible precursor N-trityl-L-aspartate dimethyl 
ester.    The analogues were evaluated as inhibitors of 3H-D-aspartate uptake in 
C17.2 neuroprogenitor cells transiently transfected to express human EAAT3.  
We report that structure activity profile of these inhibitors is quite different from 
TBOA-based analogues suggesting that subtle variations in size, substituents 
and orientation of the aromatic ring appended to the β-position of aspartate can 
noticeably influence activity at the EAATs.  In particular, substitutions at the 3-
position of the aromatic ring of L-t-β-BA are most favorable for imparting potency 
at EAAT3.  
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2. Results and Discussion 
 
2.1. Preparation of β-substituted Aspartates 
The starting material N-trityl-L-aspartate dimethyl ester (2) was prepared 
following a general procedure.  The aspartate dimethyl ester was formed using 
thionyl chloride in methanol.  N-Tritylation is achieved with triphenylmethyl 
chloride and triethylamine (Zervas and Theodorpoulos, 1956).  The resulting 
starting material was purified by two subsequent crystallizations from methanol. 
The triphenylmethyl protecting group was chosen due to ease of preparation, 
mild deprotection conditions, and the protection against alpha-carbon 
deprotonation it imparts to the molecule to avoid alpha-racemization (Scheme 1). 
Initially, beta addition was achieved by the addition of lithium 
hexamethyldisilyl amide (LiHMDS, 2 equivalents in THF) to a 1M solution of 2 in 
anhydrous THF at -32°C under inert atmosphere.  This was followed by 
quenching with the desired substituted-benzylic bromide (2-3 equivalents) and 
allowing the temperature to rise to 0°C (Humphrey, 1994).  Substituted-benzylic 
bromides are shown in Table 2 as R, A-J.  The reaction was terminated by the 
addition of 2N ammonium chloride.  This produced a mixture of 3, SS:SR with SR  
as the major component in a 1:2 to 1:1 mixture of diastereomers.  This was 
verified by detailed NMR analysis and compared to similar systems with similar 
reaction conditions reported that were accompanied by in-depth stereochemical 
determinations (Fernandez-Megia et al., 1994). 
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CO2H 1) MeOH, SOCl2
2) TrCl, Et3N TrN CO2Me
CO2Me
H
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     THF
conditions
TrN CO2Me
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TrN CO2Me
H
MeO2C Ar
+
1) HCl
2) ion exchange
H3N CO2
HO2C Ar
H3N CO2
HO2C Ar
+
1 2
3i (S,S)
3ii (S,R)
4i (S,S)
4ii (S,R)
 
Scheme 1. Synthesis of β-benzyl aspartates.  Tr = triphenyl methyl.  See 
Table 1 and Experimental Section for base, E+, and conditions. 
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N-Protecting 
group +  
additives 
Temp 
°C 
Base: E+ 
 
Time of 
rxn (hrs) 
E+ 
 
S,S : S,R 
(i:ii) 
% yield 
 
1. Trityl -35→0 2:2 
LiHMDS 
4 3F 1:2 57% 
2.  Trityl -55 2:2 
LiHMDS 
6 3F 1:11 55% 
3.  Trityl -55→0 2.5:3 
LiHMDS 
6 3F 1:2 65% 
4.  Trityl     DMPU -55 2:3 
LiHMDS 
21 3Cl 3:1 74% 
5.  Trityl  
 
-65 2:2 
LiHMDS 
21 3Cl 1:11 68% 
6.  Trityl 
 
-65 2:3 
LiHMDS 
21 3Cl 1:11 76% 
7.  Trityl  
 
-55 2.1:2.3 
KHMDS 
21 3Nitro 99:1 51% 
8.  Trityl  
 
-55 2.1:2.3 
KHMDS 
21 3F 99:1 58% 
9.  Trityl  
 
-55→0 2.1:2.3 
KHMDS 
21 3Br 2.5:1 88% 
  
Table 1.  Conditions used and results obtained in the benzylation reactions.  
S,S:S,R ratios as determined by 1H NMR. 
 
 
 
 
 
 
 
 
 
73 
 
 
 
 
Compound 
R-group 
 
+H3N
HO2C
CO2-
R
 
EAAT3 Uptake 
3H-D-Asp (25 
µM)  
 (% of Control) 
 
 
Compound 
R-group 
 
+H3N
HO2C
CO2-
R
 
EAAT3 Uptake 
3H-D-Asp (25 
µM) 
(% of Control) 
 
L-β-Benzyl-
asp 
4A 
 
 
 
4 + 2 
 
L-β-3-Br-
benzyl-asp 
4F 
Br  
 
8 + 3 
 
L-β-Benzyl-
asp 
S,S-4i 
 
 
1 + 1 
 
L-β-3-F-
benzyl-asp 
4G 
F  
 
0 + 0 
 
L-β-Methyl-
2-napthyl-
asp 
4B 
 
 
68 + 6 
 
L-β-4-F-
benzyl-asp 
4H 
F  
 
7 ± 3 
 
L-β-3,5 
Dimethyl-
benzyl-asp 
4C 
CH3
H3C
 
 
36 + 7 
 
L-β-3-Nitro-
benzyl-asp 
4I 
O2N  
 
29 + 5 
 
L-β-3-
Methyl-
benzyl-asp 
4D 
H3C  
 
33 + 3 
 
L-β-4-Nitro-
benzyl-asp 
4J 
NO2  
 
65 + 8 
 
L-β-2,6-
Dichloro-
benzyl-asp 
4E 
Cl
Cl
 
 
86 + 5 
   
 
Table 2.  Percent of control uptake in the presence of L-β-benzyl aspartate 
derivatives (control uptake with no inhibitor present is 100%). C17.2 Cells 
assayed for their ability to block 25µM 3H-D aspartate uptake in the presence of 
100µM inhibitor, n≥3.  Inhibitors in an approximate 1:1 ration of (S,S) : (S,R) 
unless specified. 
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HPLC separation of L-β-BA diastereomers 4A gave NMR spectra consistent with 
previous reports of similar aspartate syntheses (Humphrey et al., 1994; 
Fernandez-Megia et al., 1994; Hanessian et al., 1998; Sakaguchi et al., 2004).  
At this step, yields of the mixture ranged from 13.5% to 87% following 
chromatography. Yields generally improved with greater equivalents of 
substituted-benzylic bromide, Table 1: 5 vs. 6, as well as higher temperatures, 2 
vs. 3, though diastereoselectivity decreased with increasing temperature.  We 
found that the ratio of SS:SR increases to 1:11 if the temperature is decreased to 
-55°C and quenched at this cold temperature (entries 5 and 6, Table 1).  If the 
reaction temperature is allowed to rise to 0°C after addition of substituted-
benzylic bromide the ratio of SS:SR decreases to 1:2 to 1:1.  Interestingly we 
found that adding DMPU to the starting material reverses the stereochemistry to 
give SS:SR in a 3:1 mixture of diastereomers (Hanessian et al., 1998).  
When KHMDS was used in place of LiHMDS we observed a switch in 
diastereoselectivity similar to that observed by Humphrey et al., with N-benzyl-N-
9-phenylfluoren-9-yl dimethyl aspartate (Humphrey et al., 1994).  We propose 
that Li complexes tightly to the enolate but may be forming a loose cyclic chelate 
between the enolate oxygen and the nitrogen (Figure 1), similar to that 
suggested by Fernàndez-Megía and Sardina (Fernàndez-Megía et al., 1994). 
This is supported by the decrease in selectivity observed at higher temperatures, 
as well as the reversal of diastereoselectivity observed upon addition of DMPU.   
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H H
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Lithium Enolate Potassium Enolate  
Figure 1. Low temperature chelation controlled diastereomeric outcome of 
enolates using lithium and potassium bases. 
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This reversal of selectivity suggests that the metal is being complexed by DMPU, 
thereby disrupting the nitrogen oxygen chelate and allowing the molecule more 
rotational flexibility.  This would increase the probability that the Si face is open 
for attack. We hypothesize that potassium forms a cyclic enolate - α-ester 
chelation as previously proposed (Humphrey et al., 1994; Fernàndez-Megía et 
al., 1994), giving the (S,S) product (Figure 1). 
     Deprotection was achieved by heating the alkylated product (3) in 6N HCl 
to afford the chloride salt of the product.  The reaction was then neutralized to a 
pH of 7, loaded on an anion exchange resin (acetate form, 10g resin per gram 
product), and eluted using a gradient of 1-5N acetic acid.  The zwitterion was 
obtained by concentrating the ninhydrin positive fractions followed by chasing the 
product with deionized water several times.  Alternatively, the product can be 
precipitated out of ethyl acetate then water to give final product. 
  
2.2. Inhibitory Activity at EAAT3  
The compounds were evaluated in collaboration with the Bridges lab as 
inhibitors of EAAT3.  This was achieved by quantifying their ability to reduce the 
uptake of 3H-D-asparate in standard competition assays10.  In each instance the 
analogues (SS:SR ratio of an approximately 1:1) were added simultaneously with 
the radiolabel to achieve a final concentration of 100 µM and 25 µM, respectively.  
The results are summarized in Table 2 as % of Control activity, i.e., uptake in the 
absence of any inhibitor.  The replacement of the benzyl group on L-β-BA with a 
napthyl moiety (4B) resulted in a marked reduction of inhibitory activity.  
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Interestingly, when an analogous substitution is made with L-TBOA to produce L-
threo-β-(1-napthyl)methyloxaspartate (L-TNOA1) and L-threo-β-(1-
napthyl)methyloxaspartate (L-TNOA2), the inhibitory activity was retained (or 
increased) as reflected by a decrease in the IC50 with which the compounds 
blocked the uptake of 14C-glutamate into COS-1 cells expressing EAAT3 (i.e., L-
TBOA, 7.0 µM; L-TNOA1, 4.8 µM; L-TNOA2, 6.5 µM) (Shimamoto et al., 2000).  
This would suggest that the proposed lipophilic regions adjacent to the substrate 
binding domain on EAAT3 with which the benzyl groups of either L-TBOA or L-t-
β-BA interact, can only accommodate a larger napthyl group when its orientation 
is dictated by the methoxy linkage of TBOA and not the methylene linking group 
of L-t-β-BA.  Recent structural insight into these substrate binding domains has 
emerged from crystallographic studies in which the archaeal aspartate 
transporter Gltph from Pyrococcus horikoshii has been crystallized in the 
presence of either L-aspartate or L-TBOA (Boudker et al., 2007).  It was 
concluded that the binding site is positioned between two hairpin loops that 
extend from opposite sides of the membrane and likely participate in the gating of 
substrate movement.  While non-substrate inhibitors such as L-TBOA or L-t-β-BA 
can fit into this site normally occupied by L-glutamate, interaction with nearby 
lipophilic residues in the vicinity of the HP2 loop may preclude subsequent 
conformational movements that are necessary for substrate translocation, such 
as the closure of the external HP2 gate or providing access of external sodium to 
its requisite binding site.  Interestingly, the ability of an inhibitor to interact with 
EAAT3 in this manner may increase its potency as an inhibitor, but decrease its 
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ability to act as an alternative substrate.  Comparisons between the naphthyl 
derivatives of L-TBOA or L-β-BA, suggest, however, that the exact placement of 
the aromatic rings within the binding site of EAAT3 is probably distinct and may 
additionally point to structural differences between the EAAT3 and EAAT2 
subtypes. 
The addition of a methyl (4D) or nitro (4I) group to the 3 position of of L-β-
BA, as well as a methyl group to both the 3 and 5 positions (4C), resulted in a 
retention of some inhibitory activity, although to a lesser degree than found in the 
parent molecule (e.g. about 30% of Control uptake vs. 4%).  Again, this may be 
indicative of a more constrained binding arena surrounding the aromatic ring of 
L-β-BA when compared to L-TBOA.  In contrast to these compounds, the di-
substitution of chloro groups at the 2 and 6 position (4E) produced an almost 
complete loss of inhibitory activity.  In this instance the decreased ability to bind 
to EAAT3 may be attributable to steric clashes with the transporter itself or, given 
the locations on the aromatic ring, between the substituents and the carbon 
backbone of aspartate when it assumes the requisite conformation for binding.  
Comparisons among additions made at the 3 position revealed a rank order of 
inhibitory activity of: methyl (4D) ≈ nitro (4I) < bromo (4F) < fluoro (4G).  Lastly, L-
β-3-F-BA (4G) and L-β-4-F-BA (4H) inhibited EAAT3-mediated uptake to a 
similar or greater extent than observed with either L-β-3-Br-BA or the parent L-β-
BA.  This would be consistent with the steric argument that the lipophilic region 
interacting with the benzyl group of L-β-BA in the binding site of EAAT3 is 
spatially confined, as well as reflect the ability of fluoro groups to favorably 
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interact with both regional sidechain R groups and backbone peptide bonds 
(Muller et al., 2007). 
    To illustrate the diastereomeric preference of EAAT3 for ligand binding as 
well as highlight the diastereoselectivity of the benzylation reaction depending on 
base used, the individual diastereomers (S,S)4Gi and  (S,R)4Gii of L-β-3-F-BA 
4G were synthesized and evaluated as inhibitors of EAAT3.  Competitive binding 
curves were obtained using 3H-D-asparate at 1µM and varying the concentration 
of inhibitor (Figure 2).  Curve fitting using GraphPad Prism 4.0 software to the 
equation Y = 1/(1+10^(X-logIC50)), where Y is the fractional % of control and X is 
the log[Inhibitor] in M, IC50 values were obtained for the two diastereomers.  As 
reported previously, the (S,S) diastereomer is the more potent (Esslinger et al., 
2005; Shimamoto et al., 2000), and in this case (S,S)4Gi exhibits a 10-fold higher 
affinity for EAAT3 than (S,R)4Gii.   
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IC50 Curves  for S,S-3-F-βBA
and S,R-3-F-βBA
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Figure 2.  IC50 curves for (S,S)-3-F-β BA and (S,R)-3-F-β BA with [
3H-D-
aspartate] = 1 µM.  (S,S) 3-F-βBA  IC50 =  2.46+/-0.9  µM  (S,R)-3-F-β BA  
IC50 = 21.1+/-9.2  µM (IC50 +/- SEM). 
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2.3 Molecular Modeling 
The recently published crystallographic study in which L-TBOA is bound to 
the archaeal aspartate transporter Gltph provides a strategy to conformationally 
compare these two inhibitors (Boudker et al., 2007).  The similarities are readily 
apparent when the bound conformation of L-TBOA is extracted from crystal 
structure and overlaid with a computationally minimized (Esslinger et al., 2005) 
conformation of L-threo-β-BA (Figure 3). While the aromatic rings are positioned 
in a similar direction it also appears that the benzyl group of L-threo-β-BA is 
considerably closer to the carbon backbone of the amino acid than that of L-
TBOA.  In this respect the aromatic rings of the two analogues are likely 
interacting with subtly different lipophilic regions within the binding domain on 
EAAT3.  Our SAR data would suggest that the in the instance of L-threo-β-BA, 
this region of the protein is less accommodating of steric bulk than the 
comparable region delineated by L-TBOA.  Further, it is tempting to speculate 
that the ability of L-threo-β-BA to interact with these portions of the binding site 
may be a factor in its selectivity for EAAT3. 
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Figure 3a.  Overlay of L-TBOA and L-threo-β-BA using the bound 
conformation of L-TBOA and similar conformation of L-threo-β-BA.  Viewed 
by looking down perpendicular to the plane of the aromatic ring.  
 
 
 
 
Figure 3b.  Overlay of L-TBOA and L-threo-β-BA using the bound 
conformation of L-TBOA and similar conformation of L-threo-β-BA.  Viewed 
by looking parallel to the plane of the aromatic ring. 
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3. Conclusions 
 
A series of L-β-benzylaspartate derivatives have been prepared from N-
trityl-L-aspartate dimethyl ester in which diastereomeric control was achieved 
using either lithium hexamethyldisilazide to yield predominantly the (2S,3R) 
adduct in one example or potassium hexamethyldisilazide to yield predominantly 
the (2S,3S) adduct in one example and evaluated as inhibitors of the neuronal 
glutamate transporter EAAT3.  SAR data, including the inactivity of L-β-methyl-2-
napthyl-aspartate (4B) and the increased activity of L-β-3-F-benzylaspartate 
relative to the lead analogue L-β-benzylaspartate, suggest a confined interaction 
between lipophilic domains of EAAT3 and the aromatic moiety of L-β-
benzylaspartate that is distinct from previously characterized inhibitors, such as 
L-TBOA.  These finding will be further explored in pursuit of more potent and 
selective ligands for the EAAT subtypes. 
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4. Experimental Section 
 
In order to verify the purity and composition of the compounds product 
analysis was performed by high resolution mass spectrometry.  Intermediates 
were treated with trifluoroacetic acid prior to mass spectrometry to remove the 
trityl group so the signal of the molecular ions could be detected.  Proton and 
carbon NMR were taken on a Varian 400 MHz NMR in CDCl3, D2O or DMSO 
with TMS as the internal standard.  NMRs were reported as mixtures of SS:SR 
with each diastereomer being identified where possible.  Diastereomers on 
carbon NMR are indicated in parentheses where carbon peaks of each molecule 
are resolved.  Chirality was verified by optical rotation on a Perkin-Elmer 241 
Polerimeter in 1N HCl unless otherwise specified in a 1.0dm tube.  Reagents 
were purchased from Sigma (St. Louis, MO) and were used without further 
purification.  Microanalyses were performed for C, H, and N (Midwest Microlab, 
Indianapolis, IN) and were within ± 0.4% of theoretical values.  Compounds 
showing potency equal to or greater than L-β-Benzyl-Aspartate (approximate 1:1 
S,S:S,R mixture) were resolved by semi-preparative reverse phase HPLC.  The 
detection method was a Waters 486 tunable absorbance detector set at 254 nm.  
 
4.1. N-tritylamino dimethyl ester aspartate (2)  
L(+)-Aspartic acid (26 g, 100 mmol) was stirred in a round bottom flask in a 1M 
solution of Methanol (200 ml).  Thionyl chloride (22 ml, 140 mmol) was added 
dropwise.  The solution was stirred at room temperature for 48 hours.  The 
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resulting dimethyl ester aspartate hydrochloride was washed 3 times with 
methanol, 3 times with methylene chloride, 2 times with toluene and once with 
water.  The dimethyl ester aspartate was then suspended in methylene chloride 
(200ml) and dried with magnesium sulfate.  Triphenyl methyl chloride (53 g, 95 
mmol) was added followed by the dropwise addition of triethyl amine (83.6 g, 300 
mmol).  The reaction was stirred overnight then diluted with ether and filtered 
through a silica plug with a 30/70 solution of ethyl acetate/hexanes.  The filtrate 
was concentrated and rinsed 2 times with methylene chloride and recrystalized 
from methanol to yield N-tritylamino dimethyl ester aspartate 2 (70%). 1H NMR 
(400 MHz, CDCl3) δ: 7.54-7.48 (m, 6H), 7.32-7.15 (m, 9H), 3.77-3.71 (m, 1H), 
3.69 (s, 3H), 3.28 (s, 3H), 2.99-2.91 (s, 1H), 2.73-2.62, (m, 1H), 2.58-2.48 (m, 
1H).  13C NMR (100 MHz, CDCl3) δ: 173.86, 170.95, 145.61, 128.71, 127.83, 
126.48, 71.13, 53.63, 51.91, 51.71, 40.16. [α]21D = 13.3° ( ethyl acetate). 
 
4.2. General procedure for alkylation: 
Compound 2 was placed in a flame dried round bottom flask equipped with a stir 
bar.  1 M anhydrous THF was added under argon and the reaction was super-
cooled.  Once cooled 1M LiHMDS in THF (2-3 equivalents) was added via 
needle and syringe.  After approximately 20 minutes the desired substituted-
benzylic bromide (2-3 equivalents) was added.  The temperature was then 
allowed to rise to 0ºC (unless specified) and the reaction was stirred until 
quenched (4-24 hours) with 2N NH4Cl.  Water and ethyl acetate (or ether) were 
added for separation.  The water layer was subsequently washed three times 
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and the organic layers were combined and concentrated.  Flash chromatography, 
when needed, through silica gel using hexane:ethyl acetate in an approximate 
85:15 ratio gave the desired protected substituted benzylaspartate in good to 
moderate yields.  
4.3. N-tritylamino dimethyl ester β-benzylaspartate (3a) 
To 2 (1.55 g, 3.84 mmol) in 1M THF under Argon at -23°C was added LiHMDS 
(9.6 ml, 11.53 mmol).  After 15minutes benzyl bromide (1.15 ml, 9.6 mmol) was 
added and temperature allowed to rise to 0ºC at which time it was stirred for a 
subsequent 2.5 hours.  The reaction was quenched and ether was added for 
separation followed by a silica plug (85:15 Hexanes:ethyl acetate) (82.7%: 1.57 
g).  1H NMR (400 MHz, CDCl3) δ : 7.57-7.48 (m, 6H), 7.32-7.20 (m, 14H), (3.94-
3.90 (m, .5 H, S,S), 3.75-3.72 (m, .5 H, S,R)), (3.65 (s, 1.5H, S,S), 3.60 (s, 1.5H, 
S,R)), (3.28 (s, 1.5H, S,S), 3.23 (s, 1.5H, S,R)), 3.19-2.88 (m, 3H).  13C NMR 
(100 MHz, CDCl3) δ: 172.77, 172.51, 145.43, (139.15, 138.96), 129.12, 128.72, 
127.71, 126.40, 126.22, (71.07, 70.93), (58.11, 57.67), 52.82, (51.65, 51.95), 
(51.53, 51.48), (34.05, 33.47).  HRMS m/e calcd. for C13H17NO4
+ 252.1236, 
found 252.1225. 
4.4. N-tritylamino dimethyl ester β-2-napthylmethyl-aspartate (3b) 
To 2 (2.5 g, 6.2 mmol) in 1M THF under Argon at -35°C was added LiHMDS 
(18.6 mmol).  20 minutes later 2-napthyl methyl bromide was added (3.4 g, 15.5 
mmol) as a solid all at once.  Temperature was allowed to rise to 0ºC, at which 
time it was stirred for an additional 4 hours before being quenched with 2N NH4Cl 
(9 ml).  Ethyl acetate was added for separation, followed by silica column 85:15 
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hexane:ethyl acetate (1.68 g, 50%).  1H NMR (400 MHz, CDCl3) δ : 7.84-7.74 (m, 
3 H), 7.66-7.59(m, 1 H), 7.47-7.43 (m, 7H), 7.37-7.29 (m, 1 H), 7.18-7.26 (m, 
8H), 7.16-7.11(m, 1 H), 7.09-6.99 (m, 1 H)  (3.91-3.87 (m, .4H, S,S), 3.73-3.70 
(m, .6H, S,R)), (3.61 (s, 1.2 H, S,S), 3.56 (s, 1.8 H, S,R)), (3.27 (s, 1.2 H, S,S), 
3.22 (s, 1.8 H, S,R)), 3.19-2.90 (m, 3H). 13C (100 MHz, CDCl3) δ: 173.20, 172.93, 
145.76, 135.32, 133.38, 129.80, 129.07, 129.01, 128.93, 128.19, 128.08, 128.04, 
127.96, 127.00, 126.81, 126.72, 126.64, (71.41, 71.31), 60.63, 52.98, 52.02, 
49.66, 34.30.  HRMS m/e calcd. for C17H20 NO4
+
 302.1392, found 302.1388. 
4.5. N-tritylamino dimethyl ester β-3,5 dimethyl-benzylaspartate (3c) 
To 2 (3.2 g, 8.02 mmol) in 1M THF under Argon at -55°C was added LiHMDS (24 
mmol).  20 minutes later 3,5 dimethyl benzyl bromide was added (6.4 g, 32.1 
mmol) as a solid all at once.  Temperature was allowed to rise to 0ºC, at which 
time it was stirred for an additional 1.5 hours before being quenched with 2N 
NH4Cl (12 ml).  Ethyl acetate was added for separation, followed by silica column 
85:15 hexane:ethyl acetate (61%, 3.9 g).  1H NMR (400 MHz, CDCl3) δ : 7.47 (m, 
6H), 7.29-7.20 (m, 9H), 6.85-6.76 (m, 3H), (3.86-3.83 (m, .66 H, S,S), 3.72-3.68 
(m, .33H, S,R)), (3.63 (s, 1H, S,S), 3.60 (s, 2H, S,R)), (3.25 (s, 1H, S,S), 3.20 (s, 
2H, S,R)), 3.03-2.74 (m, 3H), (2.29 (5 H app. singlet, S,S), 2.17 (1H app. singlet 
S,R)).  13C (100 MHz, CDCl3) δ: (173.05, 172.96), (172.80, 172.69), 145.52, 
(139.05, 138.93), (137.78, 137.69), (128.81, 128.69), 127.93, 127.87, 127.78, 
127.17, 126.72, 126.58, 126.48, 126.37, (71.16, 70.93), (58.19, 57.79), (52.86, 
52.77), (51.78, 51.72), (51.65, 51.60), (33.93, 33.36), 21.21.  HRMS m/e calcd. 
for C13H18NO4 
+ 280.1549, found 280.1540. 
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4.6. N-tritylamino dimethyl ester β-3 methyl-benzylaspartate (3d) 
To 2 (1.86 g, 4.61 mmol) in 1M THF under Argon at -30°C was added LiHMDS 
(13.8 mmol) slowly.  20 minutes later 3 methyl benzyl bromide was slowly added 
(1.56 ml, 11.5 mmol).  Temperature was allowed to rise to 0ºC, at which time it 
was stirred for an additional 4 hours before being quenched with 2N NH4Cl (7 
ml).  Ethyl acetate was added for separation, followed by silica column 85:15 
hexane:ethyl acetate (1.05 g, 45%).  1HNMR (400 MHz, CDCl3) δ: 7.48-7.45 (m, 
7H), 7.32-7.13 (m, 10H), 7.03-6.93 (m, 2H), (3.86-3.81 (m, .66H, S,R), 3.68-3.64 
(m, p. obsc., .33H, S,S)), (3.63 (s, 1H, S,S), 3.59 (s, 2H, S,R)), (3.24 (s, 1H, S,S), 
3.19 (s, 2H, S,R)), 3.08-2.77 (m, 3H), (2.33 (s, 2H, S,R), 2.30 (s, 1H, S,S)).  
13CNMR (100 MHz, CDCl3) δ:  172.99, 172.74, 145.55, 139.15, 139.01, 129.71, 
128.83, 127.81, 126.51, 125.82, (71.16, 70.98), (58.19, 57.79), (52.89, 52.86), 
(51.84, 51.77), (51.71, 51.65), (34.02, 33.46), 21.38.  HRMS m/e calcd. for 
C14H19NO4
+ 266.1392, found 252.1225. 
4.7. N-tritylamino dimethyl ester β-2,6 dicloro-benzylaspartate (3e) 
To 2 (4.35 g, 10.78 mmol) in 1M THF under Argon at -35°C was added LiHMDS 
(32.3 mmol).  After stirring at -35°C for 15 minutes, 2,6-diclorobenzyl bromide 
was added by removing the septa and quickly adding the dry reactant (6.47 g, 
26.95 mmol).  Temperature was allowed to rise to 0ºC, at which time it was 
stirred for an additional 5 hours before being quenched with 2N NH4Cl (15 ml).  
Ethyl acetate was added for separation.  No starting material was observed by 
TLC and NMR showed disappearance of starting material with no breakdown to 
aspartic acid.  1HNMR (400 MHz, CDCl3) δ: 7.53-7.49 (m, 6H), 7.29-7.15 (m, 
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11H), 7.10-7.06 (m, 1H), (3.94-3.90 (m, .5H, S,R), 3.78 (m, .5H, S,S)), (3.63 (s, 
1.5H, S,S), 3.62, (s, 1.5H, S,R)), 3.55-3.38 (m, 2H),  (3.20 (s, 1.5H, S,S), 2.19 (s, 
1.5H, S,R)), 3.06-3.02 (m, 1H).  13CNMR (100 MHz, CDCl3) δ: (172.72, 172.51), 
(172.31, 172.17), 145.46, 135.75, 135.29, 134.90, 129.40, 128.84, 127.74, 
127.22, 127.02, 126.42, 126.34, (71.25, 70.90), (58.08, 57.70), (51.86, 51.74), 
(51.68, 51.60), (50.11, 49.25), (30.28, 29.62).  HRMS m/e calcd. for 
C13H15Cl2NO4
+ 320.0456, found, 320.0441. 
  
4.8. N-tritylamino dimethyl ester β-3 bromo-benzylaspartate (3f) 
To 2 (2.27 g, 5.63 mmol) in 1M THF under Argon at -35°C was added LiHMDS 
(16.9 mmol) slowly.  20 minutes later 3-bromo-benzyl bromide was added (3.5 g, 
14.1 mmol) as a solid all at once.  Temperature was allowed to rise to 0ºC, at 
which time it was stirred for an additional 2.5 hours before being quenched with 
2N NH4Cl (5 ml).  Ethyl acetate was added for separation, followed by silica 
column 85:15 hexane:ethyl acetate (56%, 1.8 g).  Spectra S,R, separated via 
column chromatography.  S,R comes off first followed by S,S.  Spectra reported 
for S,R  1HNMR (400 MHz, CDCl3) δ: 7.46-4.44 (m, 5H), 7.34-7.29 (m, 5H), 7.26-
7.08 (m, 9H), 3.86-3.82 (m, 1H), 3.58 (s, 3H), 3.21 (s, 3H), 2.99-2.78 (m, 3H).  
13CNMR (100MHz, CDCl3) δ: 173.04, 172.55, 145.68, 141.96, 132.15, 130.16, 
129.72, 129.05, 128.11, 127.85, 126.82, 122.63, 71.34, 58.32, 52.77, 51.96, 
33.21.  HRMS m/e calcd. for C13H16BrNO4
+ 330.0341, found 330.0336. 
 4.9. N-tritylamino dimethyl ester β-3 fluoro-benzylaspartate (3g) 
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To 2 (.5 g, 1.24 mmol) in 1M THF under Argon at -35°C was added LiHMDS (2.5 
ml) slowly.  20 minutes later 3-fluoro-benzyl bromide was slowly added (.304 ml, 
2.40 mmol).  Temperature was allowed to rise to 0ºC, at which time it was stirred 
for an additional 4 hours before being quenched with 2N NH4Cl (3 ml).  Ethyl 
acetate was added for separation, followed by silica column 85:15 hexane:ethyl 
acetate (57%, .363 g).  1HNMR (400 MHz, CDCl3) δ: 7.47-7.43 (m, 6H), 7.32-
7.18 (m, 10H), 6.98-6.83 (m, 3H), (3.86-3.82 (m, .66H, S,R), 3.64-3.60 (m, .33H, 
S,S)); (3.64 (s, 1H, S,S), 3.59 (s, 2H, S,R)); (3.25 (s, 1H, S,S), 3.20 (s, 2H, S,R)); 
3.05-2.87 (m, 3H).  13CNMR (100 MHz, CDCl3) δ: 173.04, 172.64, 161.81, 
145.86, 142.09, 130.02, 129.05, 128.11, 126.82, 124.82, (116.13, 115.91), 
(113.62, 113.41), 71.32, 58.30, 52.86, 52.08, 51.99, 33.33.  HRMS m/e calcd. for 
C13H16FNO4
+ 270.1142, found 270.1141. 
 
4.10. N-tritylamino dimethyl ester β-3 fluoro-benzylaspartate (3g, S,S) 
Trityl aspartate (.555 g, 1.38 mmol) was placed in a flame dried round bottom 
flask equipped with stir bar.  Anhydrous THF (5.5 ml) was added under argon 
and reaction was cooled to -35°C.  Once cooled 20% KHMDS in THF (3.2 ml) 
was slowly added, 20 minutes later 3-Floro benzyl bromide was slowly added 
(.39 ml, 3.16 mmol).  The reaction was stirred for an additional 21 hours before 
being quickly quenched with 2N NH4Cl (4 ml).  Separate by adding water and 
ethyl acetate.  Wash water layer two more times with ethyl acetate, combine 
organic layers and concentrate.  Purification by chromatography on silica gel 
using ethyl acetate and hexanes 15:85 gave product in 58% yield (.407 g).  
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1HNMR (400MHz, CDCL3) δ:  7.51-7.46 (m, 7H), 7.27-7.20 (m, 11H), 7.00-6.86 
(m, 1H), 3.69 (s, 3H), 3.64-3.60 (p.obsc. m, 1H-α), 3.28 (s, 3H), 2.95 (m, 1H-β); 
(2.69-2.65 (m, 1H), 2.54-2.50 (m, 1H,).  13CNMR (100MHz, CDCl3) δ: 173.04, 
172.64, 161.81, 145.86, 142.09, 130.02, 129.05, 128.11, 126.82, 124.82, 
(116.13, 115.91), (113.62, 113.41), 71.32, 58.30, 52.86, 52.08, 51.99, 33.33.   
 
4.11. N-tritylamino dimethyl ester β-3 fluoro-benzylaspartate (3g. S,R) 
Trityl aspartate (.5 g, 1.24 mmol) was placed in a flame dried round bottom flask 
equipped with stir bar.  Anhydrous THF (5 ml) was added under argon and 
reaction was cooled to -55°C.  Once cooled LiHMDS in THF (2.5 ml) was slowly 
added, 20 minutes later 3-Floro benzyl bromide was slowly added (.3 ml, 2.48 
mmol).  The reaction was stirred for an additional 21 hours before being quickly 
quenched with 2N NH4Cl (4 ml).  Separate by adding water and ethyl acetate.  
Wash water layer two more times with ethyl acetate, combine organic layers and 
concentrate.  Purification by chromatography on silica gel using ethyl acetate and 
hexanes 15:85 gave product in 55% yield (.35 g).  1HNMR (400MHz, CDCL3) δ:  
7.51-7.46 (m, 6H), 7.31-7.27 (m, 9H), 7.22 (d, 1H, J=7.33), 7.00 (d, 1H, J=7.33), 
6.94-6.92 (m, 2H), 3.95 (m, .1H, S,S), 3.68 (m, .9H, S,R), 3.65 (s, .3H, S,S), 3.60 
(s, 2.7H, S,R,), 3.27 (s, .3H, S,S), 3.22 (s, 2.7H, S,R), 3.08-2.85 (m, 3H). 
4.12 N-tritylamino dimethyl ester β-4-fluoro-benzylaspartate (3h) 
To 2 (.536 g, 1.33 mmol) in 1M THF under Argon at -30°C was added LiHMDS 
(2.66 mmol) slowly.  20 minutes later 4-fluoro-benzyl bromide was added (.33 ml, 
2.66 mmol) dropwise.  Temperature was allowed to rise to 0ºC, at which time it 
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was stirred for an additional 2 hours before being quenched with 2N NH4Cl (6 
ml).  Ethyl acetate was added for separation, followed by silica column 85:15 
hexane:ethyl acetate (.517 g, 76%).  (Found: C, 75.06; H, 6.00; N, 2.74 
C32H30FNO4 requires C, 75.13; H, 5.91; N, 2.74).  
1H NMR (400 MHz, CDCl3) δ: 
7.48-7.44 (m, 6H), 7.29-7.15 (m, 9H), 7.13-7.05 (m, 2H), 6.99-6.89 (m, 2H), 
(3.86-3.82 (m, .5H, S,R), 3.69-3.65 (m, .5H, S,S)), (3.63 (s, 1.5H, S,S), 3.58 (s, 
1.5H S,R)), (3.24 (s, 1.5H, S,S), 3.19 (s, 1.5H, S,R)), 3.09-2.78 (m, 3H).  13C 
NMR (100 MHz, CDCl3) δ: (172.83, 172.78), 172.51, (172.71, 160.28), 145.44, 
(134.85, 134.82), (134.65, 134.62), (130.45, 130.38), (130.35, 130.27), 128.77, 
128.65, 127.78, 126.52, 126.42, (115.26, 115.20), (115.05, 115.01), (71.13, 
70.99), (58.05, 57.52), 53.00, (51.89, 51.75), (51.72, 51.65), (33.26, 32.67).  
4.13. N-tritylamino dimethyl ester β-3-nitro-benzylaspartate (3i) 
To 2 (3.546 g, 8.8 mmol) in 1M THF under Argon at -23°C was added LiHMDS 
(26.4 mmol) slowly.  20 minutes later 3-nitro-benzyl bromide was added (4.7 g, 
21.97 mmol) as a solid all at once.  Temperature was allowed to rise to 0ºC, at 
which time it was stirred for an additional 4 hours before being quenched with 2N 
NH4Cl (13 ml).  Ethyl acetate was added for separation, followed by silica column 
85:15 hexane:ethyl acetate (13.5%, .64g).  1H NMR (400 MHz, CDCl3) δ: 8.20-
8.10 (m, 3H), 8.07-8.04 (m, 1H), 7.60-7.17 (m, H), (3.95-3.90 (m, .75H, S,R), 
3.76-3.70 (m, .15H, S,S)), (3.66 (s, .45H, S,S), 3.63, (s, 2.55H, S,R)), (3.28 (s, 
.45H, S,S), 3.25 (s, 2.55H, S,R)), 3.08-2.98 (m, 3H), 2.91 (s, .75H), 2.88 (s, 
.25H).  13C (100 MHz, CDCl3) δ: 172.68, 182.36, 145.32, 135.47, 135.40, 129.81, 
129.25, 128.77, 128.63, 128.33, 128.18, 127.93, 127.87, 126.99, 126.69, 126.55, 
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123.88, 123.75, 121.64, 121.56, 71.23, (57.99, 57.59), 52.25, 52.12, 51.92, 
(33.71, 32.70).  HRMS m/e calcd for C13H16N2O6
+, 297.087, found 297.1076. 
4.14. N-tritylamino dimethyl ester β-3-nitro-benzylaspartate (3i, S,S) 
Trityl aspartate (.5 g, 1.34 mmol) was placed in a flame dried round bottom flask 
equipped with stir bar.  Anhydrous THF (5 ml) was added under argon and the 
solution was cooled to -55°C.  Once cooled KHMDS (20% in THF, 2.6 mmol) was 
slowly added, 20 minutes later 3-nitro-benzyl bromide was added (.634 g, 2.9 
mmol) as a solid all at once.  The reaction was stirred for an additional 21 hours 
before being quenched with 2N NH4Cl (6 ml).  Ethyl acetate was added for 
separation.  The water layer was washed two more times and the organic layers 
were concentrated down for separation on silica in 15% ethyl acetate, 85% 
hexanes (51%, .34 g).  1H NMR (400 MHz, CDCl3) δ:   8.26-8.00 (m, 1H), 7.52-
7.37 (m, 4H), 7.52-7.16 (m, 15H), 3.63 (s, 3H), 3.58 (m, 1H β), 3.30 (s, 3H), 3.27-
3.25 (m, 1H α), 3.22-3.15 (m, 2H), 3.03-2.94 (m, 2H). 13C (100 MHz, CDCl3) δ: 
172.36, 145.34, 141.06, 135.47, 129.01, 128.77, 128.63, 127.87, 127.66, 126.55, 
123.75, 121.64, 71.23, 57.59, 52.24, 52.10, 51.91, 33.71. 
 
4.15. N-tritylamino dimethyl ester β-P-nitro benzylaspartate (3j) 
Compound 2 (3.123 g, 7.74 mmol) in 1 M anhydrous THF under argon was 
cooled to -40°C.  Once cooled 1M LHMDS (23.2 mmol) was added.  After 20 
minutes P-nitro benzyl bromide, dissolved in anhydrous THF, was added (4.18 g, 
19.35 mmol).  The temperature was then allowed to rise to 0ºC and the reaction 
was stirred for 4 hrs at which time the reaction was quenched with 2N NH4Cl 
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(10ml).  Water and ether were added for separation.  The water layer was 
subsequently washed three times and the ether layers were combined and 
concentrated down.  Chromatography through silica gel (90% hexanes 10% ethyl 
acetate and .5% triethyl amine), methylene chloride was for easier loading to give 
(3.63g, 87.0%) as a yellow solid.  1H-NMR (400 MHz, CDCl3) δ: (8.14(d, 1.55 H, 
S,R, J=8.06), 8.08 (d, .44H, S,S, J=8.06)), 7.43 (dd, 6H, J=7.33, 8.79), 7.34 (d, 
2H, J=8.79), 7.28 (dd, 2H, J=7.33), 7.26 (m, 2H), 7.26 (d, 1.55H, S,R, J=8.06), 
7.22 (d, .44H, S,S, J=8.06), 7.21 (d, 2H, J=7.33), 7.19, (d, 1H, J=7.33). 3.90-3.87 
(m, .8H, S,R), (3.63 (s, .65H, S,S), 3.57 (s, 2.33H, S,R)), (3.25 (s, .65H, S,S), 
3.24 (d, 2.33H, S,R)), 3.03-2.94 (m, 3H).  13C (100 MHz, CDCl3) δ: 172.65, 
171.98, 145.34, 129.83, 128.77, 127.92, 126.69, 123.62, 58.03, (52.25; 51.92), 
(32.94, 30.88).  HRMS m/e Calcd for C13H16N2O6
+, 297.087, found 297.1076. 
 
4.16. N-tritylamino dimethyl ester β-3-chloro benzylaspartate 
Trityl aspartate (.50 g, 1.2 mmol) was placed in a flame dried round bottom flask 
equipped with stir bar.  Anhydrous THF (5 ml) was added under argon and the 
solution was cooled to -65°C.  Once cooled 1M LHMDS in THF (2.5 ml) was 
slowly added, 20 minutes later 3-cloro-benzyl bromide was added (.47 ml, 3.6 
mmol) at which time the reaction was stirred for an additional 21 hours before 
being quenched with 2N NH4Cl (6 ml).  Ethyl acetate was added for separation.  
The water layer was washed two more times and the organic layers were 
concentrated down for separation on silica in 15% ethyl acetate, 85% hexanes 
(63%, .654 g).  1H NMR (400 MHz, CDCl3) δ: 7.46-7.42 (m, 6H), 7.25-7.22 (m, 
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7H), 7.19-7.16 (m, 5H), 7.06-7.05 (m, 1H), (3.85-3.83 (m, 1H), (3.61 (s, .3H, S,S), 
3.56 (s, 2.7, S,R)), (3.23 (s, .3H, S,S), 3.19 (s, 2.7, S,R)), 3.02-2.78 (m, 3H).  13C 
(100 MHz, CDCl3) δ: 173.10, 172.66, 146.81, 145.37, 141.31, 134.05, 129.59, 
128.93, 128.74, 127.81, 127.13, 126.54, 71.02, 58.00, 52.48, 51.77, 51.71, 
32.94.  HRMS m/e calcd. for C13H16ClNO4
+ 286.0846, found 286.0840. 
 
4.17. General Procedure for Deprotection: 
The protected β-substituted aspartate was taken up in 6N HCl and refluxed for 3-
12 hours.  The reaction was then diluted with water and washed three times with 
ether.  The water layer was concentrated and neutralized with NH4OH and 
loaded onto an Ag 1X 8 acetate form ion exchange resin in the ratio of 1g 
product to 10g resin.  The product was eluted with varying concentrations of 
acetic acid from .1 to 5N.  Product came off around 2N.  Water was lyophilized 2-
3 times to remove the acetic acid.   
 
4.18. β-Benzylaspartate (4A) 
The protected benzyl aspartate (1.496 g) was taken up in 6N HCl and refluxed 
for 3 hours.  Product came off at 2N as indicated by NMR (8.6 %, .058 g).  1H 
NMR (400 MHz, D2O) δ: 7.32-7.21 (m, 2H), 7.25-7.21 (m, 3H), (4.04 (d, .25H, 
S,S, J=3.88), 3.96 (d, .75H, S,R, J=3.88)), (3.40 (ddd .75H, S,R, J=3.88, 6.47, 
9.06), 3.24 (ddd, .25H, S,S, J=3.88, 6.47, 9.06)) 3.09-3.01 (m, 1H), 2.95-2.89 (m, 
1H). 13C (100 MHz, CDCl3) δ:  172.69, 169.64, (139.69, 138.69), 129.07, 128.42, 
96 
 
126.54, (54.85, 52,91), (49.66, 47.87), (33.46, 32.99).  HRMS m/e calcd. for 
C11H14NO4
+ 224.0923, found 224.0923.  [α]21D = +29.8°. 
 
4.19. S,S L-β-Benzylaspartate (4A) 
The solvent system comprised of a buffered solution of ammonium acetate and 
water (0.1 M at pH 6.4). Reversed phase C18 3u analytical and 10u semi-prep 
columns were used with a retention time for S,S  being 2.59 minutes and 16.00 
minutes, respectively and for S,R  3.19 minutes and 21.00 minutes, respectively.  
1H NMR (400MHz, D2O) δ: 7.29-7.25 (m, 2H), 7.21-7.17 (m, 3H), 3.89 (d, 1H, 
J=3.24), 2.99 (ddd, 1H, J=3.24, 4.53, 11.00), 2.79-2.66 (m, 2H).  13C NMR 
(400MHz, D2O) δ: 22.00, 33.46, 49.41, 55.96, 126.96, 128.96, 139.02, 176.693.  
S,S:  [α]25D = +14.11.  
 
4.20. β-2 Napthylmethylaspartate (4B) 
The protected β-alkylated aspartate (1.68 g, 3.09 mmol) was taken up in 6N HCl 
and refluxed for 4 hours.  Ethyl ether was added for separation; the water layer 
was washed 3 times and concentrated.  Product crashes out of solution upon 
neutralization with NaOH.  The pH was adjusted to about 12 and precipitated out 
of methanol (.5g, 51%).  1HNMR (400MHz, D2O) δ: 7.83-7.78 (m, 3H), 7.66 
(app.singlet, 1H), 7.47-7.35 (m, 3H), 3.60 (m, 1H, S,S), 3.27-3.25 (m, 1H, S,R), 
3.03-2.94 (m, 1H), 2.86-2.83 (m, 1H), 2.69-2.60 (m, 1H).  13CNMR (100MHz, 
DMSO) δ: (172.93. 172.82), (170.44, 170.12), 136.99, 133.65, 132.50, 129.93, 
129.29, 128.29, 128.13, 127.70, 127.50, 126.65, 126.11, (55.27, 53.18) (50.54, 
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48.62), (33.53, 31.39).  18.27 = acetic acid.  HRMS m/e Calcd for C15H16 NO4
+ 
349.9889, found 349.9902. [α]21D = +9.8. 
4.21. β-3,5 Dimethyl-benzylaspartate (4C) 
The protected β-alkylated aspartate (1.29 g, 2.47 mmol) was taken up in 6N HCl 
and heated for 24 hours at 70°C.  Ethyl ether was added for separation; the 
water layer was washed and concentrated.  NH4OH was added to adjust the pH 
to 7 and loaded onto an anion exchange resin.  Product came off at 2N (.032 g, 
8%).  1H NMR (400 MHz, D2O) δ: (6.92 (app. Singlet, .67H, S,R.); 6.91 (app. 
Singlet, .33H, S,R)), (6.88 (1.33H, app. Singlet, S,R,); 6.87 (.66H, app singlet, 
S,S)), (4.08-4.07 (m, .33H, S,S), 4.00-3.99 (m, .66H, S,R)), (3.45-3.40 (m, .66H, 
S,R), 3.26-3.21 (m, .33H, S,S)), 3.05-2.98 (m, 1H), 2.89-2.81 (m, 1H), (2.18 (br 
singlet, 5H), 2.12 (br singlet, 1H S,S)).  13C (100MHz, D2O) δ: (172.54,172.07), 
(169.43,169.37), (138.52,138.20), (137.34,137.14), (128.05,127.87; 126.78, 
(52.68,52.36), (47.90,47.46), (34.23, 32.03), 21.00.  HRMS m/e calcd. for 
C13H18NO4
+
 252.1236 found 252.1230.  [α]
21
D = +34.8°. 
4.22. β-3 Methyl-benzylaspartate (4D) 
The protected β-alkylated aspartate (.9 g, 1.77 mmol) was taken up in 6N HCl 
and heated for 24 hours at 70°C.  Ethyl ether was added for separation; the 
water layer was washed and concentrated.  NH4OH was added until the pH 
reached 6.  THF was added for solubility and the product was loaded onto an Ag 
1X 8 acetate form ion exchange resin in the ratio of 1g product to 10g resin.  
Product was eluted with varying concentrations of acetic acid from .1 to 5N in a 
4:1 ratio of water:THF.  Product comes off around 2N.  (.0765 g, 18.3%).  1HNMR 
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(400MHz, D2O) δ: 7.24-7.19 (m, 1H), 7.11-7.05 (m, 3H), (4.14-4.13 (m, .36H, 
S,S), 4.09-4.08 (m, .64H, S,R)), (3.52-3.47 (m, .64H, S,R), 3.31-3.28 (m, .36H, 
S,S)), 3.12-3.07 (m, 1H), 2.98-2.88 (m, 1H), 2.25 (s, 3H).  13CNMR (100MHz, 
CDCl3) δ: 174.89, 170.46, 139.13, 137.49, 129.78, 128.96, 127.93, 126.06, 
52.86, (47.55, 46.88), (33.76, 33.65), 20.47.  HRMS m/e calcd. for C12H16NO4
+ 
238.1079, found 238.1079.  [α]21D = +7.8° (in DI H2O, adjusted to 7.5 with 
NaOH). 
4.23. β-2,6 Dicloro-benzylaspartate (4E) 
The protected β-alkylated aspartate was dissolved in THF and 6N HCl and 
refluxed for 5 hours.  The reaction was washed with ethyl acetate and the water 
layers were combined and concentrated.  The reaction was neutralized to pH 5 
using NaOH, loaded onto an anion exchange resin and eluted with 4:1 H2O:THF 
mixture followed by a gradient of acetic acid prepared from concentrated acetic 
acid in the same 4:1 H2O:THF ratio to give a gradient from .1N to 5N.  Product 
was isolated from 2N and 5N acetic acid (1g, 37.2%).  1HNMR (400MHz, D2O) δ: 
7.37-7.32 (m, 2H), 7.21-7.14 (m, 1H), (4.05 (m, .4H, S,S), 3.96 (m, .6H, S,R)), 
3.47-3.33 (m, 2H), 3.24-3.21 (m, .6H), 3.12-3.09 (m, .4H).. 13CNMR (100MHz, 
CDCl3) δ: 171.75, 169.40, 135.23, 134.03, 129.18, 128.37, 52.80, 46.16, 28.07.  
HRMS m/e calcd. for C11H12Cl2NO4
+ 320.0456, found 320.0441.  [α]21D =  +31.7°. 
4.24. β-3 Bromo-benzylaspartate (4F) 
 The protected β-alkylated aspartate(.5 g, .873mmol) was taken up in 6N 
HCl and heated for 24 hours.  Ethyl ether was added for separation; the water 
layer was washed 3 times and concentrated.  NH4OH is added until the pH is 7.  
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THF is added for solubility and is loaded onto an Ag 1X 8 acetate form ion 
exchange resin in the ratio of 1g product to 10g resin.  Product is eluted with 
varying concentrations of acetic acid from .1 to 5N in a mixture of water:THF in a 
ratio of 4:1.  Product comes off around 2N.  Lyophilize off water 2-3 times to 
remove the acetic acid (.1 g, 38.5%).  1HNMR (400 MHz, DMSO) δ: 7.47 (m, 1H), 
7.41-7.38 (m, 1H), 7.28-7.22 (m, 2H), 4.01 (br s, .85H, α S.S) 3.82, (br s, .15H, α 
S,R), 3.25-3.21 (m, .15H, β S,R), 3.12-3.10 (m, .85H, β S,S), 3.04-3.00 (m 1H), 
3.28-2.74 (m, 1H).  13CNMR (100MHz, DMSO) δ: 171.80, 169.23, 141.69, 
131.65, 130.42, 129.27, 128.22, 121.52, 52.68, (48.16, 47.35, β C), (31.62, 
30.76, CH2), acetic acid 21.15, 172.33.  HRMS m/e calcd for C11H13BrNO4
+ 
302.0028, found 302.0014.  [α]21D = +26.9°.  
4.25. β-3 Fluoro-Benzylaspartate (4G) 
The protected β-alkylated aspartate (.678 g, 1.33 mmol) was taken up in 6N HCl 
and heated for 24 hours at 70°C.  Ethyl ether was added for separation; the 
water layer was washed 3 times and concentrated.  NH4OH was added until the 
pH reached 7 and loaded onto an ion exchange resin where product comes off 
around 2N (.115 g, 36.2%).  1H NMR (400 MHz, DMSO) δ:  7.34-7.29 (m, 1H), 
7.08-6.99 (m, 3H), (3.99 (d, .33H, S,S, J=4.40), 3.88 (d, .66H, S,R, J=4.40)), 
(3.33 (ddd, .66H, S,R, J=4.40, 6.59, 9.52), 3.20 (ddd, .33H,  S,S, J=4.40, 5.86, 
10,26)), 3.08-2.86 (m, 2H). 13C (100 MHz, DMSO) δ: (172.54, 171.89), 169.17, 
(163.18, 160.77), (141.60, 141.53), (130.15, 130.03, 129.94), 125.05, (115.63, 
115.42), (113.31, 113.16, 112.94), (52.97, 52.48), (48.89, 47.25), (33.70, 32.03, 
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30.65).  HRMS m/e for C11H13FNO4
+ calcd. 242.0829, found 242.0834.  [α]21D = 
+40°. 
The mixture of diasteromers was resolved by HPLC as well as synthetically 
prepared in ratios of 99:1, S,S:S,R and 11:1 S,R:S,S.  For HPLC resolution the 
solvent system comprised of a buffered solution of ammonium acetate and water 
(0.1 M at pH 6.4). Reversed phase C18 3u analytical and 10u semi-prep columns 
were used with a retention time for S,S  being 2.3 minutes and 18.48 minutes, 
respectively and for S,R  2.8 minutes and 27.22 minutes, respectively. 
4.26. β-3 Fluoro-Benzylaspartate (4G, S,S) 
1H NMR (400 MHz, D2O) δ: 7.30-7.26 (m, 1H), 7.06-6.94 (m, 3H), 3.94 (m, 1H), 
3.08-3.05 (m, 1H), 2.88-2.81 (m, 1H), 2.77-2.73 (m, 1H).  13C (100 MHz, DMSO) 
δ:  178.20, 172.02, 164.62, 162.21, 143.35, 131.50, 126.19, 116.81, 114.49, 
56.53, 49.31, 33.91. [α]21D = +18.3° 
4.27. β-3 Fluoro-Benzylaspartate (4G, S,R) 
1H NMR (400 MHz, D2O) δ: 7.32-7.25 (m, 1H), 7.05-6.95 (m, 3H), 3.64-3.59 (m, 
1H), 3.07-3.02 (m, 1H), 2.96-2.88 (m, 2H).  13C (100 MHz, DMSO) δ: 179.81, 
172.63, 163.22, 160.81, 140.12, 129.93, 125.11, 115.43, 112.90, 52.68, 49.74, 
28.22.  [α]21D = +38.23° 
4.28. β-4 Fluoro-benzylaspartate (4H) 
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The protected β-alkylated aspartate (.457 g, .893 mmol) was taken up in 6N HCl 
and heated for 24 hours at 75°C.  Ethyl ether was added for separation; the 
water layer is washed and concentrated.  NH4OH is added until the pH reached 
7.  THF 1:7 ratio was added for solubility and loaded onto an Ag 1X 8 acetate 
form ion exchange resin. Product is eluted with varying concentrations of acetic 
acid in a mixture of water:THF in a ratio of 4:1.  Product comes off at 2N and 5N 
acetic acid.  Lyophilize off water 2-3 times to remove the acetic acid (.156, 73%). 
Found C, 53.48; H, 4.83; N, 5.60; C11H11FNO4 1/3 H2O requires C, 53.66; H, 
4.78; N, 5.69.  1HNMR (400 MHz, D2O) δ: 7.26-7.20 (m, 2H), 7.06-7.00 (m, 2H), 
(3.98 (d, .5H, S,S, J=3.24), 3.88 (d, .5H, S,R, J=3.24)), (3.31 (ddd, .5H, S,R, 
J=3.24, 7.12, 9.71), 3.18 (ddd, .5H, S,S, J=3.24, 5.18, 9.06)), 3.05-2.84 (m, 2H).  
13CNMR (100 MHz, D2O) δ: (176.21, 176.00), (172.29, 171.81), (163.01, 162.93), 
(160.60, 160.53), (133.80, 133.39), (130.72, 130.68), (130.65, 130.59), (115.69, 
115.58), (115.47, 115.37), 54.74, (48.19, 48.03), (33.82, 32.82).  [α]21D = +116.6° 
in DI H2O adjusted to 7.5 with NaOH. 
4.29. β-3 Nitro-benzylaspartate (4I) 
The protected β-alkylated aspartate (.24 g, .446 mol) was taken up in 6N HCl and 
heated for 24 hours at 65°C.  Ethyl ether was added for separation; the water 
layer was washed and concentrated.  NH4OH was added until the pH reached 7.  
THF was added for solubility and loaded onto an ion exchange resin.  Product 
was eluted with a mixture of water:THF in a ratio of 4:1.  Product came off around 
2N.  Lyophilized off water 2-3 times to remove the acetic acid (.022 g, 18.4%). 
Product was sparingly insoluble in H2O.  
1H NMR (400 MHz, D2O) δ:  8.13-8.06 
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(m, 2H), 7.67-7.61 (m, 1H), 7.54-7.48 (m, 1H), (3.99 (d, .6H, S,S, J=3.88), 3.87 
(d, .4H, S,R, J=3.88)), (3.30 (ddd, .4H, S,R, J=3.88, 5.18, 9.17), 3.21 (ddd, .6H, 
S,S, J=3.88, 5.18, 9.06)), 3.11-3.05 (m, 1.4H), 2.97 (d,, .45 H, J=5.18) 2.94 (d, 
.25H, J=5.18).  13C (100 MHz, DMSO) δ: (173.92, 172.48), (169.50, 168.75), 
(146.79, 146.56), 139.37, 136.19, (131.76, 130.60), (123.72, 123.55), (122.23, 
122.02), 52.92, 48.83, 29.69.   HRMS m/e calcd for C11H13N2O6 269.0774, found 
269.0779. [α]21D = + 2.7° in DI H2O adjusted to 7.5 with NaOH.  [α]
21
D = -20°. 
4.30. β-3 Nitro-benzylaspartate (4I, S,S) 
The protected β-alkylated aspartate(.325 g, .603 mmol) is taken up in 6N HCl 
with a little acetone and heated for 24 hours at 65°C.  The reaction is then 
concentrated down, washed with water 2 times and placed under vacuum.  Ethyl 
acetate is added and product precipitates out, white powder.  For ease this was 
centrifuged down for 10 minutes at 4000 rpm and the supernant poured off.  The 
precipitate was dissolved in a small amount of water from which it almost 
immediately crashed out as white crystals.  This is washed with water and 
concentrated down 2 more times (.045 g, 28%). 1H NMR (400 MHz, D2O) δ: 8.10 
(s, 1H), 8.06 (d, 1H, J=8.06), 7.64 (d, 1H, J=7.33), 7.50 (t, 1H, J=8.06,7.33), 4.13 
(1H, α), 3.40-3.36 (m, 1H, β), 3.28-3.23 (m, 1H), 3.11-3.06 (m, 1H). 13C 
(100MHz, D2O) δ: 172.28, 169.29, 147.75, 141.07, 136.05, 129.69, 123.67, 
121.64, 52.79, 47.28, 33.85. 
 
4.31. β-para nitro benzylaspartate (4J) 
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The protected β-alkylated aspartate (1.35 g, 2.51 mmol) was placed in a round 
bottom flask with 6N HCl and THF, to dissolve.  Reaction was refluxed for three 
hours then washed with ethyl acetate.  The ethyl acetate layer was washed 2 
more times and the aqueous layer was concentrated down.  7.4g AgX1-8 resin 
200-400mesh size was loaded into a column and washed with two columns of 
water. Product was loaded and the column was washed with a gradient of acetic 
acid from .1N to 5N.  Faction’s 1-5 are lyophilized down (.378 g, 56%).   1H-NMR 
(400 MHz, D2O) δ: 8.04-8.00 (m, 2H), 7.39-7.34 (m, 2H), (3.99-3.88 (d, .65H, 
S,S), 3.92-3.91 (d, .35H, S,R)), (3.35-3.33 (m, .35H, S,R), 3.23-3.22 (m, .65H, 
S,S)), 3.12-2.91 (m, 2H).  13CNMR (100MHz, D2O) δ: (178.86,178.41), 
(173.37,172.64), (147.30,146.96), (146.42,146.35), (129.92,129.83), 
(123.86,123.80), (55.73,55.67), (49.40,48.99), (36.12,33.29).  HRMS m/e Calcd 
for C11H14N2O6
+ calcd. 252.1236, found 252.1225.  [α]21D = +18.52°. 
 
4.32. β-3 Chloro-benzylaspartate S,R 
1H-NMR (400 MHz, D2O) δ: 7.30-7.24 (m, 3H), 7.18-7.17 (m, 1H), (3.96 (app. d, 
.07H, S,S), 3.81 (app. d, .93H, S,R)), (3.27-3.22 (m, .91H, S,R), 3.15-3.10 (m, 
.09H, S,S)), (3.02-2.89 (m, 1.9H, S,R), 2.83-2.79 (m, .1H, S,S). 13CNMR 
(100MHz, D2O) δ: 172.01, 169.34, 141.26, 132.73, 130.06, 128.65, 127.75, 
126.34, 52.44, 49.61, 32.14. [α]21D = +25.7°. 
 
4.33 EAAT3-Mediated transport in C17.2 cells 
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EAAT3 was transiently expressed in C17.2 cells (obtained from Dr. Evan Snyder, 
Burnham Inst., La Jolla, CA) using an AAV-based vector (kindly provided by Dr. 
Mathew During, University of Auckland, NZ) pAM-CAG-EAAT3-WPRE as 
previously described (Esslinger et al., 2005). Cells between passages 10-20 
were seeded at 5 X 104 cells/well in 12 well plates and grown in complete DMEM 
supplemented with 10% fetal bovine serum, 1mM sodium pyruvate, 0.1 mM 
nonessential amino acids solution.  At 24 hours after plating, cells were 
transfected using FuGENE6  Transfection Reagent (Roche, Indianapolis, IN) in a 
ratio of 4µl of FuGENE6 to 3µg of purified plasmid DNA in accordance with 
manufacturers instructions.  The cells were used in transport assays 24 hours 
following transfection as described by Esslinger et al., 2005. Briefly, transfected 
C17.2 cells were grown in DMEM containing 10% FCS in a humid atmosphere of 
5% CO2. Near-confluent cells (plated at 5x10
4 cells/well) were rinsed with a 
physiological buffer (138 mM NaCl, 11 mM D-glucose, 5.3 mM KCl, 0.4 mM 
KH2PO4, 0.3 mM Na2HPO4, 1.1 mM CaCl2, 0.7 mM MgSO4, 10 mM HEPES, pH 
7.4) and allowed to preincubate at 37oC for 5 min.  Uptake was initiated by 
replacing the pre-incubation buffer with buffer containing 3H-D-aspartate (25µM) 
and inhibitors at the concentrations indicated.  Following a 5 min incubation, the 
media was removed by rapid suction and the cells rinsed 3 times with ice-cold 
buffer.  The cells were dissolved in 0.4N NaOH for 24 hours and analyzed for 
radioactivity by LSC and protein by the BCA (Pierce) method. Transport rates 
were corrected for background: i.e., radiolabel accumulation at 4oC. Initial studies 
confirmed that uptake quantified in this manner was linear with time and protein 
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levels and that uptake in untransfected C17.2 cells was indistinguishable from 
background.   
 
5. Acknowledgements 
The authors wish to thank J. Gerdes, M. Kavanaugh, S. Patel, C.M. Thompson, 
and T. Denton for their insightful advice regarding the studies presented in this 
manuscript.  Molecular modeling studies were conducted in the Molecular 
Computational Core Facility of the Center for Structural and Functional 
Neuroscience and HRMS were obtained in the Proteomics and Mass Spec. Core 
Facility of the Center for Structural and Functional Neuroscience.  This work was 
supported in part by NINDS NS30570 (RJB), NINDS NS045704 (CSE) and 
NCRR COBRE RR15583 (RJB, CSE). 
 
 
 
 
 
 
 
  
106 
 
 
 
 
Chapter 4.  
L-β-Benzyl-aspartate derivatives; pharmacological characterization and 
computational evaluation of a novel class of preferential EAAT3 inhibitors. 
 
 
 
 
 
Terri Mavencamp, Joseph F. Rhoderick, David Holley, John Gerdes, Michael 
Kavanaugh, C. Sean Esslinger and Richard J. Bridges 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
107 
 
 
 
 
 
 
 
Abstract 
 
Derivatives of L-β-benzyl aspartate were prepared and characterized for the 
ability to inhibit 3H-D-aspartate uptake into hEAAT1-3 expressing C17.2 cells.  
This series comprises one of the first families of EAAT3 preferring inhibitors 
identified to date.  The three most potent compounds contain a halogen 
substitution at the 3-position of the aromatic ring.  IC50 values at EAAT1-3 have 
been determined for L-β-3- (bromo-, chloro- and fluoro-) benzyl aspartate.   IC50 
values of the most potent, L-β-3-fluoro-benzyl aspartate are 7.50 µM ± 2.12, 5.56 
µM ± 0.65 and .1.95 µM ± 0.37 respectively.  Potency decreases when 
substitutions are made at the 4-postition as well as with increasing size of the 
substituent.  Computational modeling and analysis of structure activity data 
suggest the area the aromatic moiety of L-β-benzyl aspartate derivatives probe is 
1) 3-dimentionally confined, 2) more tolerant of substitutions at the 3 and 5 
positions than the 4 position, 3) at least partially distinct from the area probed by 
L-TBOA and 4) more accessible in the EAAT3 protein than EAAT1 and EAAT2. 
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1. Introduction 
 
 
Glutamate is the major excitatory neurotransmitter in the mammalian 
central nervous system (CNS).  It is capable of participating in standard fast 
synaptic communication as well as in higher order signal processing linked to 
development, synaptic plasticity, learning and memory (for review see: Balaz et 
al., 2006).  The interaction of glutamate with the ionotropic and metabotropic 
glutamate receptors mediates signal transmission, yet overstimulation of these 
receptors has been shown to result in excitotoxic conditions that could result in 
cell death.  This is believed to play a key role in disorders of the CNS such as 
stroke, epilepsy, spinal cord injury, ALS, and Alzheimer’s disease (for reviews 
see: Rao and Weiss 2004; Won et al., 2002; Malva et al., 2003; Hynd et al., 
2004).  The excitatory amino acid transporters (EAATs), clear glutamate from the 
synaptic cleft, thereby influencing the amount and/or time course that L-
glutamate is in contact with the excitatory amino acid (EAA) receptors. 
Five glutamate transporters have been identified by molecular cloning and 
functional expression and share about 50-60% homology at the amino acid level.  
EAAT1-5 along with two neutral amino acid transporters comprise the sodium 
dependent solute carrier family (SLC1) and are referred to as: EAAT1(GLAST), 
EAAT2(GLT-1), EAAT3(EAAC1), EAAT4, EAAT5, ASCT1 and ASCT2  (Storck et 
al., 1992; Pines et  al., 1992; Kanai & Heidger, 1992; Arriza et al., 1994; Fairman 
et al., 1995; Arriza et al., 1997; Kanai and Hediger, 2004).   
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Advancements in determining the structure of the EAATs have been made 
through the crystallization of a transporter homologue from Pyrococcus 
horikoshii, Gltph.  Data suggests that the transporter is a trimer with a bowl 
shaped basin facing the extracellular space.  Three binding sites lay at the 
bottom of the basin, 1 per monomer.  Each site is covered by two helical hairpins 
(HP1 and HP2) extending from 
opposite sides of the membrane 
(Yernool et al., 2004).  The 
transporter homologue was 
recently crystallized with bound 
aspartate (closed state) and bound 
L-β-threo-benzyloxy-aspartate 
(TBOA) (open state).  TBOA and 
aspartate were observed to bind 
by the same recognition points.  This validates that TBOA works in a competitive 
manner and gives credence to modeling based on the belief that the protein 
recognizes compounds by at least 3 points, the α carboxyl group, C1; the distal 
carboxyl group, C2 and the nitrogen, N.  The authors predict that two sodium 
ions bind with aspartate, one sodium coupled to the hairpin loop on the 
intracellular side HP1 and the other coupled to the hairpin loop on the 
extracellular side, HP2, of the protein.  The bulky aromatic group of TBOA is 
believed to interfere with the closing of HP2; not allowing the second sodium to 
 
Figure 1.  TBOA in the active site of the 
EAAT3 homology model. 
HP2 loop
HP1 loop
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bind thereby effectually blocking further conformational changes (Boudker et al., 
2007).   
Amino acid residues positioned to make numerous protein-substrate 
interactions in Gltph are also present in the EAATs.  Functional studies of Asp444 
and Arg447 in EAAC1 support the importance of these residues in substrate 
binding.  Asp444 is conserved among members of the SCL1 family but is 
replaced by a serine in the dicarboxylic acid transporters DctA.  When Asp444 is 
mutated in EAAC1, even to similar residues such as glutamate, almost complete 
loss of transport is observed (Teichman and Kanner, 2007).  This suggests that 
the ligand amine group is engaging in key hydrogen bonds to Asp444. 
Another residue shown to be crucial for transport is Arg447.  Arg447 is 
conserved in eukaryotic and bacterial glutamate transporters as well as in DctA, 
but is not conserved in the two neutral amino acid transporters ASCT1 and 
ASCT2.  Arg447 is involved in binding the substrate distal carboxylate group, C2.  
Mutation of Arg447 to a neutral or negative amino acid residue abolishes 
transport of L-glutamate and D- and L-aspartate but leaves cysteine transport 
intact, converting the transporter to a neutral amino acid transporter (Bendahan 
et al., 2000).   
Due to the high degree of conservation among amino acid residues 
implicated in substrate binding, the development of inhibitors that act selectively 
at one EAAT over another is an ongoing challenge.  Recently important 
advancements have been made by the addition of two potent EAAT2 preferring 
non-substrate inhibitors.  WAY-855 (3-amino-tricyclo[2.2.1.02.6[heptane-1,3-
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dicarboxylic acid) and WAY-213613 (S)-2-
amino-4-(4-(2-bromo-4,5-
difluorophenoxy)phenylamino)-4oxobutanoic 
acid (Figure 2).  WAY-855 and WAY-213613 
display potent activities at EAAT2 (1.3 µM and 
.08 µM, respectively and a 40 and 46 fold 
preference for EAAT2 over EAAT3) (Dunlop et 
al., 2003; Dunlop et al., 2005). 
An EAAT3 preferring compound was 
synthesized that belongs to the same class of 
compounds as WAY-213613, (S)-4-(9H-fluoren-
2ylamino)-2-amino-4-oxobutanoic acid (NBI-
59159).  One major difference between NBI-
59159 and WAY-213613 is the fused ring 
system found in the EAAT3 preferring compound versus the phenoxy benzene 
ring structure in the EAAT2 preferring compound (Figure 2).  NBI-59159 displays 
non-substrate activity In Xenopus oocytes expressing EAAT1-3 (inhibitory IC50 
values of 212 nM, 55 mM and 23 nM respectively) and in HEK cells expressing 
EAAT1-3 (inhibitory IC50 values of 1.03 µM, 1.4 µM and 0.09 µM, EAAT1-3 
respectively) (Dunlop et al., 2006). 
Prior to the reporting of the above compounds, our laboratories published 
the characterization of one of the first preferential EAAT3 inhibitors, L-β-benzyl-
aspartate (L-β-BA).  Kinetic analysis of 3H-D-aspartate uptake into C17.2 cells 
H2N CO2H
O
HN
H2N CO2H
O
N
H
O
Br
F
F
c. NBI-59159
b. WAY-213613
CO2H
H H
HO2C
H3N
H
a. WAY-855
 
Figure 2. Aspartamide acid 
analogues displaying 
preference for EAAT2 (a,b) 
and EAAT3 (c). 
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expressing the hEAATs demonstrated that L-threo-β-BA is the more potent 
diastereomer (Ki values 9 µM for EAAT1, 10.0 µM for EAAT2 and 0.8 µM for 
EAAT3), acts competitively, and exhibits a 10-fold preference for EAAT3 
compared to EAAT1 and EAAT2.  Electrophysiological recordings of substrate 
mediated currents in Xenopus oocytes expressing EAATs identified L-β-BA as a 
non-substrate inhibitor.  It was initially hypothesized, prior to publication of the 
Gltph crystal structure, that the observed EAAT3 preference was due to 1) the 
highly conserved positioning of the α carboxyl group, C1; the distal carboxyl 
group, C2 and the nitrogen, N, 2) nearby regions that accommodate select 
structural modifications (cyclopropyl rings, methyl groups, oxygen atoms) and 3) 
a unique region occupied by the benzyl moieties of L-TBOA, L-β-threo-BA and 
related analogs.  
In this chapter we present the in vitro pharmacological characterization of 
a family of novel analogues of L-β-BA prepared by enolate addition of a lipophilic 
head group to protected aspartate (Mavencamp et al., 2008).  The compounds 
were assayed for their ability to inhibit D-[3H] aspartic acid uptake into C17.2 
cells.  We found that the L-β-BA scaffold presents a unique opportunity to build a 
family of EAAT3 preferring molecules.  Modeling studies were carried out in 
which select compounds were docked into an EAAT3 homology model using the 
program GOLD.  The results from the docking studies suggest L-β-BA and 
derivatives bind in a manner distinct from TBOA due to the absence of the 
oxygen on the β-substituent. 
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2. Methods 
 
2.1 Chemicals and reagents 
General cell culture supplies were purchased from Becton Dickinson 
(Franklin Lakes, NJ), Corning (Corning, NY), and Life Technologies (Grand 
Island, NY).  D-[3H]Aspartic acid was purchased from Dupont NEN (Boston, MA).  
L-Aspartate.  D,L-β-threo-Benzyloxy-aspartate was obtained from Tocris (Ballwin, 
MO).  The syntheses of L-β-benzyl-aspartate derivatives were performed as 
described in (Mavencamp et al., 2008). 
 
2.2 EAAT Expression and Cell Culture  
C17.2 cells (obtained from Dr. Evan Snyder, Burnham Inst., La Jolla, CA) 
between passages 10-20 were seeded at 1 X 105 cells/well in 12 well plates and 
grown in complete DMEM supplemented with 10% fetal bovine serum, 1mM 
sodium pyruvate, 0.1 mM nonessential amino acids solution, and 0.05% 
Penicillin-Streptomycin (5,000 units/ml) and Gentamicin sulfate (0.05mg/ml).  At 
24 hours after plating, cells were transfected using Transfection Reagent (Roche, 
Molecular Biochemicals) in a ratio of 4µl of FuGene to 3µg of purified plasmid 
DNA in accordance with manufacturer’s instructions. After 24 hours, the relative 
levels of functional 3H-D-Asp uptake were determined by the method of Martin 
and Shain (1979 as described below). 
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2.3 Transporter Activity in C17 Cells 
    Transfected C17.2 cells were grown in DMEM containing 10% FCS in a 
humid atmosphere of 5% CO2. Near-confluent cells (plated at 7x10
4 - 1x105 
cells/well) were rinsed with a physiological buffer (138 mM NaCl, 11 mM D-
glucose, 5.3 mM KCl, 0.4 mM KH2PO4, 0.3 mM Na2HPO4, 1.1 mM CaCl2, 0.7 mM 
MgSO4, 10 mM HEPES, pH 7.4) and allowed to preincubate at 37
oC for 5 min.  
Uptake was initiated by replacing the pre-incubation buffer with buffer containing 
3H-D-aspartate (5-100 µM) and inhibitors (10-100 µM).  Following 5 min 
incubation, the media was removed by rapid suction and the cells rinsed 3 times 
with ice-cold buffer.  The cells were dissolved in 0.4N NaOH for 24 hours and 
analyzed for radioactivity by LSC and protein by the BCA (Pierce) method. 
Transport rates were corrected for background: i.e., radiolabel accumulation at 
4oC. Initial studies confirmed that uptake quantified in this manner was linear with 
time and protein levels and that uptake in untransfected C17.2 cells was 
indistinguishable from background.  Dose response curves for IC50 determination 
were prepared for the three most potent compounds. Concentrations of inhibitors 
were selected to span 2 log units above and below the estimated IC50. 
 3H-D-
aspartate was included at 1 µM (Shimamoto et al., 2004; Dunlop et al., 2005).  
IC50 values were determined using Kalidegraph and fit to the equation y = 1-
(m0/(m2+m0)) where 1 is the maximum,  m0 is the concentration of inhibitor and 
m2 is the IC50 value. 
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2.4  Computational Modeling 
Human EAAT3 sequence (obtained from GenBank,  
http://www.ncbi.nlm.nih.gov) was aligned with the Protein Data Bank (PDB) 
sequences for an archaeal homologue (GltPh ,2NWW.pdb) according to Yernool, 
et al., 2004; Boudker et al., 2007.  The EAAT3 homology model was constructed 
by threading the aligned sequence along 2NWW coordinates using the SwissProt 
server (http://swissmodel.expasy.org//SWISS-MODEL.html).  The resulting 
model was optimized through local energy minimizations of regions with high 
steric and electrostatic interference using the AMBER7 force field in the Tripos 
SYBYL7.3 platform.  Representations of TBOA, 2-NOA, BA, 2-napth, and 3-F-BA 
were docked using GOLD (http://www.ccdc.cam.ac.uk/) into the EAAT3 model.  
Each of the top twenty poses for each of four separate docking runs were 
evaluated for their capacity to hydrogen bond with EAAT3 R447 and D444 
residues. The top ranked poses determined by GOLDScore were incorporated 
into the homology model and visualized using PyMol1.0.   
 
3. Results 
 
3.1 L-β-Benzyl Aspartate derivatives preferentially inhibit the EAAT3 
transporter subtype.   
 To delineate the pharmacological specificity of the individual EAATs, the 
Bridges Lab employed the same expression system as was used to characterize 
L-β-benzyl aspartate, C17.2 neuroprogenitor cells and a vector adapted from an 
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Adeno-associated virus (AAV) packaging plasmid (Stone et al., 2005; Esslinger 
et al., 2005).   
 A series of L-β-substituted aspartate analogues, that included L-β-benzyl-
aspartate (L-β-BA), were screened by Fred Rhoderick of the Bridges lab, at 100 
µM for the ability to inhibit the uptake of 3H-D-aspartate (25 µM) into C17.2 cells 
expressing EAAT1, EAAT2 or EAAT3.  L-β-BA and L-β-BA derivatives were 
included in the assays as approximate 2:1 mixtures of their threo and erythro 
forms (2S,3S and 2S,3R).    The data are reported in Table 1 as the mean % of 
Control (± SEM) measured in the absence of inhibitors.  D,L-TBOA and L-β-
methyl aspartate were included in the present study so that structure activity 
comparisons would be based on assay data collected under identical conditions.   
  L-β-Methyl aspartate is approximately equipotent at the three EAATs, with 
a statically non-significant preference for EAAT3.  Consistent with literature 
reports, D,L-TBOA, a well know EAAT blocker preferentially inhibits EAAT2.  In 
accord with L-β-methyl aspartate and D,L-TBOA, L-β-benzyl aspartate utilizes β 
substitution on the aspartate backbone.  It was recently shown that L-β-BA is a 
preferential EAAT3 inhibitor.  In agreement with what is observed for TBOA, the 
threo diasteromer of L-β-BA was shown to be more active than the erythro 
diasteromer.    
 It can be seen from Table 1 that all of the L-β-BA analogues synthesized 
show a preference for EAAT3 except for 2,6-dichloro benzyl aspartate, entry 16, 
which shows very little activity at any of the transporters.  In general, 
substitutions made at the 3 position were more potent than those at the 4 
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position.  This is illustrated by comparing L-β-3-nitro-BA with L-β-4-nitro-BA, 
entries 10 and 14.  L-β-3-Nitro-BA inhibits uptake to roughly 30% of control, 
about twice the inhibition as seen with L-β-4-nitro-BA (ca. 65% of control).  
Similarly, L-β-3-floro-BA completely inhibits 3H-D-aspartate uptake at 100 µM, 
while the 4-floro substitution inhibits uptake to about 9% of control (entries 9 and 
13 respectively).  Adding a substituent to the symmetrical position, 5 of the 
aromatic ring does not appear to affect potency or selectivity.  L-β-3-Methyl-BA, 
entry 11, inhibits uptake at EAAT3 to about 33% of control and at EAAT1 and 
EAAT2 to about 70% of control.  When an additional methyl group is introduced 
to the 5 position (L-β-3,5-dimethyl-BA, entry 12) inhibitory activity is not 
significantly effected.  In general, smaller substituents showed greater potency.  
This is most easily observed among the 3-substituted halogen derivatives, 
entries 6-9.  The halogens have similar physical characteristics but range in size 
from the small fluoro to the large iodo.  The size of the substitutions is reflected in 
the potency of inhibition, ranging from complete inhibition of uptake at EAAT3 to 
about 20% inhibition for L-β-3-iodo-BA.  A striking example of a decrease in 
potency with an increase in size can be observed with 1-and 2- β substituted 
naphthyl aspartates (L-β- 1 & 2-NA) (entries 18 and 19).  Both compounds show 
a large reduction in potency from BA.  In contrast, 1 and 2 naphthyl analogues of 
TBOA, threo-β-(1-naphthyl)-methoxyaspartate and threo-β-(2-naphthyl)-
methoxyaspartate (TNOA-1 and TNOA-2), exhibit a slight increase in potency 
over the parent compound TBOA (Shimamoto et al., 2000).   
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Cmpd. 
# 
Compound 
(100 µM) 
EAAT1 
3H-D-Asp Uptake 
(% of Control) 
EAAT2 
3H-D-Asp Uptake 
(% of Control) 
EAAT3 
3H-D-Asp Uptake 
(% of Control) 
1 L-Aspartate 
 
4 ± 2  16 ± 4  15 ± 3  
2 L-β-Methyl-Asp 
 
43 ± 8  49 ± 6  32 ± 15  
3 D,L-β-threo-
Benzyloxy-Asp 
(TBOA) 
 
5 ± 2  2 ± 1  9 ± 3  
4 L-β-Benzyl-Asp 
(BA) 
 
20 ± 4  15 ± 3  4 ± 2  
5 L-β-threo-BA 
 
8 ± 1  9 ± 1  1 ± 1   
6 L-β-3-Iodo-BA 
 
50 ± 6  64 ± 3  19 ± 6  
7 L-β-3-Bromo-
BA 
 
HO O C 
N H 2 
C O OH 
B r 
 
45 ± 6  22 ± 5  8 ± 3  
8 L-β-3-Chloro-
BA 
 
21 ± 7  23 ± 2  7 ± 4  
9 L-β-3-Fluoro-BA 
 
11 ± 1  23 ± 3  0 ± 0  
Table 1. Inhibitory activity of β-substituted aspartate analogues at EAAT1, 
EAAT2 and EAAT3, all experiments were done a minimum of 3 times with the 
exception of 4-F-BA. 
HOOC
COOH
NH2
H O O C
C O O H
N H 2
C H 3
HOOC
COOH
NH2
O
HOOC
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HOOC
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F
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Cmpd 
# 
Compound 
(100 µM) 
EAAT1 
3H-D-Asp Uptake 
(% of Control) 
EAAT2 
3H-D-Asp Uptake 
(% of Control) 
EAAT3 
3H-D-Asp Uptake 
(% of Control) 
10 L-β-3-Nitro-BA 
H2N
HO2C
CO2H
NO2  
62 ± 8 75 ± 6  29 ± 5   
11 L-β-3-Methyl-
BA 
H3N
HO2C
CO2
CH3 
60 ± 4 (3)  48 ± 3  33 ± 1  
12 L-β-3,5-
Dimethy-BA 
H2N
HO2C
CO2H
CH3
CH3
 
72 ± 4  69 ± 7 36 ± 7 
13 L-β-4-Fluoro-BA 
H2N
HO2C
CO2H
F
 
21 (2) 40 (2) 9 (2) 
14 L-β-4-Nitro-BA 
H2N
HO2C
CO2H
NO2
 
80 ± 7  82 ± 12  65 ± 8   
15 L-β-4-Amino-BA 
H2N
HO2C
CO2H
NH3
 
57 ± 2  57 ± 4  21 ± 3  
16 L-β-2,6-
Dichloro-BA 
H2N
HO2C
CO2H
Cl
Cl
 
76 ± 1  100 ± 6  86 ± 5  
 
Table 1. cont.  
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Cmpd 
# 
Compound 
(100 µM) 
EAAT1 
3
H-D-Asp 
Uptake 
(% of Control) 
EAAT2 
3
H-D-Asp 
Uptake 
(% of Control) 
EAAT3 
3
H-D-Asp 
Uptake 
(% of Control) 
17 L-β-1-Napthyl-
Benzyl-Asp 
H2N
HO2C
CO2H
 
84 ± 5  92 ± 6  60 ± 4  
18 L-β-2-Napthyl-
Benzyl-Asp 
H2N
HO2C
CO2H
 
99 ± 6  92 ± 13  68 ± 6  
 
Table 1. cont.  
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3.2. IC50 determination for L-β-3-Cl-, 3-Br- and 3-F- benzyl aspartate. 
 Structures of L-β-3-cloro-benzyl aspartate, (L-β-3-Cl-BA), L-β-3-bromo-
benzyl aspartate (L-β-3-Br-BA) and L-β-3-floro-benzyl aspartate (L-β-3-F-BA) are 
shown in Table 2.  IC50 values were determined by the Bridges lab for the three 
compounds at EAATs 1, 2 and 3 in C17.2 cells expressing the human EAAT1-3 
in the presence of 1 µM 3H-D-aspartate.  The compounds were evaluated as 
mixtures of their threo and erythro (S,S:S,R) forms in an approximate 2:1 ratio.  
IC50 values were below 10 µM at EAAT3 for all three compounds, IC50 values for 
EAAT1 and EAAT2 are also presented in Table 2 with log concentration 
response curves shown in Figure 3.  L-β-3-Cl-BA is the most selective of the 
compounds with an approximate 4 and 5 fold preference for EAAT3 over EAATs 
1 and 2 respectively, 3-BrBA is 9 and 2 times more selective and L-β-3-F-BA is 4 
and 3 times more selective for EAAT3 over EAAT1 and EAAT2 respectively.   L-
β-3-F-BA is the most potent of the compounds with an IC50 value at EAAT3 of 
1.95 ±.37 µM.   
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Figure 3.  Log 
concentration response 
curves for the effects of 
3-Br-, 3-Cl- and 3-F-BA 
on 3H-D-aspartate 
uptake in C17.2 cells 
expressing hEAAT1 (●), 
hEAAT2 (■) and 
hEAAT3 (♦).  Data are 
expressed as the 
percent of control 
uptake measured in the 
absence of inhibitors 
and represent the mean 
± SEM from at least 
three independent 
experiments.  
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Compound 
 
EAAT1  EAAT2 EAAT3 
 
µM 
 
L-β-3-Bromo-
Benzyl Aspartate 
 
H2N
HO2C
CO2H
Br  
 
 
 
 
65.1 ± 25.9  
 
 
 
16.5 ± 4.06 
 
 
 
7.04 ± 1.33 
 
L-β-3-Chloro-
Benzyl Aspartate 
 
H2N
HO2C
CO2H
Cl  
 
 
 
39.6 ± 15.4 
 
 
 
31.3 ± 10.1 
 
 
 
8.03 ± 2.15 
 
L-β-3-Floro-Benzyl 
Aspartate 
 
H2N
HO2C
CO2H
F  
 
 
 
7.50 ± 2.12 
 
 
 
5.56 ± 0.65 
 
 
 
1.95 ± 0.37 
   
Table 2.  IC50 values for the inhibition of 
3H-D-aspartate uptake by hEAAT1-3 
expressed in C17.2 cells. 
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3.3 Computational studies. 
 Computational studies were carried out in collaboration with Dave Holley 
in the Gerdes lab.  Inhibitors L-β-3-F-BA, L-β-BA, L-β-2-naphthyl aspartate (L-β-
2-NA), TBOA and the naphthyl derivative of TBOA, threo-β-(2-naphthyl)-
methoxyaspartate (TNOA-2) (Shimamoto et al., 2000) were docked in an EAAT3 
protein homology model based on the crystal structure of TBOA bound Gltph 
using the program GOLD (Boudker et al., 2007).  In order to attempt correct 
evaluations of different poses we took a heuristic approach that incorporated 
known hydrogen bonding interactions involving Arg447 and Asp444 shown to be 
critical for affinity and transport (Teichman and Kanner, 2007; Bendahan et al., 
2000).   
 TBOA docked into the EAAT3 model aligned with the alpha carboxyl, 
amine and distal carboxyl of TBOA bound in the Gltph crystal structure and was 
able to achieved H-bonding interactions with Arg447 and Asp444.  Arg447 H-
bonds between docked TBOA (dark blue) and TBOA in the crystal structure (light 
blue) are shown in figure 4.  In order to emphasize the H-bonding interactions 
between Arg447 and the ligand, H-bonding interactions between the alpha 
carboxyl group and Asp444 were not highlighted, though these hydrogen bonds 
were formed.  Docked poses of TBOA revealed an interesting ability of the ether 
group to substitute for the distal carboxyl in the H-bond interaction with Arg447.  
In addition to acting as a substitute for the distal carboxyl the ether group was 
observed to participate in H-bonding interactions of the distal carboxyl with  
 
 
 
Figure 4.  TBOA from the crystal
TBOA docked by GOLD into the EAAT3 model is shown in dark blue.
 
 
 
 
 
 
 
 structure TBOA-Gltph is shown in light blue and 
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Arg447.  Figure four illustrates the ability of the distal carboxyl group and/or the 
ether of TBOA to hydrogen bond with Arg447, red dashed line.  This is 
complementary to the crystal structure which shows interaction of the distal 
carboxyl group and Arg447, yellow dashed line.  Docked poses placed the 
aromatic portion of TBOA in a lipophilic pocket near Leu408 and Met411 in hair 
pin loop 2 (HP2) and Tyr365 in trans membrane 7 (TM7) in a distinct position 
from the crystal structure.  
 Of the three L-β-BA analogues, docked poses of L-β-3-F-BA and L-β-BA 
met the criteria for correct orientation as described above (figure 5).  Docked 
poses of L-β-2-NA revealed that H-bonding interactions with either the distal 
carboxyl group and Arg447 or the alpha amine group and Asp444 predominately 
occurred.  Simultaneous H-bonding interactions were rarely observed.  On the 
infrequent occasions that both H-bonding interactions were achieved, the 
GoldScore was much lower than the scores observed for the other compounds.   
 In order to determine potential differences between the mechanisms for 
binding between the TBOA structures and the L-β-BA structures we docked the 
naphthyl derivative of TBOA, TNOA-2.  In agreement with what was observed for 
L-β-2-NA, TNOA-2 rarely made H-bonding interactions with both the distal 
carboxyl group and Arg447 and the alpha amine group and Asp444.  Significantly 
TNOA-2 could form simultaneous H-bonds between the ligand alpha amine and 
Asp444 and between the ligand ether and Arg447, effectively supplanting the 
distal carboxyl interactions (figure 6).   
 
 
Figure 5.  Docked TBOA, shown in dark blue and 
the active site of the EAAT3 model. H
with Asp444 and Arg447 are shown in yello
 
 
 
 
 
 
 
 
L-β-3-F-BA, shown in pink, in 
-bonding interactions shown for 
w.  
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L-β-3-F-BA 
 
 
Figure 6.  L-β-2-NA (purple) and TNOA
EAAT3 model.  The amine group of 
from Asp444 and cannot
 
 
 
 
 
 
-2 (light blue) in the active site of the 
L-β-2-NA, shown in blue, is positioned away 
 make the necessary H-bond interaction.  
128 
 
 
129 
 
4.  Discussion 
 
 In the present study we introduce one of the first known set of compounds 
displaying a consistent preference for EAAT3.  The data was evaluated 
pharmacologically and computationally and results suggest the reason for the 
observed selectivity is due to necessary H-bonding interactions of L-β-BA with 
key residues in the binding site.  These interactions position the aromatic moiety 
in a specific area of the protein which is more accessible in EAAT3.   
 Pharmacological data lent insight to the physical characteristics of the 
binding site, particularly the area that supports the aromatic moiety of L-β-BA and 
L-β-BA derivatives.  Two reliable trends were observed among the analogues: 
decreased potency with larger substituents and a consistent preference for 
EAAT3 compared to EAAT1 and EAAT2.  Dramatic reductions in potency were 
observed for the largest additions made to the aspartate backbone e.g., 1- and 2-
β naphthyl aspartate (L-β- 1- and 2-NA).   Significantly, 1- and 2-substituted 
naphthyl TBOA derivatives (TNOA-1 and -2) show an increase in potency from 
the original benzyl analogue (TBOA) (Shimamoto et al., 2000), reinforcing the 
conclusion that the area BA analogues probe is, at least partially, distinct from 
the area probed by TBOA analogues. Substitutions that positions the ring away 
from the aspartate backbone are not tolerated (L-β-2,6-dichloro BA) within the 
transporter binding sites (EAAT1-3).  This may be due to steric clashes with the 
protein when the aromatic moiety is forced into a different configuration.  There 
appears to be more room in the lipophilic pocket for substitutions at the 3 and 5 
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positions than at the 4 position of the aromatic ring.  This is supported by the loss 
of activity when comparing 3 and 4 substitutions (L-β-3- and 4-F-BA; L-β-3 and 4-
nitro-BA).  The retention of activity observed for L-β-3,5-dimethyl-BA compared to 
L-β-3-methyl-BA further suggests that there is more area in the lipophilic pocket 
to tolerate small groups at the 3 and 5 positions than at the 4 position.  Small 
hydrophobic substituents were found to be optimal at the C-3 position on the 
benzene ring.  The most potent and selective compound of this series, L-β-3-
fluoro-BA (L-β-3-F-BA), shows similar potency and selectivity as L-β-BA.  The 
fluoro- substitution increases the lipophilicity of the aromatic ring while imparting 
a small amount of steric bulk.  This can be compared to larger substitutions, such 
as the less potent iodo derivative, which also increase the lipophilicity of the 
aromatic moiety but with greater steric bulk.  This emphasizes the importance of 
both the size and position of the substitutions, as well as the consistent trend 
among EAAT inhibitors of increased potency with increased lipophilicity.  
 Computational analysis suggests that the difference in selectivity observed 
between L-β-BA analogues and TBOA analogues is likely due to the positioning 
of the aromatic moiety within the protein.  It has been suggested that the 
positioning of the aromatic moiety is affected by essential H-bonding interactions 
between the ligand α-amine and Asp444 and the ligand distal carboxyl group and 
Arg447 (Teichman and Kanner, 2007; Bendahan et al., 2000).  We hypothesize 
that the wide range of inhibitory activity observed with TBOA lies in the ability of 
the ether group to substitute for the distal carboxylate in H-bonding interactions 
with Arg447.  This allows the aromatic region to be placed in an area of the 
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protein that appears to be capable of tolerating more steric bulk.  BA and its 
derivatives do not have an H-bond acceptor positioned to make this key 
interaction.  Therefore the aromatic region of BA is forced into a lipophilic pocket 
which is more accessible in EAAT3, but which is 3-dimentionally confined and 
can only tolerate a limited amount of steric bulk.  We tested this hypothesis by 
docking ligands into an EAAT3 homology model using the program GOLD.  
GOLD is a computational program that optimizes the position of the ligands in the 
binding site by giving the ligands maximal flexibility while allowing the protein 
partial flexibility.  The poses are scored by GoldScore which is optimized for the 
prediction of ligand binding positions and takes into account factors such as van 
der Waals energy, H-bonding energy and ligand torsion strain (From Gold 
Support Online; 
http://www.ccdc.cam.ac.uk/products/life_sciences/gold/faqs/scientific_faq.php).  
 L-β-2-NA and TNOA-2 (L-TNOA-2 is slightly more potent at EAAT1-3 than 
L-TBOA) present a unique opportunity to explore differences between the binding 
sites of the EAAT3 and EAAT2 proteins.  The only structural difference between 
these two compounds is the presence of an ether group on the β-substituent of 
TNOA-2.  As expected from TBOA docking exercises, the ether group in TNOA-2 
allowed for H-bonding interactions with Arg447, while the ligand α-amine H-
bonded to Asp444.  The distal carboxyl of TNOA-2 rarely achieved H-bonding 
interactions while the α-amine was engaged in H-bonding interactions with 
Arg444.  Larger groups appear to have more difficulty making these H-bond 
interactions as supported by L-β-2-NA and TNOA-2, which rarely achieve them.  
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We propose that TNOA-2 maintains potency and wide spectrum inhibitory activity 
at the EAATs due to the ability of the ligand to make this key interaction between 
Arg447 and the ether of the β-substituent.  This substitution allows the ligand to 
place the naphthyl ring in the larger lipophilic pocket, in a more favorable binding 
orientation.  Interestingly (2S,3S) ethyl phenyl aspartate, a TBOA derivative with 
a carbon replacing the oxygen on the β-substituent is slightly less potent an 
inhibitor than TBOA, but shows a 2 fold preference for EAAT3 over EAAT2 
(Sakaguchi et al., 2004).  This lends credence to the idea that the absence of the 
ether on the β-substituent places the aromatic moiety into a defined area of the 
protein, an area which is more accessible in EAAT3.  We suggest that the 
reasons our docked poses of TBOA were different from the crystal structure may 
be attributed to: differences in the transporters and/or the crystal structure 
captured one of multiple binding orientations TBOA may achieve.  We 
hypothesize that the docked orientation of TBOA may be preferred in the EAATs 
and that when the aromatic moiety is larger, such as with the naphthyl (TNOA-2), 
the position shown in our docking studies is the only position TNOA-2 may take.  
 A space filling model of TBOA and L-β-BA docked in the active site of 
EAAT3 (figure 7) further illustrates these points.  Figure 7 illustrates the 
lipophilicity of the regions the benzyl moieties of TBOA and L-β-BA reside in 
(hydrophobic residues are shown in blue).  The lipophilic region the benzyl group 
of TBOA is placed in appears larger than the area the benzyl group of L-β-BA 
resides in.  In support of the pharmacological data, examination of figure 7 
suggests that there is more room to support substitutions at the 3 and 5 positions 
 
than the 4 position.  Results from the
L-β-BA has a specific manner in which it can interact with the protein and a 
restricted area in which the benzyl moiety is tolerated.  We suggest these points 
explain the selectivity observed among 
 
Figure 7.  Space filling mod
the binding site of the EAAT3 model.  Hydrophobic residues are shown in blue.  
The HP2 loop is along the right side of the picture.
 
 
 
 
 docking studies support the 
L-β-BA and L-β-BA derivatives.
el of TBOA (blue) and L-β-BA (light pink) docked in 
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5. Conclusions 
 
 This work describes the synthesis and the initial characterization of the 
biological activity of one of the first identified EAAT3 selective inhibitors, L-β-
benzyl aspartate.  L-β-BA was synthesized in an approximate 2:1 ratio of 
diasteromers (threo:erythro), using base promoted enolate addition (Mavencamp 
et al., 2008).  Kinetic analysis of 3H-D-aspartate uptake into C17.2 cells 
expressing the hEAATs demonstrated that L-threo-β-BA is the more potent 
diastereomer (Ki values of 9 µM for EAAT1, 10.0 µM for EAAT2 and 0.8 µM for 
EAAT3), acts competitively, and exhibits a 10-fold preference for EAAT3 
compared to EAAT1 and EAAT2.  Electrophysiological recordings of EAAT-
mediated currents in Xenopus oocytes further identified L-β-BA as a non-
substrate inhibitor.  Thus, the analogue binds to the transporter but is not 
translocated as a substrate.  The structure of L-β-benzyl aspartate is similar to 
TBOA, a well known wide spectrum EAAT inhibitor with a preference for EAAT2.    
This allows L-β-BA to be directly compared to TBOA, presenting an excellent 
opportunity to examine subtle differences between the EAAT3 and EAAT2 
binding sites.  L-β-BA differs from TBOA by the absence of an oxygen atom on 
the β-substituent.  Two hypotheses can be drawn from the analysis of the 
structure activity data with respect to TBOA.  The positioning of the aromatic 
group of L-β-BA in the protein binding site is different from that of TBOA due to 
the absence of the oxygen on the β-substituent and/or the difference in length of 
the β-arm.  The selectivity observed for L-β-BA is due to the unique positioning of 
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the aromatic group in the protein binding site, which appears to be better 
tolerated in EAAT3 than in EAAT1 and EAAT2.   
 L-β-BA derivatives were designed and synthesized to answer key 
questions about the binding site.  1) The steric tolerance of the binding site was 
probed by making larger aromatic substitutions to the aspartate backbone, as 
well as by varying the sizes of substitutions on the benzene ring.  2) The 
lipophilicity of the pocket was examined by making substitutions to the ring that 
both increased and decreased the lipophilicity.  3)  Substitutions to the ring were 
made that could act as a H-bond donor or as an acceptor.  4) Substitutions were 
made in different positions around the aromatic ring to help determine the 
topology of the lipophilic pocket. 
 The L-β-β-BA derivatives showed a consistent preference for EAAT3, 
suggesting that the protein region the compounds probe is more accessible in 
the EAAT3 protein than in the EAAT1 and EAAT2 proteins.  In addition, the 
derivatives revealed that the EAAT3 lipophilic pocket occupied by L-β-BA is likely 
smaller than that occupied by TBOA and that it could not tolerate much steric 
bulk over that of the benzene ring.  The lipophilicity of the binding pocket was 
determined to be important due to the increase in potency observed for 
substituents which increased the lipophilicity of the aromatic ring over those 
which decreased lipophilicity.  Substitutions to the aromatic ring suggested that 
H-bonding interactions between the ligand aromatic group and the protein were 
not likely playing a determinative role in selectivity or potency.  The three 
dimensional constraints of the pocket were determined by substitutions to the 
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aromatic ring in both the 3 and 5 positions as well as the 4 position.  
Pharmacological results suggest that the pocket expands in the direction of the 3 
and 5 positions but is constrained in the region probed by 4-substitutions.  
 The most potent and selective L-β-BA derivative, L-β-3-F-BA, highlights 
these conclusions about the EAAT3 binding site.  The 3-fluoro substitution 
resulted in an analogue displaying increased potency and selectivity over L-β-BA.  
This is hypothesized to be due to the increase in lipophilicity of the aromatic ring 
by a small substitution at the preferred 3-position. 
 Historically, selective, conformationally constrained analogues were used 
to gain insight into the EAAT binding sites.  An EAAT2 pharmacophore model 
was constructed using the low energy conformations of well known EAAT2 non-
substrate inhibitors and overlaying three main ligand groups the protein is 
hypothesized to recognize: α-amine, α-carboxyl and distal carboxyl group.  
Potential differences between the EAAT2 and EAAT3 binding sites could be 
elucidated by overlaying an EAAT3 preferring inhibitor (L-β-BA) onto the EAAT2 
pharmacophore model and observing points of diversion.  It was immediately 
obvious that the aromatic regions of L-β-BA and TBOA were in different areas 
due to the oxygen in the TBOA β-substituent and/or in the one atom longer arm 
of TBOA (Esslinger et. al., 2005).  A crystal structure of the EAAT homologue, 
Gltph, was recently published, with both aspartate and TBOA bound in the binding 
site (Yernool et al., 2004; Boudker et al., 2007).  From the crystal structure an 
EAAT3 homology model could be constructed by overlaying the EAAT3 
sequence onto the crystal structure of Gltph with TBOA bound.  From the 
137 
 
homology model, the program GOLD could be utilized to optimize the position of 
ligands in the active site.    
 Docking studies performed using the program GOLD revealed distinct 
conformations with which L-β-BA and TBOA analogues may bind in the active 
sites.  These studies suggest that the lipophilic moiety of TBOA analogues reside 
in a distinct area from the aromatic moiety of L-β-BA analogues.  This different 
placement appears to be due to the ability of the ether group of TBOA to 
substitute for crucial H-bonding interactions in the active site typically made by 
the distal carboxylate of analogues.  In contrast, L-β-BA binds in the active site in 
a distinct manner due to the absence of alternate atoms (i.e. ether) with which to 
form key H-bonding interactions in the active site.  This forces the aromatic ring 
of L-β-BA into an area of the protein that, as suggested by pharmacological data, 
is more available in the EAAT3 protein than in EAAT1 or EAAT2.  The docking 
studies suggest areas within the EAAT2 and EAAT3 proteins which may be 
exploited to design more selective and potent inhibitors.  Both the 
pharmacophore model and the conclusions from the docking studies will be 
modified as more results become available, increasing the accuracy with which 
the models dictate new synthesis.   
 An important future direction of this work is to characterize the separated 
diastereomers: L-β- threo- and erythro-3-F-BA.  In light of the results from threo- 
and erythro-BA, we hypothesize that the threo form of L-β-3-F-BA will be the 
more potent diastereomer and preliminary data suggests that this is the case.  
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More detailed assays of the threo and erythro-diasteromers are currently 
underway.   
  The next generation of EAAT3 inhibitors can be designed from 
comparisons of the current EAAT2 and EAAT3 binding site models.  An intriguing 
approach is to design a compound capable of probing both the lipophilic pocket 
that the benzyl group of TBOA resides and the lipophilic pocket that the benzyl 
group of L-β-BA probes.  An increase in potency would be predicted to occur due 
to the enhanced lipophilic interactions of the TBOA like aromatic group.  
Selectivity would be maintained by the benzyl aspartate like aromatic group that 
probes the lipophilic pocket hypothesized to be unique to EAAT3.  Due to the 
small size of the proposed lipophilic pocket in EAAT3, smaller substitutions may 
be beneficial, such as L-β-3-amine-BA.   Symmetrical substitutions to the 
aromatic ring may show an increase in selectivity, L-β-3,5-diamine-BA and L-β-
3,5-difluoro-BA could be synthesized to test this hypothesis.  Larger aromatic 
substitutions with more flexibility may be advantageous as they are less rigid and 
could possibility avoid steric interactions with the HP2 loop that are predicted to 
occur between L-β-naphthyl-BA and the EAAT3 protein.  Dibenzyl ring systems 
in place of the benzyl ring, such as diphenyl methane, or rings connected by an 
ether linkage such as diphenyl ether which is commercially available as the 
electrophile; 1-(bromomethyl)-3-phenoxybenzene, may increase the potency and 
selectivity of L-β-BA for EAAT3.        
 In addition to the synthesis of new compounds it is important to test L-β-
BA and L-β-BA derivatives for cross reactivity.  In particular, it is crucial to 
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determine if L-β-BA is interacting with the metabotropic and ionotropic glutamate 
receptors.  Cross reactivity with the ionotropic EAA receptors is not anticipated 
due to the similar template of L-β-BA and TBOA, which did not display cross 
reactivity (Shimamoto et al., 2002).  To verify this hypothesis receptor binding 
assays could be performed. 
 It is anticipated that this group of L-β-BA derivatives will be useful in 
investigating the role that EAAT3 plays in glutamate uptake as related to shaping 
the postsynaptic signal.  Additionally, L-β-BA could be used as a tool to elucidate 
the role of EAAT3 in various physiological roles, such as learning and memory, 
as well as in pathophysiological states such as those observed in ischemia and 
schizophrenia.     
 Preceding the syntheses of EAAT selective inhibitors, both EAAT knock-
out and EAAT antisense animals were utilized to study the physiological role of 
the EAATs.  EAAT3 knock-out mice present significantly reduced spontaneous 
locomotor activity at 12 months as measured in an open-field monitoring 
chamber.  The EAAT3 knock-out mice do not show neuronal loss or motor 
incoordination in rotorod testing, and learning appears unimpaired in water maze 
testing.  A major dysfunction of EAAT3 knock-out animals is the onset of 
dicarboxylic aminoaciduria due to the loss of uptake from the renal tubules by 
EAAT3 (Peghini et al., 1997).  The reason for the mild CNS deficits of knock-out 
mice may be due to compensation by other glutamate transporters during 
development.  This is supported by behavioral abnormalities observed in 
antisense treated animals including staring-freezing episodes and electrographic 
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(EEG) seizures (Sepkuty et al., 2002).  Administration of an EAAT3 specific 
inhibitor to adult mice would help clarify the effect of decreased EAAT3 on 
learning and coordination as well as on the potential to induce seizures, neuronal 
damage or dicarboxylic aminoaciduria.  These results are particularly important 
when considering the use of EAAT3 inhibitors as potential therapies.  The 
consequences of EAAT3 inhibition, particularly over long periods, are not clear 
and need to be evaluated before therapeutic applications can be seriously 
considered. 
Due to the availability of EAAT2 specific inhibitors, more is known about 
the role of EAAT2 in glutamate uptake than any other EAAT.  From these studies 
we can conclude that EAAT2 uptake plays a role in shaping the postsynaptic 
signal when the synapse is tightly ensheathed by glial cells and the volume of the 
synapse is restricted.  The EAAT2 preferring inhibitors, DHK and WAY-855, have 
been utilized to assess the role of EAAT2 in clearing glutamate from the synaptic 
cleft.  When DHK was used to selectively inhibit EAAT2, a threefold increase in 
the amplitude of mGluR1 mediated EPSCs from oriens-lacunosum molecular 
interneurons in hippocampal slices was observed.  In contrast, when TBOA was 
used to block the EAATs a greater than 15 fold increase in the EPSCs was 
observed suggesting a prominent role for EAAT1 and/or EAAT3 (Huang et al., 
2004).  In agreement with the results gained from DHK, the more potent, 
selective EAAT2 inhibitor WAY-855 did not cause excitotoxicity in rat 
hipppocampal slices, but when TBOA was applied significant neuronal death was 
observed (Selkirk et al., 2005).   
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 Due to the lack of EAAT3 selective inhibitors, the role of EAAT3 in shaping 
the excitatory post synaptic response among excitatory circuits in varying parts of 
the brain is not as clearly defined as for EAAT2.  In the past the role of EAAT3 
was determined by studying the role of EAAT2 and comparing this to the effects 
of blocking all of the EAATs then ascribing the difference to EAAT1 and/or 
EAAT3.  This was further followed up by experiments done in knock out EAAT1 
and EAAT3 animals (Huang et al., 2004; Selkirk et al., 2005).  Now that EAAT3 
selective inhibitors are available, the contribution of EAAT3 to variables such as 
the duration, amplitude and decay of the post synaptic response could be directly 
examined using electrophysiological techniques.  Glutamate uptake by the 
EAATs is the main mechanism by which glutamate is cleared from the synaptic 
cleft in brain regions that are tightly ensheathed by glial cells.  Hence, one would 
be expect the time course of the postsynaptic response to be prolonged by 
EAAT3 transport inhibition (Overstreet et al., 1999).  In contrast, brain regions 
where glutamate clearance is mainly attributed to diffusion, uptake blockers 
would not be expected to show significant changes in the duration of the 
postsynaptic responses (Isaacson and Nicoll, 1993).  In addition, it would be of 
interest to determine if EAAT3 contributes to the presynaptic neuronal pool of 
glutamate.  If EAAT3 did contribute to this pool, blocking EAAT3 might be 
expected to change the probability of release as measured by paired pulse 
ratios.   
 Glutamate that escapes the synaptic cleft has been shown to affect 
neighboring synapses.  This phenomenon is termed spillover (Scanziani et al., 
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1997; Kullman and Asztely, 1998).  The perisynaptic localization of EAAT3 on 
neurons implicates EAAT3 in controlling the extent of spillover, and thus the 
extent to which glutamate stimulates receptors outside of the synaptic cleft.  
Spillover of glutamate from excitatory mossy fibers has been shown to inhibit 
GABA release by activating presynapic mGluRs on inhibitory interneuron axons 
within the cerebellar glomerulus and the hippocampus.  This may be a way of 
sharpening the output of select cells by inhibiting neighboring boutons. (Vogt and 
Nicoll, 1998; Mitchell and Silver, 2000).  Blocking EAAT3 may increase the 
inhibition of GABA release by allowing more glutamate to stimulate the 
presynaptic mGluRs.  This could be measured directly with the use of an EAAT3 
selective inhibitor.     
 The localization of EAAT3 to presynaptic GABA neurons led to the 
hypothesis that EAAT3 played a role in GABA synthesis.  In order to test the role 
of EAAT3 in GABA synthesis, rats were administered EAAC1 antisense 
oligonucleotides which resulted in a 60% decrease in EAAC1 expression.   
Behavioral abnormalities, including staring-freezing episodes and electrographic 
seizures, were observed along with a decrease in miniature inhibitory post 
synaptic currents (mIPSCs) in whole cell patch clamp recordings of CA1 
pyramidal neurons and a 50% loss of hippocampal GABA levels (Sepkuty et al., 
2002).  These results suggest that EAAT3 plays a significant role in controlling 
the amount of GABA in the hippocampus.  An EAAT3 blocker offers a direct 
method with which to examine the role of EAAT3 in GABA synthesis and release.  
In addition, an EAAT3 blocker could directly and reversibly block EAAT3 to 
143 
 
determine the time course with which blocking EAAT3 decreases GABA 
synthesis as well the time course to recover full GABA activity after the EAAT3 
blocker is removed.    
 Long term potentiation (LTP) is the cellular basis for learning and memory 
(Larkman and Jack, 1995; Bennett, 2000).  LTP works by strengthening 
synapses either presynaptically, by increasing the probability of release or 
postsynaptically, by altering the sensitivity of the cell to glutamate (Kawamura et 
al., 2004).  Contextual fear conditioning is a form of learning in which fear is 
associated with a neutral stimulus and learning can be measured by the ability of 
the neutral stimulus to elicit fear.  LTP and contextual fear conditioning increase 
the uptake of glutamate from the synaptic cleft and increase the membrane 
expression of EAAT3.  These results suggest that the uptake of glutamate by 
EAAT3 may be a component of plasticity at glutamatergic synapses (Levenson et 
al., 2002).  This hypothesis could be tested in vivo with animal models 
administered an EAAT3 selective inhibitor and submitted to fear conditioning.  
Fear conditioning could be accomplished by administering electrical shocks 
associated with a neutral stimulus and measuring freezing behavior 24 hours 
later when the neutral stimulus was administered.  An EAAT3 blocker 
administered before fear conditioning would be predicted to decrease freezing 
behavior, which would suggest a learning impairment.  In vitro experiments may 
help elucidate the mechanism responsible for the learning impairment.  Levenson 
induced LTP by high frequency stimulation (HFS) of the Schaffer-collateral 
pathway in the hippocampus and observed an increase in the uptake of 
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glutamate and in the membrane expression of EAAT3 as measured by western 
blots.  He predicted that decreasing diffusion to inhibitory presynaptic mGluRs, 
and/or to limiting NMDA activation to prevent toxicity may be the reason for the 
increase in transport activity (Levenson et al., 2002).  Our development of an 
EAAT3 blocker provides a strategy to determine if LTP is affected by blocking 
EAAT3.    
 One area where EAAT3 inhibitors may be therapeutically useful is in 
alleviating damage during brain ischemia.  Brain ischemia is an important 
therapeutic target as it is the third cause of death in industrialized countries. 
Glutamate release contributes to neuronal damage observed during ischemia 
and is hypothesized to be due, in part, to the reversal of the EAATs, particularly 
EAAT3 (Rossi et al., 2000).  The reversal of the EAATs has been observed 
under conditions of ATP depletion or elevated extracellular potassium levels 
(Anderson et al., 2001).  The cytosolic concentration of glutamate in neurons is 
approximately 10mM, much higher than the 3mM observed in glial cells.  This 
suggests that EAAT3 is more likely to release glutamate than a glial transporter 
(Camacho and Massieu, 2006).  Of the glial transporters EAAT1 is a more likely 
candidate than EAAT2.  EAAT2 does not appear to run in reverse, as supported 
by the EAAT2 knock down rats which undergo transient middle cerebral artery 
occlusion (MCAO) and display more damage.  These results suggest that EAAT2 
aids in clearing glutamate from the synaptic cleft during ischemia.  Administration 
of an EAAT3 inhibitor post transient MCAO and examination of the damage as 
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marked by infarct volume, brain edema and mortality would answer many 
important questions about the role of EAAT3 in ischemia.  
 EAAT3 inhibitors are emerging as potential pharmaceuticals in the 
development of novel antipsychotics.  The glutamate hypofunction model states 
that the positive, negative and cognitive symptoms of schizophrenia are 
associated with reduced stimulation of NMDA.  This is supported by the 
application of NMDA antagonists, which produce schizophrenia like symptoms 
and are used as a model of schizophrenia.  From these observations it can be 
hypothesized that Increasing stimulation of NMDA may alleviate symptoms of 
schizophrenia.  If EAAT3 controls the amount of glutamate available to stimulate 
NMDA receptors this indicates it as a potential drug target.  Consistent with this 
is altered EAAT3 levels in persons with schizophrenia as well as in rats and 
persons treated by antipsychotic medications (McCullumsmith and Meador-
Woodruff, 2002; Schmitt et al., 2003). The EAAT3 inhibitor, NBI-59159, displays 
an approximate 5 and 40 fold selectivity over EAAT2 and EAAT1.  This 
compound was shown to decrease amphetamine-stimulated locomotor activity in 
mice (Dunlop and Marquis, 2006).  Further support of the role of EAAT3 inhibition 
in decreasing amphetamine-stimulated locomotor activity is the application of a 
selective EAAT2 inhibitor WAY-855 which did not influence amphetamine-
stimulated locomotion (Dunlop and Marquis, 2006).  Because the 5 fold 
selectivity reported for NBI-59159  over EAAT2 is less than the selectivity 
observed for L-β-threo-BA and derivatives of L-β-BA, it would advantageous to 
compare the results from Dunlop and Marquis with results obtained from 
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administration of L-β-threo-BA and/or L-β-threo-3-F-BA to amphetamine 
stimulated mice.      
 In summary, the excitatory amino acid transporters (EAATs) play a central 
role in regulating extracellular glutamate levels in the Central Nervous System 
(CNS).  These uptake systems are capable of influencing the amount and/or time 
course with which L-glutamate is in contact with the EAA receptors.  Among five 
identified isoforms, EAAT3 is the most abundant subtype present on neurons and 
is widely expressed throughout the forebrain and cerebellum.  The synthesis of 
selective inhibitors and the creation of a binding site model will aid in elucidating 
the roles of EAAT3 in CNS function.  EAAT3 has been implicated in a variety of 
both physiological and pathophysiological processes including long term 
potentiation, schizophrenia, neurodegeneration and ischemia.  Its roles however, 
remain undefined, due to the lack of reagents with which to selectively modulate 
its activity.  Specifically, work in our laboratories has led to the first EAAT3 
preferring inhibitor and the first family of EAAT3 preferring inhibitors.  We suggest 
that these analogues will serve as excellent tools with which to study the 
specialized roles of EAAT3 in the CNS.  
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Appendix A:   
History of 1,2-asymmetric induction 
 
 The synthesis of unnatural amino acids has assumed an important role in 
a variety of pharmacological systems.  This has created a demand for stereo-
controlled methodologies based on amino acids.  1,2-asymmetric induction in the 
alkylation of aspartic acid ester enolates is one area that has received 
considerable attention. 
 In 1990 Dunn et al., studied the regioselective β-benzylation of N-
phenylfluorenyl 2,3 diester (α-tert-butyl,  β-methyl) at the β-carbon with KHMDS 
and benzyl bromide at -78°C.  This reaction yielded 2S,3S : 2S,3R (S,S:S,R) in a 
2:1 ratio.  The ratio of diastereomers can be affected by a number of factors.  
One way to increase the diasteromeric yield is to increase the reactivity of the 
electrophile.  Consistent with this observation the ratio of S,S:S,R increased to 
7:1 when the electrophile was switched from benzyl bromide to benzyl iodide.  
Dener et al., 1993, also used the N-phenylfluorenyl protecting group (2,3 diester- 
α-methyl, β-methyl) aspartate, alkylation at the β-carbon with ethyl triflate and got 
a  2:1 SS:SR ratio.  After optimizing the mole percents of base and ethyl triflate 
the ratio increased to 18:1, displaying the importance of the stoichiometry of the 
base and electrophile to substrate (Dener et al., 1993).    
 β-addition of N-phenylfluorenyl 2,3 diester (α-methyl,  β-methyl) was used 
for hydroxylation using MoOPH with KHMDS at -78 - -65 °C and got SS:SR in a 
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3:1 ratio.  LHMDS reversed this ratio to 1:8 and adding DMPU and HMPU 
reversed this to 8:1 and 11:1 respectively.  (Fernandez-Megia, 1994) 
 Altering the N-protecting group to replace both amine hydrogen atoms by 
adding an N-benzyl group to the amine in addition to the N-phenylfluorenyl group 
increased the stereoselectivity to 30:1 at -23 °C.  Complications arose with this 
scheme as the methyl ester could not be hydrolyzed without epimerization at C-3 
(Dunn et al., 1990).  
 In order to correct this the β-methyl ester was replaced with a β-benzyl 
ester and diasteromeric ratios at -23°C decreased to 12:1 and 25:1 using benzyl 
bromide and benzyl iodide respectively.  In contrast alkylation of dibenzyl amine 
gave almost no diastereoselectivity (Dunn et al., 1990). 
 Substituting methyl for t-butyl as the α-ester protecting group dramatically 
affected the diasteromeric outcome.  N-phenylfluorenyl 2,3 diester (α-methyl, β-
benzyl) aspartate gave ratios of 1:1.5 S,S to S,R at -23°C with either benzyl 
bromide or benzyl iodide, interestingly the preference for S,R was reversed when 
the temperature was decreased to -78°C to 2.5:1 (Denner et al., 1993).   
A paper by Humphrey et al., 1994 describes the diastereoselective β-alkylation of 
the D-isomer, N-benzyl phenylfluorenyl, 2-3 diester (α-methyl, β-methyl) 
aspartate.  Enolate formation with KHMDS at -23 °C favored formation of the R,R 
diastereomer in excess of 50:1.  Interestingly, Humphrey also observed that 
switching the base to LiHMDS reverses this selectivity to 1:50 (R,R:R,S).   
 The N-protecting group, carbobenzyloxy with LiHMDS as a base at -78°C 
gave diasteromeric ratios of 3:1, S,S:S,R (Parr et. al. 1996).  Interestingly with  
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N-Pro.  
Group 
Base E+ Ester protecting  
Groups 
SR:SS 
ratio 
Temp Paper 
PhF 
 
KHMDS BnBr α -t Bu β-CH3 1:2 -78 Dunn, 1990 
PhF 
 
KHMDS BnI α -t Bu β-CH3 1:7 -78 Dunn, 1990 
BnPhF KHMDS (2) BnBr (2) α -t Bu β-CH3 1:30 
 
-20 
 
Dunn, 1990 
BnPhF 
 
KHMDS BnBr α -t Bu β-Bn 1:12 -23 Dunn, 1990 
BnPhF 
 
KHMDS BnI α -t Bu β-Bn 1:25 -23 Dunn, 1990 
BnPhF 
 
KHMDS BnBr/bnI α - Bn  β-Bn 1:1.6 -23 Dunn, 1990 
BnPhF 
 
KHMDS BnBr/BnI α - CH3 β-Bn 1.5:1 -23 Dunn, 1990 
BnPhF 
 
KHMDS BnI α - CH3 β-Bn 1:2.5 -78 Dunn, 1990 
BnPhF KHMDS BnBr α - CH3 β-CH3 1:50 -23 Humphrey, 
1994 
BnPhF LiHMDS BnBr α - CH3 β-CH3 50:1 -23 
-78 
Humphrey, 
1994 
CBZ LiHMDS 
+DMPU\HM
PA 
Cycloheyn
yl Bromide 
α - CH3 β-CH3 75:25 -78 Hanessian, 
1998 
CBZ LiHMDS 
+DMPU 
\HMPA 
Cycloheyn
yl Bromide 
α–TMSE β-CH3 99:1 -78 Hanessian 
1998 
CBZ LiHMDS MeI α -t Bu β-CH3 1:3 -78 Parr, 1996 
PhF KHMDS Ethyl 
triflate 
α - CH3 β- CH3 1:18 -75-0 Dener 1992 
PhF KHMSD MoOPH α - CH3 β- CH3 1:3 -78 –  
-65 
Fernandez-
Megia, 1994 
PhF LiHMDS MoOPH α - CH3 β- CH3 8:1 -78 –  
-65 
Fernandez-
Megia, 1994 
PhF LDA MoOPH α - CH3 β- CH3 1:2 -78 –  
-65 
Fernandez-
Megia, 1994 
PhF LiHMDS 
DMPU 
MoOPH α - CH3 β-CH3 1:8 -78 –  
-65 
Fernandez-
Megia, 1994 
PhF N-
BuLi/LHMD
S 
MoOPH α - CH3 β-CH3 20:1 -78 –  
-65 
Fernandez-
Megia, 1994 
PhF N-
BuLi/LiHMD
S +HMPA 
MoOPH α - CH3 β-CH3 1:2 -78 –  
-65 
Fernandez-
Megia, 1994 
Table 1.  Diasteromeric control of 1,2 asymmetric induction as reported in the 
literature. 
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DMPU or HMPA as a co-solvent/additive S,R formation was favored over S,S, 
75:25 to 99:1, S,R;S,S (Hanessian, 1998). 
 Attempts to improve these results were also performed using various 
solvents (ethyl ether, toluene) as well as additives (HMPA or DMPU), which 
modify the enolate aggregation state.  Another important factor is the 
temperature, maintaining the reaction at a temperature below -50°C has been 
shown to improve 1,2-asymmetric induction.  An interesting issue stemming from 
reaction temperature is the way in which the reaction is quenched.  Parr et al., 
1999, found that a mixture of diasteromeric products resulted from quenching 
their 1,2 asymmetric induction reaction by pouring an aqueous acid solution into 
the reaction at a low temperature followed by warming.  Conversely, If they 
poured the cold reaction into an aqueous acid solution they obtained a single 
diastereomer.   
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Appendix B: 
Synthetic Schemes of β-substituted Aspartates: 
 
 This appendix describes the synthesis used to prepare the β-substituted 
analogues.  In particular the details not covered in chapter two of this dissertation 
are covered including failed schemes, abandoned 
synthetic routes as well as the reasoning behind the 
routes chosen.  
 
Protecting groups: 
Trityl: 
 The N-triphenylmethyl protecting group was 
initially chosen for the ease of which large amounts of 
starting material can be prepared as well as for its large size which was 
hypothesized to protect from alpha racemization (for 
preparation see chapter 2 methods).  This protection 
from alpha racemization is observed at temperatures 
below 0°C, as reactions carried out at temperatures 
exceeding 0°C yield racemic products.   
Benzyl phenyl fluorenyl:  
 For preparation of N-benzyl phenyl fluorenyl 
dimethyl ester aspartate see Humphrey et al., 1994. 
 
 
Figure 2. 
Triphenylmethyl 
protecting group. 
N
 
Figure 3. Benzyl 
phenyl fluorenyl 
protecting group 
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Carbobenzyloxy:  
 The CBZ-Carbobenzyloxy protecting group 
was also used.  N-CBZ-L-aspartate dimethyl ester 
was prepared by dissolving aspartate in 3M sodium 
hydroxide, adding toluene then 1.5 equivalents 
benzyl chloroformate drop wise.  The reaction was 
stirred for 24 hours at a pH greater than 10, the pH 
was adjusted with NaOH when necessary.  The reaction was then acidified with 
6N HCl to a pH of about 1, extracted into ethyl acetate, washed with brine, dried 
with magnesium sulfoxide, filtered and rotovaped.  Esterification is achieved by 
adding 1.4 equivalents thionyl chloride drop wise to the starting material in 
methanol and allowing the reaction to proceed for 48 hours.  The product does 
not crystallize so concentration by rotary evaporation followed by chasing with 
methanol, methylene chloride, toluene and hexane is sufficient to remove excess 
solvents and water.   
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Figure 4. 
Carbobenzyloxy 
protecting group. 
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CBZ sm: 1H NMR (400 MHz, CDCl3) δ: 7.38-7.28 (m, 5H), 5.81-5.78 (m, 1H), 
4.65-4.60 (m, 1H), 3.72 (s, 3H), 3.64 (s, 3H), 3.02-2.97 (m, 1H), 2.84-2.80 (m, 
1H).  13C (100 MHz CDCl3) δ: 171.17, 171.05, 155.82, 136.00, 128.42, 128.10, 
128.01, 67.00, 52.71, 51.95, 50.22, 36.34. 
 
Alkylation of N-CBZ-dimethyl ester with 3-cloro benzyl bromide, LiHMDS + 
DMPU : 
 In an oven dried round bottom flask with stir bar 3.6 equivalents of 
LiHMDS  and 3ml DMPU were cooled to -55°C under argon.  .513g N-CBZ-
dimethyl ester was added in 12 ml THF slowly by a syringe.  About 2 hours later 
3 equivalents of 3-cloro-benzyl bromide was slowly added and the reaction 
proceeded for 21 hours when it was quenched with 10 ml of 10% HCl, the 
reaction rose to room temperature and was extracted into ethyl acetate and 
concentrated for separation on a silica column (.2mg, 27%) 
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1H NMR (400 MHz, CDCl3) δ: 7.38-7.16 (m, 9H), 5.19-5.08 (m, 2H), 4.49-4.46 
(m, 1H), 3.69 (s, 3H), 3.63 (s, 3H), 3.39-3.34 (m, 1H), 3.08-3.03 (m, 1H), 2.80-
2.75 (m, 1H). 
   
Deprotection of N-CBZ-dimethyl ester β-3-cloro-benzyl-aspartate 
 Hydrogenation of starting material (.2g) in ethanol with acetic acid (.25ml) 
and Palladium on Carbon (.15g) under 50 psi for 25 hours did not remove the 
CBZ protecting group.  The NMR was messy and hard to define.   
 
Alkylation of N-CBZ-dimethyl ester with 4-bromo-benzyl bromide 
 The alkylation was carried out in the presence of DMPU, 2.1 equivalents 
of LiHMDS and 3 equivalents of 4-benzyl bromide in the manner described for 
alkylation of N-CBZ-dimethyl ester with 3-cloro-benzyl bromide (58%)  
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Deprotection of N-CBZ-dimethyl ester β-4-bromo-benzyl-aspartate 
 Deprotection under the conditions given for N-CBZ 3-cloro-benyl aspartate 
did not go to completion.  The resultant material from the hydrogenation was 
taken on and deprotected with 6N HCl for 24 hours.  The water layer was 
extracted with ethyl acetate and product was precipitated out of water.  NMR was 
too messy to assign peaks to. 
 
Benzyl Phenyl fluorenyl:  N-BPF-dimethyl ester-3-F-Benzyl-Aspartate 
 In a dry round bottom flask, .5g of N-BPfl-dimethyl aspartate was 
dissolved in 5 ml THF.  2M KHMDS was added drop wise at -23°C.  20 minutes 
later 3-floro-benzyl bromide was added drop wise and the reaction proceeded for 
53 hours at which time it was quenched with 8ml saturated NH4Cl.  The product 
was extracted into ether.  Organic layers were combined washed with brine and 
subsequently concentrated.  The product was isolated on a silica column to give 
a 16% yield. 
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Deprotection of N-BPF-dimethyl ester-3-F-Benzyl-Aspartate 
 To N-BPF-dimethyl ester-3-F-Benzyl-Aspartate (.1g, .166mm) in 
methylene chloride (2ml) and ethyl acetate (2ml) concentrated HCl and methanol 
(15ml) were added with 10% palladium on carbon (.1g).  Hydrogenation under 52 
psi for 24 hours followed by filter through celite and heated to 65°C for 24 hours 
followed by washing with ethyl acetate and concentration of the aqueous layer 
yielded an absolute mess, yellow gooey layer that was incomprehensible by 
NMR.   
 
Deprotection of N-trityl-L-β-substituted aspartate dimethyl ester 
 The most commonly used deprotection scheme was to heat the alkylated 
intermediate in 6N HCl for 24 hours at about 80°C.  The aqueous layer was then 
washed with ether to remove trityl chloride and concentrated to give the chloride 
salt of the product.  Next an anion exchange resin was used in the ratio of 1:10 
product:resin, weight:weight and eluted with varying fractions of acetic acid from 
.1N to 5N with product coming off from 1N to 5N.  This method resulted in yields 
from 8% to 73%.   
 Another deprotection scheme was to de-tritylate with 1N HCl in ethanol, 
heat 1-2 minutes in a water bath, evaporate ethanol and triturate with ether.  With 
N-trityl diester p-nitro benzyl aspartate to diester p-nitro benzyl aspartate the 
yield was 37% with this method.  Next the alkylated product can be added to a 
2N solution of LiOH or KOH in ethanol, stirring at room temperature for 30 
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minutes.   As the product is de-methylated it crashes out of solution.  The 
problem we encountered with this method is that both methyl groups are often 
not saponified and the yields are very low, less than10%. 
 The easiest deprotection scheme is to deprotect in 6N acid at 80°C and 
concentrate down the sample, rotovap off excess HCl by 2-3 water rinses and 
dried on the high vac.  Next the product is precipitated out of ethyl acetate 
(sample must be very dry and free of excess Cl-) followed by precipitation from 
water.  With this method yields are consistently higher, 75%, though some 
product is lost due to incomplete removal of methyl peaks even at reaction times 
greater than 30 hours. 
 
Aromatic ring transformations 
3-Nitro Benzyl Bromide: aldehyde to bromide 
 3nitro benzaldehyde was transformed to 3 nitro benzyl alcohol using 1 
equivalent sodium borohydride in ethanol.  The reaction was stirred at room 
temperature until starting material spot disappeared by TLC (30/70 Ethyl 
acetate/Hexanes).  The reaction was quenched by adding ammonium chloride 
(saturated), extracted with ethyl acetate and dried over magnesium sulfate.  3-
nitro benzyl alcohol was transformed to 3-nitro benzyl bromide under argon by 
adding dry ether and drop wise addition of 1 equivalent phosphorous tribromide 
(PBr3).  The reaction was monitored by TLC (50/50 ethyl acetate/hexane).  Cold 
water was added drop wise to quench the reaction.  The product was extracted 
into ether and washed with brine then filtered through a silica plug.   
171 
 
3-methoxy Benzyl Bromide 
 3 methoxy benzyl alcohol was transformed to 3 methoxy benzyl bromide 
using the same procedure as for 3 nitro benzyl alcohol.   
 
2-benzyl fluorenyl 
 Attempts to synthesize 2-benzyl fluorenyl from 2-fluorenyl aldehyde 
started with the successful transformation of 2-fluorenyl aldehyde to 2 fluorenyl 
alcohol.   This was acheived by a standard reduction in ethanol and addition of 
sodium borohydride and quenching with water.  The reaction was worked up by 
extracting product into ethyl acetate layer, yield 90%.   
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1H NMR (400 MHz, CDCl3) δ: 7.32-7.25 (m, 1H), 7.79-7.73 (m, 2H), 7.55-7.50 
(m, 2H), 7.40-7.22 (m, 3H),  4.74 (m, 2H), 3.86 (m, 2H), 1.74 (m, 1H).   
 
OH 
172 
 
 Attempts to convert the alcohol moiety to bromine were achieved using 
phosphorous tribromine in methylene chloride at -10°C under argon.  The 
reaction appeared to proceed as indicated by the disappearance of the alcohol 
proton at 1.74. 
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1H NMR (400 MHz, CDCl3) δ: 7.80-7.75 (m, 2H), 7.59-7.55 (m, 2H), 7.43-7.31 
(m, 3H),  4.62 (s, 2H), 3.92 (s, 2H).   
 
Alkylations of N-Trityl dimethyl ester aspartate with LiHMDS base 
Alkylation with 3-methoxy benzyl bromide 
 Alkylation with 3-methoxy benzyl bromide proved to be extremely difficult.  
The reaction was allowed to proceed for 2 hours with 2 and 1.5 equivalents of 
base and electophile respectively.  There appeared to be a product spot above 
the starting material on TLC using 30/70 ethyl acetate/hexanes, but upon work 
up this spot could not be positively identified as product. 
173 
 
 3-methoxy benzyl bromide was converted to 3-methoxy benzyl iodide by 
the addition of 10 equivalents of sodium iodide to 3-methoxy benzyl iodide in 
acetone.  The reaction was allowed to reach room temperature and stir 
overnight.  This method showed very light staining under the starting material 
spot via TLC that may have been product.  After deprotection and ion exchange 
no product was isolated.   
 Another method used to attempt alkylation was to tosylate the three 
methoxy benzyl alcohol using tosyl chloride.  This method was also unsuccessful 
though it could have been due to the age of tosyl chloride and the storage 
conditions; outside of a desiccator.  
 In addition to tosylate the mesolate was made from 3-methoxy benzyl 
alcohol and chloromesolate.  This was performed in a dry round bottom flask in 
1M dry methylene chloride, 2 equivalents pyridine were added and 1.5 
equivalents of chloromesolate.  The reaction was diluted with ether, washed with 
1N HCL, dried with magnesium sulfate and roto-vaped with ether.  When 
alkylation was attempted no appreciable product was discerned. 
 
Alkylation with cinnamyl chloride 
 Alkylation with cinnamyl chloride began by the conversion of the chloride 
to iodide via sodium iodide and acetone.  The alkylation reaction did not proceed 
below 0°C, and above it yielded racemic product.  
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Alkylation with phenyl ethyl bromide 
 The alkylation ran for 5 hours at 0°C with 3 equivalents base and 2.5 
equivalents electrophile gave no product.  The starting material was converted 
from phenyl ethyl bromide to phenyl ethyl iodide employing the same reaction 
conditions as described for 3-methoxy benzyl bromide, this yielded a faint spot 
above starting material by TLC that was not taken on.    
 The mesolate was then made from benzyl ethyl alcohol and chloro-
mesolate.  This was performed in a dry round bottom flask in 1M dry methylene 
chloride.  2 equivalents of pryidine were added and 1.5 equivalents of 
chloromesolate.  The reaction was diluted with ether, washed with 1N HCL, dried 
with magnesium sulfate and rotovaped with ether.  When alkylation was 
attempted no appreciable product was discerned. 
 Finally triflouoro methyl sulfonic acid was reacted with phenethylalcohol to 
form trifluoromethyl sulfonic leaving group.  This was achieved by adding a 
solution of trifluoromethylsulfonic (1.4eq) acid in dry chloroform (3 eq) to a 
solution of pyridine and phenethylalcohol (.8eq) on ice under argon.  The transfer 
was difficult due to using a needle and getting it jammed, perhaps from moisture, 
I may have only transferred about 70% of the solution.  A cannula may have 
been easier.  A precipitate was formed upon addition and the clear supernant 
was concentrated with argon and taken up in dry THF for the next (alkylation) 
step.  The alkylation was carried out with 3.5 equivalents of LiHMDS and 2.5 
equivalents of phenethyltrifluoromethylsulfonic acid.  The 
phenethyltrifluoromethylsulfonic acid was difficult to transfer due to extreme 
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insolubility in THF, sonication did not solubilize it so I had to crush it up and 
transfer it to the reaction via a needle.  Reaction proceeded for 4 hours.  By TLC, 
reaction appears to have gone but upon separation by silica column no product 
could be discerned.   
 
2-Nitro Benzyl Bromide 
 Reaction carried out with 2.5 equivalents of base and 3.5 equivalents of 2-
nitro Benzyl bromide.  The reaction went for 4.5 hours at what time no alkylation 
appeared to occur.   
 
Propargyl Bromide 
 Reaction carried out with 3 equivalents LiHMDS and 2.5 equivalents of 
propargyl bromide.  At 4.5 hours at 0°C no reaction could be observed by TLC.  
Propargly bromide was old and may have been wet explaining the lack of 
product.   
 
2-benzyl fluorenyl  
 Unfortunately attempts to alkylate N-trityl-diester aspartate with 2-benzyl 
fluorenyl were unsuccessful.   
 
Additives to Alkylation 
 Manganese bromide (MnBr2) 1.4 equivalents added to starting material in 
THF, 3 equivalents LiHMDS and 2.5 equivalents BnBr.  Reaction proceeded 
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about 60% in 5 hours at -30°C.  Unfortunately at this time additives were only 
used with the aim of increasing yields not for effects on diasteromeric control. 
 
DMPU 
 DMPU was added to alkylations with CBZ (Appendix A; Hanessian, 1998; 
Fernandez-Megia, 1994) and trityl.  Alkylation of N-trityl-dimethyl ester aspartate 
with 3-benzyl bromide gave yields of 74% post silica column in a 1:3 ratio of 
threo:erythro (Mavencamp et al., 2008).  Though DMPU does affect 
diasteromeric control and often increases ratios, it is very difficult to remove, 
causing problems during deprotection and requiring an ion exchange column for 
a clean final sample.   
 
Diasteromeric Enrichment Procedure 
 Diasteromeric enrichment can be achieved by heating the mixture in a 
small amount of water (compound will not be dissolved) much as you would 
approach a crystallization procedure.  Heat for about 20 minutes until no more 
material dissolves.  The material is then hot-filtered and dried.  This gives an 
approximate 11:1 enrichment of threo:erythro or S,S:S,R even when starting with 
a mixture of mostly erythro. 
 
2,3 diester N-trityl asparatate conversion to 2, ester 3 amino, N-trityl 
aspartate 
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 Conversion from the distal carboxyl group to the amine was achieved by 
heating the starting material (.130g) in 3.3 ml methanol and 1 ml concentrated 
NH4OH to about 80°C in a pressure tube for 3 days.  Product is extracted into 
ethyl acetate and concentrated then taken up in 6N HCl for deprotection.   
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1H NMR (400 MHz, CDCl3) δ: 7.51-7.30 (m, 5H), 7.29-7.16 (m, 10H), 3.63-3.66 
(m, 1H),  3.26 (s, 3H), 2.60-2.55 (m, .5H), 2.34-2.31 (m, .5H), 1.95-1.93 (m, 1H). 
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1H NMR (400 MHz, D20) δ: 7.20-7.17 (m, .8H), 6.94-6.85 (m, 2H), 3.62 (s, 1H), 
3.09-3.05 (m, .6H), 2.90-2.78 (m, 1.4H). 
There may be residual trityl in the final product or another impurity may be a 
small amount of starting material in with the amide.   
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Appendix C.   NMR Spectra of Synthesized Compounds. 
4.1. N-tritylamino dimethyl ester aspartate (2)  
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4.3. N-tritylamino dimethyl ester β-benzyl aspartate (3a) 
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4.4. N-tritylamino dimethyl ester β-2-napthyl methyl aspartate (3b)  
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4.5. N-tritylamino dimethyl ester β-3,5 dimethyl-benzyl aspartate (3c) 
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4.6. N-tritylamino dimethyl ester β-3 methyl-benzyl aspartate (3d)  
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4.7. N-tritylamino dimethyl ester β-2,6 dicloro-benzyl aspartate (3e) 
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4.8. N-tritylamino dimethyl ester β-3 bromo-benzyl aspartate (3f) 
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4.9. N-tritylamino dimethyl ester β-3 fluoro-benzyl aspartate (3g) 
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4.10. N-tritylamino dimethyl ester β-3 fluoro-benzylaspartate (3g, S,S) 
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4.11. N-tritylamino dimethyl ester β-3 fluoro-benzylaspartate (3g. S,R) 
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4.12 N-tritylamino dimethyl ester β-4-fluoro-benzyl aspartate (3h) 
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4.13. N-tritylamino dimethyl ester β-3-nitro-benzyl aspartate (3i) 
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4.14. N-tritylamino dimethyl ester β-3-nitro-benzylaspartate (3i, S,S) 
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4.15. N-tritylamino dimethyl ester β-P-nitro benzyl aspartate (3j) 
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4.16. N-tritylamino dimethyl ester β-3-chloro benzylaspartate 
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5
Chemical Shift (ppm)
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
 
220 200 180 160 140 120 100 80 60 40 20 0 -20
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
 
 
TrHN
MeO2C
CO2Me
Cl
 
TrHN
MeO2C
CO2Me
Cl
 
193 
 
4.18. β-Benzyl aspartate (4A) 
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4.19. S,S L-β-Benzylaspartate (4A) 
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4.20. β-2-Napthyl methyl aspartate (4B) 
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4.21. β-3,5 Dimethyl-benzyl aspartate (4C) 
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4.22. β-3 Methyl-benzyl aspartate (4D) 
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4.23. β-2,6 Dicloro-benzyl aspartate (4E) 
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4.24. β-3 Bromo-benzyl aspartate (4F) 
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4.25. β-3 Fluoro-Benzyl aspartate (4G) 
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)  
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
 
 
+H3N
-O2C
CO2H
F
 
+H3N
-O2C
CO2H
F
 
201 
 
4.26. β-3 Fluoro-Benzylaspartate (4G, S,S) 
Spectra a from synthesis with KHMDS, spectra b from HPLC (spectra b. 
reported). 
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Carbon data from HPLC, spectra reported. 
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4.27. β-3 Fluoro-Benzylaspartate (4G, S,R) 
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4.28. β-4-Fluoro-benzyl aspartate (4H) 
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4.29. β-3-Nitro-benzyl aspartate (4I) 
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4.30. β-3 Nitro-benzylaspartate (4I, S,S) 
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4.31. β-para-nitro-benzyl aspartate (4J) 
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4.32. β-3 Chloro-benzylaspartate S,R 
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